{"items": "663", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker - Ansys  ( NASDAQ:ANSS ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/equities/24/01/36685633/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-th", "time_published": "20240118T205452", "authors": ["Neil Dennis"], "summary": "The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the \"buy everything\" sentiment that powered equity indices higher in the final quarter of 2023 is over. This is now a stock picker's market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/MarcChaikin_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.129835, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.162802", "ticker_sentiment_score": "0.281674", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.162802", "ticker_sentiment_score": "0.263153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANSS", "relevance_score": "0.318897", "ticker_sentiment_score": "0.110557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.392537", "ticker_sentiment_score": "0.214586", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.162802", "ticker_sentiment_score": "0.114804", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.08183", "ticker_sentiment_score": "0.081535", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.162802", "ticker_sentiment_score": "0.114804", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83", "url": "https://www.investors.com/news/technology/ultragenyx-pharm-stock-earns-ibd-stock-upgrae-with-rs-rating-jump-to-83/", "time_published": "20240118T194100", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY", "JULIE MAK"], "summary": "When building your watch list, look for stocks with an 80 or higher RS Rating. Ultragenyx Pharm ( RARE ) stock just cleared that benchmark with an upgrade from 75 to 83. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.289123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Celularity Releases CEO Letter to Shareholders", "url": "https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html", "time_published": "20240118T184000", "authors": ["Inc.", "Celularity"], "summary": "FLORHAM PARK, N.J., Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here.", "banner_image": "https://ml.globenewswire.com/Resource/Download/4d9ece5e-b6e6-4461-9e3b-1444b18ac538", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.203825, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CELU", "relevance_score": "0.342002", "ticker_sentiment_score": "0.174416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.027164", "ticker_sentiment_score": "0.165451", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Instil  ( TIL )  Stock Rises More Than 20% in a Week: Here's Why", "url": "https://www.zacks.com/stock/news/2212365/instil-til-stock-rises-more-than-20-in-a-week-heres-why", "time_published": "20240118T172800", "authors": ["Zacks Equity Research"], "summary": "Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.078865, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.472338", "ticker_sentiment_score": "0.037074", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.326283", "ticker_sentiment_score": "0.25761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TIL", "relevance_score": "0.472338", "ticker_sentiment_score": "0.025118", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.401331", "ticker_sentiment_score": "0.22721", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novartis'  ( NVS )  Strong Portfolio, Pipeline to Fuel Growth in 2024", "url": "https://www.zacks.com/stock/news/2212312/novartis-nvs-strong-portfolio-pipeline-to-fuel-growth-in-2024", "time_published": "20240118T171100", "authors": ["Zacks Equity Research"], "summary": "Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default174.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.322222, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.108222", "ticker_sentiment_score": "0.289381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLCO", "relevance_score": "0.054236", "ticker_sentiment_score": "0.128775", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.16171", "ticker_sentiment_score": "0.171706", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.108222", "ticker_sentiment_score": "0.067357", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.131658", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.054236", "ticker_sentiment_score": "0.088771", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is it a Good Idea to Invest in Intellia  ( NTLA )  Stock Now?", "url": "https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now", "time_published": "20240118T165000", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.103398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.371523", "ticker_sentiment_score": "0.034133", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.19117", "ticker_sentiment_score": "0.311717", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.803061", "ticker_sentiment_score": "0.216001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBYI", "relevance_score": "0.313218", "ticker_sentiment_score": "0.200468", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Invest in Avadel  ( AVDL )  Stock Now", "url": "https://www.zacks.com/stock/news/2212231/heres-why-you-should-invest-in-avadel-avdl-stock-now", "time_published": "20240118T153500", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.890401"}], "overall_sentiment_score": 0.222308, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.079656", "ticker_sentiment_score": "0.150831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVDL", "relevance_score": "0.63188", "ticker_sentiment_score": "0.341461", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FUSN", "relevance_score": "0.451494", "ticker_sentiment_score": "0.033041", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.158519", "ticker_sentiment_score": "0.077285", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.382925", "ticker_sentiment_score": "0.227507", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buy These 4 Low-Beta Stocks to Counter Market Volatility", "url": "https://www.zacks.com/stock/news/2211917/buy-these-4-low-beta-stocks-to-counter-market-volatility", "time_published": "20240118T123600", "authors": ["Nilanjan Banerjee"], "summary": "It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/40448.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.235185, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.163909", "ticker_sentiment_score": "0.246955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OSUR", "relevance_score": "0.217346", "ticker_sentiment_score": "0.220313", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.163909", "ticker_sentiment_score": "0.234933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OTTR", "relevance_score": "0.217346", "ticker_sentiment_score": "0.172961", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "89bio Shows Rising Relative Strength; Still Shy Of Key Threshold", "url": "https://www.investors.com/ibd-data-stories/89bio-shows-rising-relative-strength-still-shy-of-key-threshold/", "time_published": "20240118T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "89bio Shows Rising Relative Strength. Still Shy Of Key Threshold Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.367671, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Ultragenyx Pharm Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-ultragenyx-pharm-shows-rising-relative-strength/", "time_published": "20240118T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When building your watch list, look for stocks with an 80 or higher RS Rating. Ultragenyx Pharm ( RARE ) just cleared that benchmark with an upgrade from 75 to 83. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.295746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ironwood Pharm Cl A Reaches 80-Plus Relative Strength Rating Benchmark", "url": "https://www.investors.com/ibd-data-stories/ironwood-pharm-cl-a-reaches-80-plus-relative-strength-rating-benchmark/", "time_published": "20240118T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Ironwood Pharm Cl A ( IRWD ) entered a new percentile Thursday, with an increase from 79 to 86. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.367298, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.16849", "ticker_sentiment_score": "0.151137", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Exelixis  ( EXEL )  Outperforms on Cabometyx and Pipeline Progress", "url": "https://www.zacks.com/stock/news/2211554/exelixis-exel-outperforms-on-cabometyx-and-pipeline-progress", "time_published": "20240117T162900", "authors": ["Zacks Investment Research"], "summary": "Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default16.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.177932, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.108958", "ticker_sentiment_score": "0.065325", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.108958", "ticker_sentiment_score": "0.090499", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.626755", "ticker_sentiment_score": "0.22375", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN ) , Sanofi's Dupixent Gets Label Update in US", "url": "https://www.zacks.com/stock/news/2211552/regeneron-regn-sanofis-dupixent-gets-label-update-in-us", "time_published": "20240117T162100", "authors": ["Zacks Equity Research"], "summary": "The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.156449, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.108222", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.266246", "ticker_sentiment_score": "0.165459", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.266246", "ticker_sentiment_score": "0.12043", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aclaris  ( ACRS )  Stock Rises on Appointment of New Interim CEO", "url": "https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo", "time_published": "20240117T161400", "authors": ["Zacks Equity Research"], "summary": "Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.084847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.392948", "ticker_sentiment_score": "0.032746", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.2215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACRS", "relevance_score": "0.136113", "ticker_sentiment_score": "0.039469", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.331765", "ticker_sentiment_score": "0.197928", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2211296/regeneron-and-petco-health-and-wellness-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20240117T131800", "authors": ["Zacks Equity Research"], "summary": "Chicago, IL - January 17, 2024 - Zacks Equity Research shares Regeneron Pharmaceuticals ( REGN Quick QuoteREGN - ) as the Bull of the Day and Petco Health and Wellness ( WOOF Quick QuoteWOOF - ) as the Bear of the Day.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.129375, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LNVGF", "relevance_score": "0.060236", "ticker_sentiment_score": "0.115003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.149842", "ticker_sentiment_score": "0.080993", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.12013", "ticker_sentiment_score": "0.113842", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.149842", "ticker_sentiment_score": "0.056864", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.060236", "ticker_sentiment_score": "0.051019", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOOF", "relevance_score": "0.208593", "ticker_sentiment_score": "-0.003416", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bull of the Day: Regeneron Pharmaceuticals  ( REGN ) ", "url": "https://www.zacks.com/commentary/2211051/bull-of-the-day-regeneron-pharmaceuticals-regn", "time_published": "20240117T093000", "authors": ["Ethan Feller"], "summary": "The Biotechnology company enjoys a litany of bullish catalysts on the horizon ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default21.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.242725, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.20698", "ticker_sentiment_score": "0.072522", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.20698", "ticker_sentiment_score": "0.231906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.20698", "ticker_sentiment_score": "0.072522", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Price Strength: Apellis Pharmaceuticals", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-apellis-pharmaceuticals-2/", "time_published": "20240117T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Apellis Pharmaceuticals ( APLS ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 84 to 92. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.417093, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.498188", "ticker_sentiment_score": "0.624568", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.136121", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.136121", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Strength: Dynavax Technologies", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-dynavax-technologies-2/", "time_published": "20240117T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Dynavax Technologies ( DVAX ) had its Relative Strength ( RS ) Rating upgraded from 68 to 75 Wednesday -- a welcome improvement, but still short of the 80 or better score you look for. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.436059, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.666827", "ticker_sentiment_score": "0.542556", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.301315", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.15347", "ticker_sentiment_score": "0.14219", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.301315", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Roche's  ( RHHBY )  Tecentriq Subcutaneous Gets Approval in the EU", "url": "https://www.zacks.com/stock/news/2210990/roches-rhhby-tecentriq-subcutaneous-gets-approval-in-the-eu", "time_published": "20240116T172900", "authors": ["Zacks Equity Research"], "summary": "Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default308.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098513, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.130217", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.065327", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.130217", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Add Blueprint  ( BPMC )  Stock to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now", "time_published": "20240116T165100", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160975, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZLAB", "relevance_score": "0.053509", "ticker_sentiment_score": "0.179755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BPMC", "relevance_score": "0.106778", "ticker_sentiment_score": "0.124776", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.31282", "ticker_sentiment_score": "0.029893", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.211652", "ticker_sentiment_score": "0.182292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBYI", "relevance_score": "0.262805", "ticker_sentiment_score": "0.164932", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Basal Cell Carcinoma Treatment Market To Reach $10.7 Billion In 2028 At A CAGR Of More Than 9% As Per The Business Research Company's Basal Cell Carcinoma Treatment Global Market Report 2024", "url": "https://www.benzinga.com/pressreleases/24/01/g36645145/basal-cell-carcinoma-treatment-market-to-reach-10-7-billion-in-2028-at-a-cagr-of-more-than-9-as-pe", "time_published": "20240116T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Basal Cell Carcinoma Treatment Global Market Report 2024, the basal cell carcinoma treatment market is set to witness robust growth, expanding from $6.69 billion in 2023 to an estimated $7.42 billion in 2024, ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.257437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05339", "ticker_sentiment_score": "0.27599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.05339", "ticker_sentiment_score": "0.27599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.05339", "ticker_sentiment_score": "0.27599", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36636996/dupixent-dupilumab-u-s-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-with-mo", "time_published": "20240116T120000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.041162, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.054408", "ticker_sentiment_score": "0.010001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.1301", "ticker_sentiment_score": "0.008547", "ticker_sentiment_label": "Neutral"}]}, {"title": "Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight", "url": "https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html", "time_published": "20240115T220500", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.165054, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCDA", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNYA", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDL", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCPH", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.093561", "ticker_sentiment_score": "0.092837", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBIGF", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "WINT", "relevance_score": "0.070242", "ticker_sentiment_score": "0.050911", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHXQ", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "EWTX", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "TENX", "relevance_score": "0.023441", "ticker_sentiment_score": "0.113992", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vir Biotechnology  ( VIR )  Gains 21.7% in 3 Months: Here's Why", "url": "https://www.zacks.com/stock/news/2210312/vir-biotechnology-vir-gains-217-in-3-months-heres-why", "time_published": "20240115T163200", "authors": ["Zacks Equity Research"], "summary": "After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default0.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.063767, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.121037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.121037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.677751", "ticker_sentiment_score": "0.026165", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Keytruda Ok'd by FDA for Expanded Cervical Cancer Use", "url": "https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-okd-by-fda-for-expanded-cervical-cancer-use", "time_published": "20240115T143000", "authors": ["Zacks Equity Research"], "summary": "FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.116433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FUSN", "relevance_score": "0.316439", "ticker_sentiment_score": "0.023179", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.064973", "ticker_sentiment_score": "0.009134", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.052545", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.193207", "ticker_sentiment_score": "0.045776", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virpax: A Promising Stock In A Sickly Biotech Market", "url": "https://www.forbes.com/sites/lawrencelight/2024/01/14/virpax-a-promising-stock-in-a-sickly-biotech-market/", "time_published": "20240114T130000", "authors": ["Larry Light"], "summary": "Biotech always is a tough line of work, with a high failure rate because the research folks' ideas don't pan out, or even if they do, the Food and Drug Administration fails to approve their applications. Of the three FDA stages needed to greenlight a drug, the first has a mere 9% approval rate.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a2ef10da7904ef829d856a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.073166, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.061949", "ticker_sentiment_score": "0.165124", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRPX", "relevance_score": "0.061949", "ticker_sentiment_score": "-0.125278", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.061949", "ticker_sentiment_score": "-0.145062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cytokinetics  ( CYTK )  Down on Report of Novartis Not Interested", "url": "https://www.zacks.com/stock/news/2209728/cytokinetics-cytk-down-on-report-of-novartis-not-interested", "time_published": "20240112T194700", "authors": ["Zacks Equity Research"], "summary": "Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.166093, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.654522", "ticker_sentiment_score": "0.242155", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.058089", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.04437", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.075161", "ticker_sentiment_score": "0.04437", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.067603", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rebounds As Nvidia Leads; Bitcoin ETFs, Tesla Fall: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-rebounds-nvidia-tesla-jpmorgan-bitcoin-etfs-in-focus/", "time_published": "20240112T191300", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Market Rebounds As Nvidia Leads. Bitcoin ETFs, Tesla Fall: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/Stock-bounce-05-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.99489"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.007321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.068371", "ticker_sentiment_score": "0.028338", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.091075", "ticker_sentiment_score": "0.060214", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.136242", "ticker_sentiment_score": "0.010052", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.068371", "ticker_sentiment_score": "0.189572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.022815", "ticker_sentiment_score": "-0.000921", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.068371", "ticker_sentiment_score": "0.028338", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.045612", "ticker_sentiment_score": "0.128458", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.113705", "ticker_sentiment_score": "0.011467", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.068371", "ticker_sentiment_score": "0.131736", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBH", "relevance_score": "0.068371", "ticker_sentiment_score": "-0.140846", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.022815", "ticker_sentiment_score": "0.001816", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.022815", "ticker_sentiment_score": "-0.111175", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.136242", "ticker_sentiment_score": "-0.148914", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPR", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.045612", "ticker_sentiment_score": "0.027908", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.068371", "ticker_sentiment_score": "0.002016", "ticker_sentiment_label": "Neutral"}, {"ticker": "WT", "relevance_score": "0.022815", "ticker_sentiment_score": "0.120065", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.091075", "ticker_sentiment_score": "0.027513", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXNX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.045612", "ticker_sentiment_score": "0.128458", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.068371", "ticker_sentiment_score": "0.087256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.136242", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.045612", "ticker_sentiment_score": "0.027908", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNPR", "relevance_score": "0.068371", "ticker_sentiment_score": "-0.001011", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEO", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWN", "relevance_score": "0.068371", "ticker_sentiment_score": "0.150164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DAL", "relevance_score": "0.136242", "ticker_sentiment_score": "-0.020069", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GCO", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANF", "relevance_score": "0.068371", "ticker_sentiment_score": "0.131736", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPE", "relevance_score": "0.180967", "ticker_sentiment_score": "-0.001504", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.068371", "ticker_sentiment_score": "0.026257", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.091075", "ticker_sentiment_score": "-0.023423", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.246923", "ticker_sentiment_score": "0.097548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Regeneron Just Hit A Record High - Again", "url": "https://www.investors.com/news/technology/regn-stock-hits-a-record-high-again-as-it-tacks-on-new-wins/", "time_published": "20240112T182200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Hits A Record High - Again - As It Tacks On New Wins Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.259275, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.346108", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.06211", "ticker_sentiment_score": "0.115369", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.06211", "ticker_sentiment_score": "0.337735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.06211", "ticker_sentiment_score": "0.190789", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36611580/regeneron-pharmas-pipeline-makes-this-analyst-turn-bullish", "time_published": "20240112T151810", "authors": ["Priya Nigam"], "summary": "Regeneron Pharmaceuticals Inc REGN won a lawsuit last month against Viatris Inc VTRS over its Eylea patent. While the performance of the company's Dupixent treatment is likely to be strong in the near term, chronic obstructive pulmonary disease ( COPD ) is likely to offer \"a meaningful ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/12/lab.microscope-3184432_1920.image_by_fernando_zhiminaicela_from_pixabay_.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.220436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.85246", "ticker_sentiment_score": "0.321814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.320974", "ticker_sentiment_score": "0.242787", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It", "url": "https://www.investors.com/news/technology/biotech-stocks-forge-a-paradigm-shift-in-immunology-and-big-pharma-pays-handsomely-for-it/", "time_published": "20240112T140000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "There's A Paradigm Shift In Immunology. And Big Pharma Is Paying Richly For It Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-Merck-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.130928, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.023838", "ticker_sentiment_score": "-0.146266", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.047654", "ticker_sentiment_score": "0.208731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROIV", "relevance_score": "0.047654", "ticker_sentiment_score": "-0.00099", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.023838", "ticker_sentiment_score": "-0.000896", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.047654", "ticker_sentiment_score": "-0.155656", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.118764", "ticker_sentiment_score": "-0.008046", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results", "url": "https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results", "time_published": "20240111T152800", "authors": ["Zacks Equity Research"], "summary": "Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.156779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXEL", "relevance_score": "0.220475", "ticker_sentiment_score": "0.057037", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.220475", "ticker_sentiment_score": "0.132471", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.074345", "ticker_sentiment_score": "-0.034075", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.111315", "ticker_sentiment_score": "0.148748", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Invest in Ocuphire Pharma  ( OCUP )  Now", "url": "https://www.zacks.com/stock/news/2208705/heres-why-you-should-invest-in-ocuphire-pharma-ocup-now", "time_published": "20240111T124100", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.17852, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OCUP", "relevance_score": "0.450496", "ticker_sentiment_score": "0.309775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.291644", "ticker_sentiment_score": "0.167218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.34648", "ticker_sentiment_score": "0.18715", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Acadia Healthcare  ( ACHC )  Inks JV to Better Serve Texas Residents", "url": "https://www.zacks.com/stock/news/2208468/acadia-healthcare-achc-inks-jv-to-better-serve-texas-residents", "time_published": "20240110T175600", "authors": ["Zacks Equity Research"], "summary": "Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/3163.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.194333, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMPH", "relevance_score": "0.21258", "ticker_sentiment_score": "0.202196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHC", "relevance_score": "0.654738", "ticker_sentiment_score": "0.298904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.21258", "ticker_sentiment_score": "0.171626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.21258", "ticker_sentiment_score": "0.173239", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.160277", "ticker_sentiment_score": "0.113644", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Regeneron Stock Help You Retire a Millionaire?", "url": "https://www.fool.com/investing/2024/01/10/could-regeneron-stock-help-you-retire-millionaire/", "time_published": "20240110T150700", "authors": ["Prosper Junior Bakiny"], "summary": "The blossoming biotech might give more than a nudge to investors in this project.", "banner_image": "https://media.ycharts.com/charts/efd468ad9fdc12575fb40a3a32d5b2b7.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.343731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.1172", "ticker_sentiment_score": "0.251411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LTRCF", "relevance_score": "0.1172", "ticker_sentiment_score": "0.180431", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.058759", "ticker_sentiment_score": "0.087036", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK to Buy Private Biotech, Strengthen Respiratory Pipeline", "url": "https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline", "time_published": "20240110T122900", "authors": ["Zacks Equity Research"], "summary": "GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.198639, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.170878", "ticker_sentiment_score": "0.082617", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.170878", "ticker_sentiment_score": "0.082617", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.612033", "ticker_sentiment_score": "0.24724", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBYI", "relevance_score": "0.253866", "ticker_sentiment_score": "0.074239", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Down as Q4 Eylea Preliminary Sales Disappoint", "url": "https://www.zacks.com/stock/news/2207560/regeneron-regn-down-as-q4-eylea-preliminary-sales-disappoint", "time_published": "20240109T162400", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.216616, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.089639", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.192694", "ticker_sentiment_score": "0.178837", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bayer  ( BAYRY )  Elinzanetant Meets Goals in Late-Stage Studies", "url": "https://www.zacks.com/stock/news/2207070/bayer-bayry-elinzanetant-meets-goals-in-late-stage-studies", "time_published": "20240108T162600", "authors": ["Zacks Equity Research"], "summary": "Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.146346, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.068331", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.259037", "ticker_sentiment_score": "0.191192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRDA", "relevance_score": "0.195814", "ticker_sentiment_score": "0.068331", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.065866", "ticker_sentiment_score": "0.183478", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016", "url": "https://www.zacks.com/stock/news/2207060/5-stocks-in-sp-500-etf-that-braved-the-worst-start-since-2016", "time_published": "20240108T161000", "authors": ["Sweta Killa"], "summary": "The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default362.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.998947"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.043367, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.147216", "ticker_sentiment_score": "-0.211324", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EG", "relevance_score": "0.147216", "ticker_sentiment_score": "0.09022", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYY", "relevance_score": "0.195419", "ticker_sentiment_score": "0.126045", "ticker_sentiment_label": "Neutral"}, {"ticker": "IP", "relevance_score": "0.195419", "ticker_sentiment_score": "0.113619", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.266286", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.195419", "ticker_sentiment_score": "0.127566", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.098456", "ticker_sentiment_score": "0.085644", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Slumps As Its Biggest Moneymaker Falls Short", "url": "https://www.investors.com/news/technology/regn-stock-slumps-as-us-eylea-sales-disappoint-exel-stock-slammed-on-guidance/", "time_published": "20240108T145100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "REGN Stock Slumps As U.S. Eylea Sales Disappoint, EXEL Stock Slammed On Guidance Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-Regeneron02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.149157, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.615462", "ticker_sentiment_score": "-0.308546", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXEL", "relevance_score": "0.722944", "ticker_sentiment_score": "-0.179488", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.172097", "ticker_sentiment_score": "0.458082", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae  ( cemiplimab )  in Multiple Countries", "url": "https://www.prnewswire.com/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html", "time_published": "20240108T123000", "authors": ["Medison Pharma"], "summary": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae ( cemiplimab ) in ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1527224/MEDISON_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079524", "ticker_sentiment_score": "0.139789", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.039811", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae  ( cemiplimab )  in Multiple Countries", "url": "https://www.prnewswire.com/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028356.html", "time_published": "20240108T123000", "authors": ["Medison Pharma"], "summary": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae ( cemiplimab ) in ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1527224/MEDISON_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079524", "ticker_sentiment_score": "0.139789", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.039811", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae  ( cemiplimab )  in Multiple Countries", "url": "https://www.prnewswire.com/apac/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028440.html", "time_published": "20240108T123000", "authors": ["Medison Pharma"], "summary": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae ( cemiplimab ) in ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1527224/MEDISON_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079524", "ticker_sentiment_score": "0.139789", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.039811", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae  ( cemiplimab )  in Multiple Countries", "url": "https://www.newswire.ca/news-releases/medison-pharma-announces-agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-r-cemiplimab-in-multiple-countries-819240771.html", "time_published": "20240108T123000", "authors": ["Medison Pharma"], "summary": "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae ( cemiplimab ) in ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1527224/MEDISON_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079524", "ticker_sentiment_score": "0.139789", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.039811", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Rating Lowered to Buy at StockNews.com", "url": "https://www.defenseworld.net/2024/01/06/regeneron-pharmaceuticals-nasdaqregn-rating-lowered-to-buy-at-stocknews-com.html", "time_published": "20240106T094845", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Regeneron Pharmaceuticals ( NASDAQ:REGN - Free Report ) from a strong-buy rating to a buy rating in a research report sent to investors on Friday.", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.276884, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.00293", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.00293", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.00293", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.043342", "ticker_sentiment_score": "0.082922", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.722944", "ticker_sentiment_score": "0.385041", "ticker_sentiment_label": "Bullish"}]}, {"title": "Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024", "url": "https://www.globenewswire.com/news-release/2024/01/05/2804868/0/en/Regeneron-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results-and-Host-Conference-Call-and-Webcast-on-February-2-2024.html", "time_published": "20240105T210500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.247838", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36517619/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-con", "time_published": "20240105T210500", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.110515, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.219809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss", "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/", "time_published": "20240105T180100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.130124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.404098", "ticker_sentiment_score": "0.232614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.350564", "ticker_sentiment_score": "0.141762", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.120431", "ticker_sentiment_score": "0.106572", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.060388", "ticker_sentiment_score": "0.337437", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Top 10% Stock Is Playing A Game Of Whiplash", "url": "https://www.investors.com/news/technology/kymr-stock-whiplash-shares-surge-then-topple-after-275-million-offering/", "time_published": "20240105T151600", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "KYMR Stock Whiplash: Shares Surge, Then Topple After $275 Million Offering Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-kymera-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}], "overall_sentiment_score": -0.024361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.524949", "ticker_sentiment_score": "0.247639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.143216", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.16171", "ticker_sentiment_score": "0.092165", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.081276", "ticker_sentiment_score": "-0.145926", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.081276", "ticker_sentiment_score": "0.345837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.143216", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024", "url": "https://www.zacks.com/stock/news/2206307/3-top-biotech-stocks-worth-adding-to-your-portfolio-in-2024", "time_published": "20240105T144900", "authors": ["Ekta Bagri"], "summary": "REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.311849, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.215894", "ticker_sentiment_score": "0.183985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.108958", "ticker_sentiment_score": "0.175182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.108958", "ticker_sentiment_score": "0.175182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.054607", "ticker_sentiment_score": "0.150973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.054607", "ticker_sentiment_score": "0.13707", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/24/01/36510191/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-300-today", "time_published": "20240105T143018", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 3.2% on an annualized basis producing an average annual return of 12.97%. Currently, Regeneron Pharmaceuticals has a market capitalization of $99.38 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Select Medical  ( SEM )  Unveils Separation Plan for Concentra", "url": "https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra", "time_published": "20240104T165500", "authors": ["Zacks Equity Research"], "summary": "Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.181483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EHC", "relevance_score": "0.22335", "ticker_sentiment_score": "0.133041", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEM", "relevance_score": "0.47672", "ticker_sentiment_score": "0.102995", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.329551", "ticker_sentiment_score": "0.219576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.05654", "ticker_sentiment_score": "0.153198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.22335", "ticker_sentiment_score": "0.129675", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza\u00ae \u25bc  ( evinacumab )  for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia  ( HoFH )  - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36488124/ultragenyx-receives-positive-recommendation-from-nice-in-the-u-k-for-evkeeza-evinacumab-for-adoles", "time_published": "20240104T130029", "authors": ["Globe Newswire"], "summary": "NOVATO, Calif., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE today announced that the National Institute for Health and Care Excellence ( NICE ) has issued a final draft guidance recommending Evkeeza\u00ae ( evinacumab ) to NHS England.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.178528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.117486", "ticker_sentiment_score": "0.071766", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.029472", "ticker_sentiment_score": "0.023335", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza\u00ae \u25bc  ( evinacumab )  for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia  ( HoFH ) ", "url": "https://www.globenewswire.com/news-release/2024/01/04/2803980/20739/en/Ultragenyx-Receives-Positive-Recommendation-from-NICE-in-the-U-K-for-Evkeeza-evinacumab-for-Adolescents-and-Adults-Aged-12-Years-and-Older-with-Homozygous-Familial-Hypercholesterol.html", "time_published": "20240104T130000", "authors": ["Ultragenyx Pharmaceutical Inc."], "summary": "NOVATO, Calif., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced that the National Institute for Health and Care Excellence ( NICE ) has issued a final draft guidance recommending Evkeeza\u00ae ( evinacumab ) to NHS England.", "banner_image": "https://ml.globenewswire.com/Resource/Download/121a9bda-7a64-41f8-85e8-1693a2dfa977", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.185752, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.089129", "ticker_sentiment_score": "0.074229", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.029765", "ticker_sentiment_score": "0.025274", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.", "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets", "time_published": "20240104T123000", "authors": ["Globe Newswire"], "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.287429, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.039745", "ticker_sentiment_score": "0.095935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.158", "ticker_sentiment_score": "0.04959", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Momentum Stocks to Buy for January 3rd", "url": "https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd", "time_published": "20240103T150000", "authors": ["Zacks Equity Research"], "summary": "SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/1476.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.178979, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 5 Momentum Picks for January After a Fabulous 2023", "url": "https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023", "time_published": "20240103T131500", "authors": ["Nalak Das"], "summary": "We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c5/37823.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.28589, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.040553", "ticker_sentiment_score": "0.167769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHOP", "relevance_score": "0.16117", "ticker_sentiment_score": "0.310749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.081001", "ticker_sentiment_score": "0.212602", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.040553", "ticker_sentiment_score": "0.204173", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BGNE", "relevance_score": "0.16117", "ticker_sentiment_score": "0.15802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPLK", "relevance_score": "0.239698", "ticker_sentiment_score": "0.34804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CASY", "relevance_score": "0.121241", "ticker_sentiment_score": "0.25721", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.16117", "ticker_sentiment_score": "0.164297", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buy These 4 Low-Beta Stocks to Counter Market Volatility", "url": "https://www.zacks.com/stock/news/2204825/buy-these-4-low-beta-stocks-to-counter-market-volatility", "time_published": "20240103T125000", "authors": ["Nilanjan Banerjee"], "summary": "It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/40448.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.206826, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BZ", "relevance_score": "0.16849", "ticker_sentiment_score": "0.136775", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRN", "relevance_score": "0.16849", "ticker_sentiment_score": "0.302283", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.16849", "ticker_sentiment_score": "0.194426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OTTR", "relevance_score": "0.22335", "ticker_sentiment_score": "0.133565", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea\u00ae  ( aflibercept ) ", "url": "https://www.globenewswire.com/news-release/2024/01/03/2803065/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html", "time_published": "20240103T083000", "authors": ["Alvotech"], "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech's proposed biosimilar to Eylea\u00ae ( aflibercept ) .", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.144288, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "0.553883", "ticker_sentiment_score": "0.229794", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.025325", "ticker_sentiment_score": "0.059221", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.025325", "ticker_sentiment_score": "0.059221", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.025325", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTUS", "relevance_score": "0.025325", "ticker_sentiment_score": "0.059221", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea\u00ae  ( aflibercept ) ", "url": "https://www.globenewswire.com/news-release/2024/01/03/2803066/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html", "time_published": "20240103T083000", "authors": ["Alvotech"], "summary": "The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea\u00ae ( aflibercept ) met its primary endpoint in patients with neovascular ( wet ) Age-related Macular Degeneration ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.141925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "0.551009", "ticker_sentiment_score": "0.2259", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.025166", "ticker_sentiment_score": "0.059158", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.025166", "ticker_sentiment_score": "0.059158", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.025166", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTUS", "relevance_score": "0.025166", "ticker_sentiment_score": "0.059158", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Lower Premarket Today? - Viatris  ( NASDAQ:VTRS ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36408741/regeneron-celebrates-legal-win-court-upholds-eylea-medication-patent", "time_published": "20231228T134657", "authors": ["Vandana Singh"], "summary": "Wednesday, a court ruling that found Viatris Inc's VTRS replica of Regeneron Pharmaceuticals Inc's REGN eye drug, Eylea ( aflibercept ) , violated patent rights. The decision from the U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/28/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.209945, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.359014", "ticker_sentiment_score": "0.051145", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.56296", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/12/28/regeneron-pharmaceuticals-nasdaqregn-upgraded-at-stocknews-com.html", "time_published": "20231228T063048", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report issued on Thursday. REGN has been the topic of several other research reports.", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.293832, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.086713", "ticker_sentiment_score": "0.214498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.043421", "ticker_sentiment_score": "0.072525", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.086713", "ticker_sentiment_score": "0.214498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.043421", "ticker_sentiment_score": "0.072525", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBARF", "relevance_score": "0.086713", "ticker_sentiment_score": "0.214498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.769014", "ticker_sentiment_score": "0.467612", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36400246/how-is-the-market-feeling-about-regeneron-pharmaceuticals", "time_published": "20231227T164519", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has fallen 12.42% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.34% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/12/36366734/unpacking-the-latest-options-trading-trends-in-regeneron-pharmaceuticals", "time_published": "20231222T173219", "authors": ["Benzinga Insights"], "summary": "Benzinga's options scanner has just identified more than 8 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative value of $289,480. Concurrently, our algorithms picked up 4 puts, worth a total of 195,130.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}], "overall_sentiment_score": 0.057119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.686288", "ticker_sentiment_score": "0.079276", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.129634", "ticker_sentiment_label": "Neutral"}]}, {"title": "Where Will Regeneron Pharmaceuticals Be in 1 Year?", "url": "https://www.fool.com/investing/2023/12/22/where-will-regeneron-pharmaceuticals-be-in-1-year/", "time_published": "20231222T144500", "authors": ["David Jagielski"], "summary": "Can the stock continue its market-beating ways?", "banner_image": "https://g.foolcdn.com/editorial/images/758512/a-team-of-scientists-reviewing-results-in-a-lab.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.281756, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.063425", "ticker_sentiment_score": "0.154152", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.12645", "ticker_sentiment_score": "0.167282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.063425", "ticker_sentiment_score": "-0.044099", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/12/36343340/1000-invested-in-regeneron-pharmaceuticals-10-years-ago-would-be-worth-this-much-today", "time_published": "20231221T140019", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 11.69%. Currently, Regeneron Pharmaceuticals has a market capitalization of $91.71 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2023/12/18/2798125/0/en/Regeneron-Announces-Presentation-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20231218T210500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "TARRYTOWN, N.Y., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.320974", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36291426/regeneron-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference", "time_published": "20231218T210500", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.094709, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.299478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anti-Inflammatory Therapeutics Market Analysis 2024-2028: Market Size, Growth Rate, Leading Regions And Segments As Per The Business Research Company's Anti-Inflammatory Therapeutics Global Market Report 2024", "url": "https://www.benzinga.com/pressreleases/23/12/g36286285/anti-inflammatory-therapeutics-market-analysis-2024-2028-market-size-growth-rate-leading-regions-a", "time_published": "20231218T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's anti-inflammatory therapeutics global market report 2024, the anti-inflammatory therapeutics market has experienced consistent growth, evolving from $109.88 billion in 2023 to $114.71 billion in 2024 at a ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.304713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.06211", "ticker_sentiment_score": "0.133417", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.06211", "ticker_sentiment_score": "0.133417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Price Over Earnings Overview: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/12/36284407/price-over-earnings-overview-regeneron-pharmaceuticals", "time_published": "20231218T151535", "authors": ["Benzinga Insights"], "summary": "In the current market session, Regeneron Pharmaceuticals Inc. REGN stock price is at $850.63, after a 0.99% decrease. However, over the past month, the company's stock increased by 6.48%, and in the past year, by 15.96%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.183458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.058809", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Almost 2024: 3 Top Stocks to Buy Before the New Year", "url": "https://www.fool.com/investing/2023/12/17/its-almost-2024-3-top-stocks-to-buy-before-the-new/", "time_published": "20231217T100000", "authors": ["Adria Cimino"], "summary": "You can pick these players up for a great price right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758282%2Fgettyimages-new-year-2024-fireworks.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.326636, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.048133", "ticker_sentiment_score": "0.012947", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.237204", "ticker_sentiment_score": "0.049243", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.237204", "ticker_sentiment_score": "0.332851", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.096091", "ticker_sentiment_score": "0.025951", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.048133", "ticker_sentiment_score": "0.012947", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.048133", "ticker_sentiment_score": "0.158813", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Stocks to Buy Before 2024 That Can Set You Up For Life", "url": "https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/", "time_published": "20231214T140000", "authors": ["David Jagielski"], "summary": "These stocks are still relatively cheap, but don't expect them to stay that way for long.", "banner_image": "https://g.foolcdn.com/editorial/images/757806/a-couple-smiling-and-talking-with-an-advisor.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.377741, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.155118", "ticker_sentiment_score": "0.287652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.155118", "ticker_sentiment_score": "0.233808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCL", "relevance_score": "0.155118", "ticker_sentiment_score": "0.157337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.103778", "ticker_sentiment_score": "0.126438", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.051999", "ticker_sentiment_score": "0.189578", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: What To Do As Rally Runs", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-market-rally-runs-on-fed-rate-cut-shift/", "time_published": "20231214T114200", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Rise As Market Rally Runs On Fed Rate-Cut Shift. What To Do Now Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.014438, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.146202", "ticker_sentiment_score": "0.025365", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.203582", "ticker_sentiment_score": "-0.006401", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.231884", "ticker_sentiment_score": "0.014447", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.259881", "ticker_sentiment_score": "-0.00583", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.203582", "ticker_sentiment_score": "-0.105018", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.088039", "ticker_sentiment_score": "0.122924", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.058759", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.1172", "ticker_sentiment_score": "0.029224", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.029399", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.088039", "ticker_sentiment_score": "0.089746", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.058759", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda", "url": "https://www.prnewswire.com/news-releases/chronic-inflammatory-demyelinating-polyneuropathy-market-to-register-positive-growth-during-the-study-period-20192032-evaluates-delveinsight--key-companies-to-watch-out---octapharma-argenx-immunovant-sciences-sanofi-janss-302013061.html", "time_published": "20231212T220100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period ( 2019 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.07309, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMVT", "relevance_score": "0.078611", "ticker_sentiment_score": "0.003097", "ticker_sentiment_label": "Neutral"}, {"ticker": "CABA", "relevance_score": "0.052455", "ticker_sentiment_score": "0.033781", "ticker_sentiment_label": "Neutral"}, {"ticker": "RLYB", "relevance_score": "0.026241", "ticker_sentiment_score": "0.027812", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.026241", "ticker_sentiment_score": "-0.057694", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNAC", "relevance_score": "0.052455", "ticker_sentiment_score": "0.033781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOAF", "relevance_score": "0.026241", "ticker_sentiment_score": "-0.057694", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.052455", "ticker_sentiment_score": "0.015001", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.052455", "ticker_sentiment_score": "0.033781", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.026241", "ticker_sentiment_score": "0.027812", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCBJF", "relevance_score": "0.026241", "ticker_sentiment_score": "-0.057694", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.026241", "ticker_sentiment_score": "0.027812", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.078611", "ticker_sentiment_score": "0.003095", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development", "url": "https://www.benzinga.com/pressreleases/23/12/g36194201/vanqua-bio-advances-clinical-candidate-for-parkinsons-disease-expands-leadership-team-to-support-f", "time_published": "20231212T123000", "authors": ["Globe Newswire"], "summary": "CHICAGO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase ( GCase ) , will enter clinical development in the first quarter of 2024, with an initial ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.192865, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.047092", "ticker_sentiment_score": "0.088836", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Intellia Therapeutics Become the Next CRISPR Therapeutics?", "url": "https://www.fool.com/investing/2023/12/12/could-intellia-become-the-next-crispr-therapeutics/", "time_published": "20231212T110000", "authors": ["Adria Cimino"], "summary": "Intellia is approaching the finish line.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757864%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.209856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.051663", "ticker_sentiment_score": "0.094949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.051663", "ticker_sentiment_score": "0.094949", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.254042", "ticker_sentiment_score": "0.130543", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36176742/regn-analyzing-regeneron-pharmaceuticalss-short-interest", "time_published": "20231211T141522", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 6.99% since its last report. The company recently reported that it has 1.40 million shares sold short, which is 1.53% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year", "url": "https://www.globenewswire.com/news-release/2023/12/11/2793753/0/en/Regeneron-Named-on-Dow-Jones-Sustainability-World-Index-for-Fifth-Consecutive-Year.html", "time_published": "20231211T123000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced its inclusion on the Dow Jones Sustainability World Index ( DJSI World ) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.363736, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.174167", "ticker_sentiment_score": "0.14098", "ticker_sentiment_label": "Neutral"}]}, {"title": "Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes", "url": "https://www.globenewswire.com/news-release/2023/12/11/2793480/0/en/Latest-Odronextamab-Data-in-Relapsed-Refractory-Follicular-Lymphoma-Showed-Compelling-Responses-and-Overall-Maintenance-of-Patient-Reported-Outcomes.html", "time_published": "20231211T003000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response ( CR ) , with a 23-month median duration of response and 24-month median duration of CR ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.104358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.084068", "ticker_sentiment_score": "0.05084", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.016844", "ticker_sentiment_score": "0.048448", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes", "url": "https://www.globenewswire.com/news-release/2023/12/10/2793465/0/en/Updated-Odronextamab-Data-from-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-Pivotal-Trial-Showed-Deep-and-Durable-Responses-and-the-Potential-of-ctDNA-To-Predict-Long-term-Out.html", "time_published": "20231210T173000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate ( ORR ) , with 31% achieving a complete response ( CR ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.076065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.081441", "ticker_sentiment_score": "0.044342", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.016316", "ticker_sentiment_score": "0.048273", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Posts Positive Data on Blood Cancer Candidate", "url": "https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate", "time_published": "20231208T170700", "authors": ["Zacks Equity Research"], "summary": "Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.130541, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.158173", "ticker_sentiment_score": "0.180437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRDA", "relevance_score": "0.158173", "ticker_sentiment_score": "0.06536", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.209819", "ticker_sentiment_score": "0.078045", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/12/08/could-regeneron-stock-help-you-become-a/", "time_published": "20231208T124500", "authors": ["David Jagielski"], "summary": "Regeneron has been an excellent investment in recent years. Can that trend continue?", "banner_image": "https://g.foolcdn.com/editorial/images/756929/rich-couple-on-a-boat.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.280712, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.112532", "ticker_sentiment_score": "0.253139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.056407", "ticker_sentiment_score": "0.156951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.056407", "ticker_sentiment_score": "0.156951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.112532", "ticker_sentiment_score": "0.067261", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36130463/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and-depth-of-response-in-patients-wit", "time_published": "20231207T120045", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Dec. 07, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the primary endpoint analysis from the pivotal trial ( LINKER-MM1 ) investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014386, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.090702", "ticker_sentiment_score": "0.021905", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma", "url": "https://www.globenewswire.com/news-release/2023/12/07/2792394/0/en/Updated-Linvoseltamab-Pivotal-Data-Demonstrated-Strong-Rates-and-Depth-of-Response-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma.html", "time_published": "20231207T120000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "71% objective response rate, with 46% achieving a complete response or better after 11 months of median ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.059712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.074287", "ticker_sentiment_score": "0.050778", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.018597", "ticker_sentiment_score": "0.049944", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO", "url": "https://www.globenewswire.com/news-release/2023/12/07/2792241/0/en/Regeneron-to-Share-Progress-of-Novel-Combination-Therapies-in-Oncology-at-ESMO-IO.html", "time_published": "20231207T073000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "First dose-escalation results for REGN5668 ( MUC16xCD28 ) , a costimulatory bispecific, in combination with Libtayo\u00ae ( cemiplimab ) showed encouraging initial activity in patients with recurrent ovarian cancer ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.096838, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.057545", "ticker_sentiment_score": "0.014011", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.011519", "ticker_sentiment_score": "0.038884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise", "url": "https://www.investors.com/news/regeneron-pharmaceuticals-sees-relative-strength-rating-rise-to-71/", "time_published": "20231206T204500", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY", "GLENN LARKIN"], "summary": "Regeneron Pharmaceuticals ( REGN ) had its Relative Strength ( RS ) Rating upgraded from 68 to 71 before the market opened Wednesday -- a welcome improvement, but still short of the 80 or better score you prefer to see. Was this the cause of the small gap up at the open?", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.370791, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.669956", "ticker_sentiment_score": "0.49969", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers", "url": "https://www.globenewswire.com/news-release/2023/12/05/2790782/0/en/Replimune-Shares-Initial-Primary-Analysis-Results-from-CERPASS-Clinical-Trial-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma-and-Presents-New-Data-from-IGNYTE-Clinical-Trial-of-RP1-.html", "time_published": "20231205T120000", "authors": ["Replimune Group Inc"], "summary": "RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": -0.01217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.016691", "ticker_sentiment_score": "0.163105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.083309", "ticker_sentiment_score": "0.023136", "ticker_sentiment_label": "Neutral"}]}, {"title": "You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.", "url": "https://www.fool.com/investing/2023/12/04/you-dont-have-to-pick-a-winner-in-gene-editing-do/", "time_published": "20231204T133000", "authors": ["George Budwell"], "summary": "The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756902%2Fgrowth-trend.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.250693, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.068698", "ticker_sentiment_score": "0.27273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.136888", "ticker_sentiment_score": "0.32749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRBU", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.068698", "ticker_sentiment_score": "0.140565", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Important History Lesson for Gene-Editing Investors", "url": "https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/", "time_published": "20231202T133000", "authors": ["George Budwell"], "summary": "Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756820%2Fbiotech-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.127419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.040691", "ticker_sentiment_score": "-0.095989", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.081276", "ticker_sentiment_score": "0.096784", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.12165", "ticker_sentiment_score": "0.115922", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.040691", "ticker_sentiment_score": "0.050122", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040691", "ticker_sentiment_score": "0.094399", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.040691", "ticker_sentiment_score": "0.050122", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.003598", "ticker_sentiment_label": "Neutral"}]}, {"title": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/laryngeal-cancer-therapeutics-market-size-to-grow-by-usd-575-25-million-from-2022-2027-accord-healthcare-ltd-amgen-inc-astrazeneca-plc-athenex-inc-and-more-among-the-major-companies-in-the-market--technavio-302002789.html", "time_published": "20231201T223500", "authors": [], "summary": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054932, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLDX", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.053456", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNXQ", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANL", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/12/36047567/1000-invested-in-regeneron-pharmaceuticals-15-years-ago-would-be-worth-this-much-today", "time_published": "20231201T170021", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.44% on an annualized basis producing an average annual return of 29.82%. Currently, Regeneron Pharmaceuticals has a market capitalization of $89.41 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2191965/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20231201T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.284941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061315", "ticker_sentiment_score": "0.071003", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotech Stocks To Watch Before December 2023", "url": "https://stockmarket.com/featured/3-biotech-stocks-to-watch-before-december-2023-2023-11-27", "time_published": "20231127T153843", "authors": ["Jonathan Phillip"], "summary": "The biotechnology sector is a dynamic and innovative field that combines biological sciences with technology. It encompasses a range of companies focusing on medical research, pharmaceuticals, and genetic engineering. These companies work on groundbreaking treatments, vaccines, and technologies.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/07/REGN-Stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999896"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999987"}], "overall_sentiment_score": 0.14494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.296582", "ticker_sentiment_score": "-0.017807", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.296582", "ticker_sentiment_score": "-0.075704", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.296582", "ticker_sentiment_score": "0.136713", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN ) , Sanofi's Dupixent Succeeds in 2nd COPD Study", "url": "https://www.zacks.com/stock/news/2189807/regeneron-regn-sanofis-dupixent-succeeds-in-2nd-copd-study", "time_published": "20231127T153500", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.211496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.181137", "ticker_sentiment_score": "0.208896", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.181137", "ticker_sentiment_score": "0.149449", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.297301", "ticker_sentiment_score": "0.24614", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Plots A Major Expansion That Could Add $4 Billion In Sales", "url": "https://www.investors.com/news/technology/regn-stock-rises-as-it-plans-a-major-expansion-for-blockbuster-dupixent/", "time_published": "20231127T152900", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Rises As It Plans A Major Expansion For Blockbuster ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.105605, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.355588", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.409742", "ticker_sentiment_score": "-0.053802", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35955998/sanofiregenerons-blockbuster-prescription-drug-dupixent-shows-additional-promise-in-chronic-lung-", "time_published": "20231127T141724", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY announced the second Dupixent ( dupilumab ) Phase 3 chronic obstructive pulmonary disease ( COPD ) trial ( NOTUS ) showed that Dupixent significantly reduced exacerbations.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/27/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.049627, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.367865", "ticker_sentiment_score": "0.010215", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.575055", "ticker_sentiment_score": "0.1622", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease", "url": "https://www.globenewswire.com/news-release/2023/11/27/2785840/0/en/Dupixent-dupilumab-Significantly-Reduced-COPD-Exacerbations-in-Second-Positive-Phase-3-Trial-Accelerating-FDA-Submission-and-Confirming-Potential-to-Become-First-Approved-Biologic-.html", "time_published": "20231127T063000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation ( i.e., blood eosinophils \u2265300 cells per \u03bcL ) , confirming results from ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.031477, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.03458", "ticker_sentiment_score": "0.051254", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.112048", "ticker_sentiment_score": "0.027358", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease", "url": "https://www.globenewswire.com/news-release/2023/11/27/2785836/0/en/Press-Release-Dupixent-significantly-reduced-COPD-exacerbations-in-second-positive-Phase-3-trial-accelerating-FDA-submission-and-confirming-potential-to-become-first-approved-biolo.html", "time_published": "20231127T063000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.043442, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.023418", "ticker_sentiment_score": "0.041381", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.139804", "ticker_sentiment_score": "0.03173", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease", "url": "https://www.benzinga.com/pressreleases/23/11/g35953326/press-release-dupixent-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial-a", "time_published": "20231127T063000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.038492, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.022881", "ticker_sentiment_score": "0.039327", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.170315", "ticker_sentiment_score": "0.047297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals  ( KNSA )  Up 14.7% YTD: Here's How", "url": "https://www.zacks.com/stock/news/2189297/kiniksa-pharmaceuticals-knsa-up-147-ytd-heres-how", "time_published": "20231124T190500", "authors": ["Zacks Equity Research"], "summary": "Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.17701, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.278222", "ticker_sentiment_score": "0.144661", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.14131", "ticker_sentiment_score": "0.382264", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGND", "relevance_score": "0.278222", "ticker_sentiment_score": "0.160682", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.14131", "ticker_sentiment_score": "0.179405", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  Stock Rallies 10% YTD: What Lies Ahead?", "url": "https://www.zacks.com/stock/news/2189105/regeneron-regn-stock-rallies-10-ytd-what-lies-ahead", "time_published": "20231124T162900", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.269371, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.184363", "ticker_sentiment_score": "0.142608", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.244109", "ticker_sentiment_score": "0.201738", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.184363", "ticker_sentiment_score": "0.173186", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight", "url": "https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html", "time_published": "20231122T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129719, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.013173", "ticker_sentiment_score": "0.120239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "INO", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNSP", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.026343", "ticker_sentiment_score": "0.037824", "ticker_sentiment_label": "Neutral"}, {"ticker": "KZIA", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.039505", "ticker_sentiment_score": "0.102193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052656", "ticker_sentiment_score": "0.017928", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMRX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "VBIV", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039505", "ticker_sentiment_score": "0.022299", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNAC", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "KTRA", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.039505", "ticker_sentiment_score": "-0.000967", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is CRISPR Therapeutics the Best Gene-Editing Stock?", "url": "https://www.fool.com/investing/2023/11/22/is-crispr-therapeutics-the-best-gene-editing-stock/", "time_published": "20231122T123000", "authors": ["George Budwell"], "summary": "The biotech's first-mover advantage bodes well for its long-term prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755786%2Fresearcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.262065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.075043", "ticker_sentiment_score": "-0.004045", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.037563", "ticker_sentiment_score": "0.176057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRME", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2186419/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20231120T112007", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.159934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068112", "ticker_sentiment_score": "0.034069", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}]}, {"title": "You Don't Have to Pick a Winner in Biotech. Here's Why.", "url": "https://www.fool.com/investing/2023/11/18/you-dont-have-to-pick-biotech-winner-heres-why/", "time_published": "20231118T100000", "authors": ["Adria Cimino"], "summary": "If you invest over the long term, you'll increase your chances of victory.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755345%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999981"}], "overall_sentiment_score": 0.339494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.056943", "ticker_sentiment_score": "0.093937", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.093937", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.015155", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/11/35852568/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-200-today", "time_published": "20231117T170021", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 7.81% on an annualized basis producing an average annual return of 19.06%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.89 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35831982/how-is-the-market-feeling-about-regeneron-pharmaceuticals", "time_published": "20231116T163022", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has fallen 4.67% since its last report. The company recently reported that it has 1.31 million shares sold short, which is 1.43% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia  ( NTLA )  Rises on EC's Orphan Drug Tag for HAE Candidate", "url": "https://www.zacks.com/stock/news/2184720/intellia-ntla-rises-on-ecs-orphan-drug-tag-for-hae-candidate", "time_published": "20231115T160700", "authors": ["Zacks Equity Research"], "summary": "The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.156889, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.380978", "ticker_sentiment_score": "0.20054", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.380978", "ticker_sentiment_score": "0.261568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.196344", "ticker_sentiment_score": "0.43873", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.718675", "ticker_sentiment_score": "0.374365", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - XBiotech  ( NASDAQ:XBIT ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35776284/dr-alan-kivitz-to-chair-xbiotechs-natrunix-program-in-rheumatoid-arthritis", "time_published": "20231114T140000", "authors": ["Globe Newswire"], "summary": "AUSTIN, Texas, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- XBiotech XBIT today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019213, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.039614", "ticker_sentiment_score": "0.037048", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.039614", "ticker_sentiment_score": "0.037048", "ticker_sentiment_label": "Neutral"}, {"ticker": "XBIT", "relevance_score": "0.271921", "ticker_sentiment_score": "0.151912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.039614", "ticker_sentiment_score": "0.037048", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.039614", "ticker_sentiment_score": "0.037048", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.039614", "ticker_sentiment_score": "0.037048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia  ( NTLA )  Beats on Q3 Earnings, Provides Pipeline Update", "url": "https://www.zacks.com/stock/news/2182117/intellia-ntla-beats-on-q3-earnings-provides-pipeline-update", "time_published": "20231110T113000", "authors": ["Zacks Equity Research"], "summary": "Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.078529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.228073", "ticker_sentiment_score": "-0.062971", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIX", "relevance_score": "0.33628", "ticker_sentiment_score": "0.041347", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.172097", "ticker_sentiment_score": "0.388276", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.782008", "ticker_sentiment_score": "0.263106", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why This Potential Regeneron Rival Just Rocketed 14%", "url": "https://www.investors.com/news/technology/cldx-stock-rockets-as-it-looks-to-take-on-a-regeneron-sanofi-blockbuster/", "time_published": "20231106T173100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "CLDX Stock Rockets As It Looks To Take On A Regeneron, Sanofi ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-celldex-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.060389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLDX", "relevance_score": "0.595343", "ticker_sentiment_score": "0.035874", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.165031", "ticker_sentiment_score": "-0.1226", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.165031", "ticker_sentiment_score": "0.050198", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.165031", "ticker_sentiment_score": "-0.034312", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/11/06/2773898/0/en/BioNTech-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update.html", "time_published": "20231106T114500", "authors": ["BioNTech SE"], "summary": "Conference call and webcast scheduled for November 6, 2023, at 8:00 am ET ( 2:00 pm ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9e2e00e-f790-4d54-a01f-4c85716b01bd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.166712, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOSUF", "relevance_score": "0.007918", "ticker_sentiment_score": "0.0167", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.031664", "ticker_sentiment_score": "0.088908", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.007918", "ticker_sentiment_score": "0.0167", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.007918", "ticker_sentiment_score": "0.004095", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.102651", "ticker_sentiment_score": "0.068473", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.279104", "ticker_sentiment_score": "0.184834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.007918", "ticker_sentiment_score": "0.0167", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35597373/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind-analyst-review", "time_published": "20231103T193225", "authors": ["Vandana Singh"], "summary": "Thursday, Regeneron Pharmaceuticals Inc REGN reported better-than-expected Q3 earnings. Piper Sandler notes that the most significant short-term driver for Regeneron is the impending interim analysis of the Phase 3 NOTUS study in chronic obstructive pulmonary disorder, scheduled for Q4 2023.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.293289, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.592095", "ticker_sentiment_score": "0.535528", "ticker_sentiment_label": "Bullish"}]}, {"title": "Market Rally Back In Force As Yields Plunge: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/", "time_published": "20231103T165559", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-bullfightingbear-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.004916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.070882", "ticker_sentiment_score": "0.015254", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.061816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.040029", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.053192", "ticker_sentiment_score": "0.124905", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044243", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.352867", "ticker_sentiment_label": "Bearish"}, {"ticker": "ALGM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.040517", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.158635", "ticker_sentiment_score": "-0.062061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044087", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.088537", "ticker_sentiment_score": "0.057142", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.028361", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMC", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.017742", "ticker_sentiment_score": "0.107", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.088537", "ticker_sentiment_score": "-0.014717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.024925", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.0443", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RELY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.006008", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.035476", "ticker_sentiment_score": "0.147308", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.053192", "ticker_sentiment_score": "0.167262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.15563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.001911", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBOE", "relevance_score": "0.035476", "ticker_sentiment_score": "0.13248", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCJ", "relevance_score": "0.088537", "ticker_sentiment_score": "0.001072", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.019707", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETSY", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.020024", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "TM", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx  ( RARE )  Q3 Earnings and Revenues Miss Estimates", "url": "https://www.zacks.com/stock/news/2178339/ultragenyx-rare-q3-earnings-and-revenues-miss-estimates", "time_published": "20231103T154300", "authors": ["Zacks Equity Research"], "summary": "Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.090125, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RPRX", "relevance_score": "0.042723", "ticker_sentiment_score": "0.083371", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.44433", "ticker_sentiment_score": "0.183116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLS", "relevance_score": "0.169676", "ticker_sentiment_score": "-0.011616", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.085324", "ticker_sentiment_score": "0.064749", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.169676", "ticker_sentiment_score": "0.133903", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.127682", "ticker_sentiment_score": "0.153951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KYKOF", "relevance_score": "0.042723", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35587285/regeneron-to-highlight-scientific-advancements-across-diversified-pipeline-in-difficult-to-treat-b", "time_published": "20231103T110014", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Nov. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104477, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.08687", "ticker_sentiment_score": "0.014546", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.172713", "ticker_sentiment_score": "0.048539", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.043499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH", "url": "https://www.globenewswire.com/news-release/2023/11/03/2773090/0/en/Regeneron-to-Highlight-Scientific-Advancements-Across-Diversified-Pipeline-in-Difficult-to-Treat-Blood-Cancers-and-Disorders-at-ASH.html", "time_published": "20231103T110000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.12075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.08687", "ticker_sentiment_score": "0.053108", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.08687", "ticker_sentiment_score": "0.051057", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.021758", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.021758", "ticker_sentiment_score": "0.049888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35569003/regenerons-skin-drugs-propel-revenue-in-q3-witnesses-strong-demand-for-higher-dose-version-of-fla", "time_published": "20231102T175354", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate. Revenues increased 15% Y/Y to $3.36 billion, beating the consensus of $3.235 billion. Dupixent global net sales ( recorded by Sanofi ) increased 33% to $3.10 billion versus the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/02/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.155876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.340915", "ticker_sentiment_score": "-0.059022", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.116914", "ticker_sentiment_score": "-0.050231", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.116914", "ticker_sentiment_score": "0.11655", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Q3 Earnings & Sales Top, Eylea Sales Decline", "url": "https://www.zacks.com/stock/news/2177618/regeneron-regn-q3-earnings-sales-top-eylea-sales-decline", "time_published": "20231102T163100", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.256047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.233108", "ticker_sentiment_score": "0.283905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.047278", "ticker_sentiment_score": "0.12557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.277958", "ticker_sentiment_score": "0.270466", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron sees strong initial demand for higher-dose Eylea", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-beats-quarterly-profit-estimates-eczema-treatment-strength-2023-11-02/", "time_published": "20231102T155900", "authors": ["Sriparna Roy"], "summary": "Regeneron sees strong initial demand for ...", "banner_image": "https://graphics.reuters.com/REGENERON-RESULTS/mypmgwyzdpr/chart.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.168794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.24289", "ticker_sentiment_score": "0.100748", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.122894", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.122894", "ticker_sentiment_score": "0.186521", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron's High-Dose Eylea Is Off To A Strong Start", "url": "https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q3-2023/", "time_published": "20231102T133836", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Regeneron Stock Edges Higher As High-Dose Eylea Delivers A ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.240187, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.744196", "ticker_sentiment_score": "0.54515", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings - Roku  ( NASDAQ:ROKU ) , Wendy's  ( NASDAQ:WEN ) , Paramount Global  ( NASDAQ:PARA ) , Peloton Interactive  ( NASDAQ:PTON ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35559421/us-stocks-on-track-for-solid-start-amid-lingering-fed-optimism-traders-eye-earnings-from-market-bel", "time_published": "20231102T111924", "authors": ["Shanthi Rexaline"], "summary": "After the Federal Reserve's decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. Positive earnings reports may bolster this rally, and the decline in bond yields, driven by rising rate-cut expectations, could be viewed favorably by ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/nyse_shutter_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.162501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.132611", "ticker_sentiment_score": "0.091357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.044386", "ticker_sentiment_score": "0.152804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMND", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWKS", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.044386", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.088635", "ticker_sentiment_score": "0.184545", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years", "url": "https://www.fool.com/investing/2023/11/02/1-supercharged-growth-stock-that-could-make-you-a/", "time_published": "20231102T104500", "authors": ["George Budwell"], "summary": "Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753225%2Fgrowth-trend.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.321361, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.193207", "ticker_sentiment_score": "0.299801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.129516", "ticker_sentiment_score": "-0.007223", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.193207", "ticker_sentiment_score": "0.204048", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Reports Third Quarter 2023 Financial and Operating Results", "url": "https://www.globenewswire.com/news-release/2023/11/02/2772055/0/en/Regeneron-Reports-Third-Quarter-2023-Financial-and-Operating-Results.html", "time_published": "20231102T103000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Nov. 02, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the third quarter of 2023 and provided a business update.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.188923, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.011687", "ticker_sentiment_score": "0.070813", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.011687", "ticker_sentiment_score": "0.066545", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.011687", "ticker_sentiment_score": "0.066545", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.046724", "ticker_sentiment_score": "0.048704", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.023372", "ticker_sentiment_score": "0.084862", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.011687", "ticker_sentiment_score": "0.070813", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.058387", "ticker_sentiment_score": "0.072018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rally Gains Steam As Powell Signals No More Rate Hikes", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-gains-steam-as-fed-chief-powell-signals-no-more-rate-hikes/", "time_published": "20231101T205533", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones futures were little changed hours, along with S&P 500 futures and Nasdaq futures, after Fed chief Jerome Powell signaled the rates will stay on hold into next year. Roku ( ROKU ) and MercadoLibre were among a slew of earnings Wednesday night, with Palantir Technologies ( PLTR ) , Eli ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-Jerome-Powell-03-fed.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.142972, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.107135", "ticker_sentiment_score": "0.099701", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.107135", "ticker_sentiment_score": "0.012043", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.107135", "ticker_sentiment_score": "-0.028084", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.107135", "ticker_sentiment_score": "0.01197", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.02686", "ticker_sentiment_score": "0.172995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.263657", "ticker_sentiment_score": "0.132174", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.080458", "ticker_sentiment_score": "0.056724", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.107135", "ticker_sentiment_score": "0.071799", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.02686", "ticker_sentiment_score": "0.215006", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.160099", "ticker_sentiment_score": "-0.041109", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.133692", "ticker_sentiment_score": "0.008339", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.053689", "ticker_sentiment_score": "-0.079734", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.107135", "ticker_sentiment_score": "0.053395", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.053689", "ticker_sentiment_score": "-0.079734", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.080458", "ticker_sentiment_score": "-0.027407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/11/35548168/regeneron-pharmaceuticals-unusual-options-activity", "time_published": "20231101T200105", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.132526, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.765728", "ticker_sentiment_score": "-0.023605", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.105141", "ticker_sentiment_score": "-0.131764", "ticker_sentiment_label": "Neutral"}]}, {"title": "EYLEA\u00ae HD  ( aflibercept )  Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35548096/eylea-hd-aflibercept-injection-8-mg-data-presentations-at-aao-reinforce-efficacy-and-safety-profil", "time_published": "20231101T200000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced long-term outcomes and new analyses of pivotal clinical data for EYLEA\u00ae HD ( aflibercept ) Injection 8 mg will be presented at the American Academy of Ophthalmology ( AAO ) annual meeting in ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.081358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079026", "ticker_sentiment_score": "0.043043", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.01583", "ticker_sentiment_score": "0.106134", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01583", "ticker_sentiment_score": "0.040179", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: Regeneron Pharmaceuticals  ( REGN )  Earnings Analysis -- Should Investors Brace for Impact?", "url": "https://stocknews.com/news/regn-otsky-gild-jazz-regeneron-pharmaceuticals-regn-earnings-analysis-should-investors-brace-for/", "time_published": "20231101T180255", "authors": ["StockNews.com Staff"], "summary": "REGN: Regeneron Pharmaceuticals ( REGN ) Earnings Analysis ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/04/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999612"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.214468, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.52395", "ticker_sentiment_score": "0.248758", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.054114", "ticker_sentiment_score": "0.172807", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.172807", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/10/35520855/100-invested-in-regeneron-pharmaceuticals-15-years-ago-would-be-worth-this-much-today", "time_published": "20231031T173015", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.12% on an annualized basis producing an average annual return of 28.39%. Currently, Regeneron Pharmaceuticals has a market capitalization of $84.49 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-third-quarter-financial-results/", "time_published": "20231031T113917", "authors": ["Investing News Network"], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 2023 1 . References in this release to \"non-GAAP\" measures, measures presented \"on a non-GAAP basis\" and \"free cash flow\" ( computed by subtracting capital expenditures from operating cash flow ) refer to ...", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.128468, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.01615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDYA", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.01615", "ticker_sentiment_score": "0.193788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution", "url": "https://www.globenewswire.com/news-release/2023/10/31/2770046/0/en/Kiniksa-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html", "time_published": "20231031T113000", "authors": ["Kiniksa Pharmaceuticals", "Ltd."], "summary": "- ARCALYST\u00ae ( rilonacept ) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d9c74849-9de0-4f1f-807c-990609944292", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999767"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.057522, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.020335", "ticker_sentiment_score": "-0.167092", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KNSA", "relevance_score": "0.040656", "ticker_sentiment_score": "0.04054", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS", "url": "https://www.prnewswire.com/news-releases/amgen-reports-third-quarter-financial-results-301972231.html", "time_published": "20231031T110000", "authors": ["Amgen"], "summary": "THOUSAND OAKS, Calif., Oct. 31, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 20231.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.128413, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.016053", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.016053", "ticker_sentiment_score": "0.193681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.016053", "ticker_sentiment_score": "0.021825", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.016053", "ticker_sentiment_score": "0.021825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.016053", "ticker_sentiment_score": "0.021825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.016053", "ticker_sentiment_score": "0.021825", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient", "url": "https://www.fool.com/investing/2023/10/30/gene-therapy-could-be-on-the-cusp-of-major-breakth/", "time_published": "20231030T123000", "authors": ["George Budwell"], "summary": "This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752824%2Fpharma-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.12974, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.051999", "ticker_sentiment_score": "0.013965", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.155118", "ticker_sentiment_score": "0.002808", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week - Lattice Semiconductor  ( NASDAQ:LSCC ) , Exact Sciences  ( NASDAQ:EXAS ) , Amgen  ( NASDAQ:AMGN ) , STMicroelectronics  ( NYSE:STM ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35484208/apple-amd-palantir-earnings-on-deck-this-week-as-market-seeks-positive-catalysts-in", "time_published": "20231030T074015", "authors": ["Shanthi Rexaline"], "summary": "The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, data suggests S&P 500 companies may be on track to break a fourth-quarter earnings-declining streak.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Phongphan_on_Shutterstock_16.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.155659, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSTR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTH", "relevance_score": "0.0864", "ticker_sentiment_score": "0.195087", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.0864", "ticker_sentiment_score": "0.026184", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHKP", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNO", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.129284", "ticker_sentiment_score": "-0.016206", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.195087", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EA", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.0864", "ticker_sentiment_score": "-0.10532", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.195087", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.0864", "ticker_sentiment_score": "0.185074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EAT", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOFI", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEN", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.0864", "ticker_sentiment_score": "0.185074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "D", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRO", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRGRF", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.0864", "ticker_sentiment_score": "0.284455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BUD", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.0864", "ticker_sentiment_score": "0.284455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NCLH", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.129284", "ticker_sentiment_score": "0.104299", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPWR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.0864", "ticker_sentiment_score": "-0.10532", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWKS", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.0864", "ticker_sentiment_score": "0.284455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WOLF", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.0864", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.0864", "ticker_sentiment_score": "0.284455", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More - Target  ( NYSE:TGT ) , CVS Health  ( NYSE:CVS ) , Rite Aid  ( OTC:RADCQ ) , Novartis  ( NYSE:NVS ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35478496/are-your-eyes-at-grave-risk-fda-issues-dangerous-warning-over-popular-drops-from-cvs-target-card", "time_published": "20231028T164912", "authors": ["Nabaparna Bhattacharya"], "summary": "The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multiple specific over-the-counter eye drop products from prominent brands.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/28/shutterstock_414875569.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.04359, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.082023", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.352557", "ticker_sentiment_score": "-0.063876", "ticker_sentiment_label": "Neutral"}, {"ticker": "RADCQ", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.082023", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALC", "relevance_score": "0.072876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.072876", "ticker_sentiment_score": "0.112837", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.145145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.132958", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.145145", "ticker_sentiment_score": "0.139517", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.145145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.216215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?", "url": "https://www.fool.com/investing/2023/10/28/intellia-therapeutics-will-soon-make-biotech-histo/", "time_published": "20231028T113000", "authors": ["Alex Carchidi"], "summary": "There's more to being a good investment than doing groundbreaking science.", "banner_image": "https://g.foolcdn.com/editorial/images/752228/scientist-configures-tilting-machine.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.146889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.045054", "ticker_sentiment_score": "0.061769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045054", "ticker_sentiment_score": "0.040691", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.465709", "ticker_sentiment_score": "0.253353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2173690/regeneron-regn-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231027T123700", "authors": ["Zacks Equity Research"], "summary": "Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.185872, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.120632", "ticker_sentiment_score": "-0.00229", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.120632", "ticker_sentiment_score": "0.098521", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.27676", "ticker_sentiment_score": "0.246419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.040348", "ticker_sentiment_score": "0.016915", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.040348", "ticker_sentiment_score": "0.036471", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.27676", "ticker_sentiment_score": "0.225294", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35450111/regeneron-shares-preliminary-results-showing-gene-therapy-improves-auditory-responses-in-child-wit", "time_published": "20231026T200007", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced preliminary, positive safety and efficacy results from the first patient ( <2 years of age ) dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy ( DB-OTO ) in children ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095938, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.115416", "ticker_sentiment_score": "0.090525", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.070809", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia  ( NTLA )  Focuses on Developing Gene-Editing Therapies", "url": "https://www.zacks.com/stock/news/2170217/intellia-ntla-focuses-on-developing-gene-editing-therapies", "time_published": "20231023T134000", "authors": ["Zacks Equity Research"], "summary": "Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.261376, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.237358", "ticker_sentiment_score": "0.478488", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.159569", "ticker_sentiment_score": "0.053858", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.868974", "ticker_sentiment_score": "0.436411", "ticker_sentiment_label": "Bullish"}]}, {"title": "Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE", "url": "https://markets.businessinsider.com/news/stocks/regeneron-dupixent-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-with-eoe-1032726139", "time_published": "20231023T022012", "authors": ["markets.businessinsider.com"], "summary": "Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.046408, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.499789", "ticker_sentiment_score": "0.498711", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.263942", "ticker_sentiment_score": "0.329424", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ", "url": "https://www.globenewswire.com/news-release/2023/10/22/2764338/0/en/Press-Release-Dupixent-dupilumab-Phase-3-Results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-EoE.html", "time_published": "20231022T190000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.027571", "ticker_sentiment_score": "0.041305", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.109956", "ticker_sentiment_score": "-0.003392", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35365800/press-release-dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-chi", "time_published": "20231022T190000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ( EoE ) Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.002412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.026518", "ticker_sentiment_score": "0.039154", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.145065", "ticker_sentiment_score": "-0.003879", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ", "url": "https://markets.businessinsider.com/news/stocks/press-release-dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726107", "time_published": "20231022T190000", "authors": ["markets.businessinsider.com"], "summary": "Press Release: Dupixent\u00ae (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ...", "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=MTAwMDg4NTI2NCM0MDE2NTU3NTEjMTAxMTExMA==", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.026444", "ticker_sentiment_score": "0.039139", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.157655", "ticker_sentiment_score": "0.009544", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis  ( EoE ) ", "url": "https://markets.businessinsider.com/news/stocks/dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726106", "time_published": "20231022T185900", "authors": ["markets.businessinsider.com"], "summary": "Dupixent\u00ae (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis ...", "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=ODk2MzU1NCM1ODg0ODA2IzIwMDYyNTA=", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.050724, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.048839", "ticker_sentiment_score": "0.04288", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.10719", "ticker_sentiment_score": "0.015611", "ticker_sentiment_label": "Neutral"}]}, {"title": "Libtayo\u00ae  ( cemiplimab )  Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma  ( CSCC ) ", "url": "https://www.globenewswire.com/news-release/2023/10/21/2764294/0/en/Libtayo-cemiplimab-Neoadjuvant-Treatment-Demonstrates-Encouraging-Event-Free-Survival-in-Patients-with-Resectable-Cutaneous-Squamous-Cell-Carcinoma-CSCC.html", "time_published": "20231021T124800", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.077658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.056116", "ticker_sentiment_score": "0.025006", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.011232", "ticker_sentiment_score": "0.049849", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron and Sanofi Provide Update on Dupixent\u00ae  ( dupilumab )  sBLA for Chronic Spontaneous Urticaria", "url": "https://www.globenewswire.com/news-release/2023/10/20/2764256/0/en/Regeneron-and-Sanofi-Provide-Update-on-Dupixent-dupilumab-sBLA-for-Chronic-Spontaneous-Urticaria.html", "time_published": "20231020T210000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) and Sanofi today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response Letter ( CRL ) for the supplemental Biologics License Application ( sBLA ) ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.041152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.060267", "ticker_sentiment_score": "0.05109", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.143987", "ticker_sentiment_score": "0.027139", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Extend Losses; This Solar Stock Crashes", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-extend-losses-from-market-sell-off-solaredge-crashes-on-warning/", "time_published": "20231020T121100", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Extend Losses From Market Sell-Off. SolarEdge ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-eclipse-solar-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": -0.002432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.067919", "ticker_sentiment_score": "0.077381", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.101725", "ticker_sentiment_score": "0.101858", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.067919", "ticker_sentiment_score": "-0.172678", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.168726", "ticker_sentiment_score": "0.001457", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.101725", "ticker_sentiment_score": "0.073962", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.168726", "ticker_sentiment_score": "0.016968", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.101725", "ticker_sentiment_score": "-0.044764", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03399", "ticker_sentiment_score": "0.008803", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.101725", "ticker_sentiment_score": "0.001111", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.101725", "ticker_sentiment_score": "0.042585", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.168726", "ticker_sentiment_score": "-0.177213", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.101725", "ticker_sentiment_score": "0.001111", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.101725", "ticker_sentiment_score": "-0.044764", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.101725", "ticker_sentiment_score": "0.079746", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.135347", "ticker_sentiment_score": "0.034724", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/10/35337733/100-invested-in-this-stock-20-years-ago-would-be-worth-6-000-today", "time_published": "20231019T190021", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 15.45% on an annualized basis producing an average annual return of 22.72%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.68 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intellia's  ( NTLA )  IND for Gene-Editing Therapy Gets FDA Clearance", "url": "https://www.zacks.com/stock/news/2169049/intellias-ntla-ind-for-gene-editing-therapy-gets-fda-clearance", "time_published": "20231019T154600", "authors": ["Zacks Equity Research"], "summary": "Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.206486, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.270773", "ticker_sentiment_score": "0.502456", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.182506", "ticker_sentiment_score": "0.059067", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.644033", "ticker_sentiment_score": "0.360918", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks Mixed After Jobless Claims", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-jobless-claims-tesla-stock-dives-elon-musk-cybertruck-warnings/", "time_published": "20231019T144200", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Falls On Jobless Claims. Tesla Stock Dives On Elon ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.045744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AA", "relevance_score": "0.094143", "ticker_sentiment_score": "0.057437", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.156258", "ticker_sentiment_score": "-0.046992", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.094143", "ticker_sentiment_score": "0.099622", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.062843", "ticker_sentiment_score": "0.115057", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.156258", "ticker_sentiment_score": "-0.006918", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.094143", "ticker_sentiment_score": "0.098105", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.156258", "ticker_sentiment_score": "0.034863", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.031446", "ticker_sentiment_score": "0.106306", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.094143", "ticker_sentiment_score": "-0.00542", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.125297", "ticker_sentiment_score": "0.091192", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.186979", "ticker_sentiment_score": "-0.055732", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.062843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.094143", "ticker_sentiment_score": "0.062249", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Under-the-Radar Biotech Stocks to Buy in 2023", "url": "https://www.fool.com/investing/2023/10/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/", "time_published": "20231019T121500", "authors": ["Jim Halley"], "summary": "These three lesser-known biotech companies are profitable and growing revenue.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149308, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.20279", "ticker_sentiment_score": "0.048305", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.016493", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stumbles As It Aims For A First-Ever In CRISPR Gene Editing", "url": "https://www.investors.com/news/technology/ntla-stock-stumbles-as-intellia-aims-for-a-first-ever-in-crispr-gene-editing/", "time_published": "20231018T143800", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "The Food and Drug Administration gave Intellia Therapeutics ( NTLA ) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed lower at the open.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-intelliatherapeutics-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.054805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.034344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.606706", "ticker_sentiment_score": "-0.145803", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron builds on Together for CHANGE\u2122 initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN", "url": "https://www.globenewswire.com/news-release/2023/10/18/2762503/0/en/Regeneron-builds-on-Together-for-CHANGE-initiative-with-five-year-5-million-commitment-to-fuel-the-STEM-talent-pipeline-in-Nashville-TN.html", "time_published": "20231018T133000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Commitment builds on Regeneron's longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search ( STS ) and Regeneron International Science and Engineering Fair ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.510349, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.10863", "ticker_sentiment_score": "0.127115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Housing Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-housing-data-netflix-tesla-earnings-next/", "time_published": "20231018T121600", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures dropped Wednesday, along with S&P 500 futures and Nasdaq futures, ahead of key housing data. Up next, Netflix ( NFLX ) and Tesla ( TSLA ) will report their quarterly earnings results after the close. The Commerce Department's housing starts and building permits report is due ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.078847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.062679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.093897", "ticker_sentiment_score": "0.139343", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.186498", "ticker_sentiment_score": "0.040902", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.062679", "ticker_sentiment_score": "-0.106297", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.155853", "ticker_sentiment_score": "0.080598", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.093897", "ticker_sentiment_score": "0.061784", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.124971", "ticker_sentiment_score": "0.077569", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.031364", "ticker_sentiment_score": "0.00873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.124971", "ticker_sentiment_score": "0.012177", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.093897", "ticker_sentiment_score": "0.063902", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.093897", "ticker_sentiment_score": "0.139343", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.21686", "ticker_sentiment_score": "0.088343", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062679", "ticker_sentiment_score": "0.162858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.093897", "ticker_sentiment_score": "0.062208", "ticker_sentiment_label": "Neutral"}]}, {"title": "Price Over Earnings Overview: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/10/35289588/price-over-earnings-overview-regeneron-pharmaceuticals", "time_published": "20231017T141516", "authors": ["Benzinga Insights"], "summary": "In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $844.27, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.18%, but in the past year, went up by 17.75%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.107116, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.399204", "ticker_sentiment_score": "0.046466", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia's  ( NTLA )  HAE Candidate Gets EMA's PRIME Designation", "url": "https://www.zacks.com/stock/news/2166668/intellias-ntla-hae-candidate-gets-emas-prime-designation", "time_published": "20231016T163900", "authors": ["Zacks Equity Research"], "summary": "The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.120453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DCPH", "relevance_score": "0.279015", "ticker_sentiment_score": "0.097057", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.211191", "ticker_sentiment_score": "0.133043", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.407962", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.7887", "ticker_sentiment_score": "0.073056", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks Near 52-Week Highs Still Worth Buying", "url": "https://www.fool.com/investing/2023/10/16/2-healthcare-stocks-near-52-week-highs-still-worth/", "time_published": "20231016T132600", "authors": ["George Budwell"], "summary": "These two large-cap biopharma companies could have more room to run.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F751034%2Fgrowth-stock.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.329024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.349575", "ticker_sentiment_score": "0.21068", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.349575", "ticker_sentiment_score": "0.33828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.072217", "ticker_sentiment_score": "0.170891", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.143843", "ticker_sentiment_score": "0.230118", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures Rise As Netflix, Tesla Earnings Loom", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-tesla-earnings-loom-lululemon-surges-on-sp-news/", "time_published": "20231016T121700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures rose Monday ahead of a big week of earning reports, headlined by Netflix ( NFLX ) and Tesla ( TSLA ) . Meanwhile, Lululemon Athletica ( LULU ) jumped on news that the company will join the S&P 500 index this week.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.127382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.070207", "ticker_sentiment_score": "0.062244", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.174335", "ticker_sentiment_score": "0.075356", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.070207", "ticker_sentiment_score": "-0.054204", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.174335", "ticker_sentiment_score": "0.026112", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.105141", "ticker_sentiment_score": "0.157877", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.035138", "ticker_sentiment_score": "0.107945", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.070207", "ticker_sentiment_score": "-0.312709", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNH", "relevance_score": "0.139872", "ticker_sentiment_score": "0.097439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.174335", "ticker_sentiment_score": "0.033145", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.070207", "ticker_sentiment_score": "0.062244", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.208464", "ticker_sentiment_score": "0.039608", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.035138", "ticker_sentiment_score": "0.043454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.070207", "ticker_sentiment_score": "0.217439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.070207", "ticker_sentiment_score": "0.175048", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35257414/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to-treat-ca", "time_published": "20231015T220523", "authors": ["Globe Newswire"], "summary": "Event-free survival of investigational use of Libtayo\u00ae ( cemiplimab ) in neoadjuvant cutaneous squamous cell carcinoma ( CSCC ) from Phase 2 trial to be featured in oral presentation TARRYTOWN, N.Y., Oct. 15, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.112071, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.071357", "ticker_sentiment_score": "-0.054547", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.017862", "ticker_sentiment_score": "0.006412", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO", "url": "https://www.globenewswire.com/news-release/2023/10/15/2760264/0/en/Regeneron-to-Showcase-Progress-from-Innovative-Oncology-Portfolio-in-Several-Difficult-to-Treat-Cancers-at-ESMO.html", "time_published": "20231015T220500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Event-free survival of investigational use of Libtayo\u00ae ( cemiplimab ) in neoadjuvant cutaneous squamous cell carcinoma ( CSCC ) from Phase 2 trial to be featured in oral presentation ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.068095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.059607", "ticker_sentiment_score": "0.025035", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.023861", "ticker_sentiment_score": "0.039687", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years", "url": "https://www.fool.com/investing/2023/10/14/2-growth-stocks-that-could-deliver-parabolic-retur/", "time_published": "20231014T162022", "authors": ["George Budwell"], "summary": "These two gene-editing stocks could be diamonds in the rough.", "banner_image": "https://media.ycharts.com/charts/13a23d9c41fd1008fa98d5440b7c7580.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.21784, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055109", "ticker_sentiment_score": "0.127992", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.060122", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.128748", "ticker_sentiment_label": "Neutral"}, {"ticker": "IEX", "relevance_score": "0.055109", "ticker_sentiment_score": "0.060122", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.055109", "ticker_sentiment_score": "0.067012", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.552966", "ticker_sentiment_score": "0.358668", "ticker_sentiment_label": "Bullish"}]}, {"title": "Two AI Stocks Lead 5 Resilient Names Near Buy Points", "url": "https://www.investors.com/news/ai-stocks-avgo-and-anet-lead-5-resilient-names-near-buy-points/", "time_published": "20231014T144400", "authors": ["JED GRAHAM", "Investor's Business Daily"], "summary": "AI stocks Broadcom ( AVGO ) and Arista Networks ( ANET ) lead this weekend's watch list of five names near buy points. In addition to AVGO and ANET, the list includes Costco Wholesale ( COST ) , Regeneron Pharmaceuticals ( REGN ) , and Chinese gaming leader NetEase ( NTES ) .", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-broadcom-logo-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.967645"}], "overall_sentiment_score": 0.187671, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.098794", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.22792", "ticker_sentiment_score": "0.10734", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.033006", "ticker_sentiment_score": "0.020194", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.098794", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.098794", "ticker_sentiment_score": "0.132448", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.065957", "ticker_sentiment_score": "-0.118217", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.290415", "ticker_sentiment_score": "0.247943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.290415", "ticker_sentiment_score": "0.27176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.351015", "ticker_sentiment_score": "0.190575", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.033006", "ticker_sentiment_score": "0.088729", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.033006", "ticker_sentiment_score": "0.040397", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.131463", "ticker_sentiment_score": "0.10146", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Action Plan: A Change Of Season As Netflix, Tesla Face Tests", "url": "https://www.investors.com/research/investing-action-plan/investing-action-plan-a-change-of-season-as-netflix-tesla-face-tests/", "time_published": "20231013T214500", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Investing Action Plan: A Change Of Season As Netflix, Tesla Face ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-fallleaves-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.08389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.091597", "ticker_sentiment_score": "0.091347", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.045874", "ticker_sentiment_score": "0.089595", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.045874", "ticker_sentiment_score": "0.032889", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.068764", "ticker_sentiment_score": "0.033399", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.045874", "ticker_sentiment_score": "0.17754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.045874", "ticker_sentiment_score": "0.080844", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.022947", "ticker_sentiment_score": "0.01108", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.022947", "ticker_sentiment_score": "-0.008963", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.045874", "ticker_sentiment_score": "0.016984", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVS", "relevance_score": "0.045874", "ticker_sentiment_score": "0.067379", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.045874", "ticker_sentiment_score": "0.016984", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.068764", "ticker_sentiment_score": "0.033399", "ticker_sentiment_label": "Neutral"}, {"ticker": "FITB", "relevance_score": "0.045874", "ticker_sentiment_score": "-0.009969", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.068764", "ticker_sentiment_score": "0.033399", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.045874", "ticker_sentiment_score": "0.020974", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.137018", "ticker_sentiment_score": "-0.034349", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.091597", "ticker_sentiment_score": "0.012766", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.045874", "ticker_sentiment_score": "0.016984", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.045874", "ticker_sentiment_score": "0.123449", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.045874", "ticker_sentiment_score": "0.067704", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.045874", "ticker_sentiment_score": "-0.092", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.045874", "ticker_sentiment_score": "0.032889", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.045874", "ticker_sentiment_score": "0.101496", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLD", "relevance_score": "0.045874", "ticker_sentiment_score": "-0.122362", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?", "url": "https://www.investors.com/research/ibd-stock-of-the-day/regn-stock-regeneron-bulls-bears-clash-eylea-mojo/", "time_published": "20231013T183500", "authors": ["REINHARDT KRAUSE", "Investor's Business Daily"], "summary": "Regeneron Pharmaceuticals ( REGN ) is the IBD Stock of the Day as the biotech giant trades near an all-time high ahead of its earnings report due Nov. 2. The big debate for REGN stock: Will the company get its mojo back in its core eye disease treatment business?", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/SOTD-10-13-23.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.083871, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.05628", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.059785", "ticker_sentiment_score": "0.059213", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.590628", "ticker_sentiment_score": "0.206575", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.119235", "ticker_sentiment_score": "0.150492", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics", "url": "https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html", "time_published": "20231013T154500", "authors": ["Research and Markets"], "summary": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.144187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.073209", "ticker_sentiment_score": "0.139168", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.073209", "ticker_sentiment_score": "0.08925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Mixed As Banks Start A New Earnings Season", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-mixed-as-banks-start-a-new-earnings-season/", "time_published": "20231013T144800", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "The stock market wavered in the first hour of trading Friday with major indexes showing mixed results. Meanwhile, earnings season got underway with big banks the first to report third-quarter numbers. The Nasdaq notched down 0.3% on the stock market today.", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-bank-10-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.135035, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.145145", "ticker_sentiment_score": "0.070488", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.145145", "ticker_sentiment_score": "0.08199", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.145145", "ticker_sentiment_score": "0.198373", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.145145", "ticker_sentiment_score": "0.08199", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.216215", "ticker_sentiment_score": "0.196205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PGR", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.168323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.072876", "ticker_sentiment_score": "0.039797", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.085735", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.145145", "ticker_sentiment_score": "0.280301", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sanofi reaps rewards of immunology investment with eczema results", "url": "https://www.marketwatch.com/story/sanofi-reaps-rewards-of-immunology-investment-with-eczema-results-9ce642b0", "time_published": "20231013T140000", "authors": ["Eleanor Laise"], "summary": "Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.", "banner_image": "https://images.mktw.net/im-867618/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.24028, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KNBWF", "relevance_score": "0.112008", "ticker_sentiment_score": "0.099052", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.151207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.151207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KYKOF", "relevance_score": "0.112008", "ticker_sentiment_score": "0.099052", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.675825", "ticker_sentiment_score": "0.369096", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J  ( JNJ )  to Report Q3 Earnings, Its First After Unit Spin-Off", "url": "https://www.zacks.com/stock/news/2165582/jj-jnj-to-report-q3-earnings-its-first-after-unit-spin-off", "time_published": "20231013T134900", "authors": ["Zacks Equity Research"], "summary": "J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149943, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.130453", "ticker_sentiment_score": "0.063321", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.173333", "ticker_sentiment_score": "-0.063835", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.257442", "ticker_sentiment_score": "0.135924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.215702", "ticker_sentiment_score": "0.094996", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.173333", "ticker_sentiment_score": "0.080645", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Brilliant Growth Stocks to Buy and Hold Forever", "url": "https://www.fool.com/investing/2023/10/12/2-brilliant-growth-stocks-to-buy-and-hold-forever/", "time_published": "20231012T125700", "authors": ["George Budwell"], "summary": "These two growth stocks could be genuine wealth escalators.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750582%2Finnovation.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.357442, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.056674", "ticker_sentiment_score": "0.077922", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.713735", "ticker_sentiment_score": "0.267539", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.381255", "ticker_sentiment_score": "0.529685", "ticker_sentiment_label": "Bullish"}]}, {"title": "Down 45%, Is Intellia a Buy?", "url": "https://www.fool.com/investing/2023/10/10/down-45-percent-is-intellia-a-buy/", "time_published": "20231010T180000", "authors": ["Adria Cimino"], "summary": "Intellia's operating in the high-growth field of gene editing.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.309655, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.058615", "ticker_sentiment_score": "0.240035", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.286864", "ticker_sentiment_score": "0.290813", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Cathie Wood Stock Is Poised to Double, Says Wall Street", "url": "https://www.fool.com/investing/2023/10/10/this-cathie-wood-stock-poised-to-double-says-wall-/", "time_published": "20231010T140700", "authors": ["Prosper Junior Bakiny"], "summary": "Almost anything is possible in the volatile biotech industry.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.17462, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.052801", "ticker_sentiment_score": "0.059954", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.610722", "ticker_sentiment_score": "0.369126", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight", "url": "https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html", "time_published": "20231009T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009725, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036338", "ticker_sentiment_score": "0.033442", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.124364", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.034129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054483", "ticker_sentiment_score": "0.032874", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.036338", "ticker_sentiment_score": "0.047119", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35143608/antibody-drug-conjugates-market-revenue-to-hit-29-6-billion-globally-by-2030-exclusive-study-by-th", "time_published": "20231009T120410", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Antibody drug conjugates ( ADC ) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody ( mAbs ) covalently attached to a cytotoxic drug via a chemical linker.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.138172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.174903", "ticker_sentiment_score": "0.089155", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.301052", "ticker_sentiment_score": "0.09182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKBO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087985", "ticker_sentiment_score": "0.057624", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/10/35131743/pe-ratio-insights-for-regeneron-pharmaceuticals", "time_published": "20231006T193018", "authors": ["Benzinga Insights"], "summary": "In the current market session, Regeneron Pharmaceuticals Inc. REGN stock price is at $830.00, after a 0.13% decrease. However, over the past month, the company's stock increased by 1.13%, and in the past year, by 14.93%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": -0.04018, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.068711", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna", "url": "https://www.zacks.com/stock/news/2161291/the-zacks-analyst-blog-highlights-novavax-alx-oncology-regeneron-pharmaceuticals-intellia-and-moderna", "time_published": "20231006T085900", "authors": ["Zacks Investment Research"], "summary": "Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.155556, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.195182", "ticker_sentiment_score": "0.058056", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.233183", "ticker_sentiment_score": "0.104583", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.27063", "ticker_sentiment_score": "0.091829", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.11787", "ticker_sentiment_score": "0.004529", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.11787", "ticker_sentiment_score": "0.004529", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates DelveInsight | Leading Companies in the Market - Kyowa Kirin Acceleron, Cumberland, Horizon, CSL Behring, Seagen, Janssen", "url": "https://www.prnewswire.com/news-releases/diffuse-cutaneous-systemic-sclerosis-market-to-proliferate-at-a-considerable-growth-rate-by-2032-estimates-delveinsight--leading-companies-in-the-market---kyowa-kirin-acceleron-cumberland-horizon-csl-behring-seagen-janssen-301947923.html", "time_published": "20231005T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061731, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMMB", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBP", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPIX", "relevance_score": "0.05133", "ticker_sentiment_score": "0.057639", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.05133", "ticker_sentiment_score": "0.057639", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.05133", "ticker_sentiment_score": "0.016846", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}, {"ticker": "TALS", "relevance_score": "0.076929", "ticker_sentiment_score": "0.027273", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.076929", "ticker_sentiment_score": "0.057667", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.076929", "ticker_sentiment_score": "0.057667", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.076929", "ticker_sentiment_score": "0.057667", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.025679", "ticker_sentiment_score": "0.074732", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.05133", "ticker_sentiment_score": "0.057639", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025679", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More", "url": "https://www.zacks.com/stock/news/2160940/biotech-stock-roundup-nvax-up-on-updates-alxo-gains-on-study-data-more", "time_published": "20231005T145800", "authors": ["Zacks Equity Research"], "summary": "Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.162562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.167904", "ticker_sentiment_score": "0.079946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.209004", "ticker_sentiment_score": "0.132684", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.249531", "ticker_sentiment_score": "0.120357", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.084423", "ticker_sentiment_score": "0.008282", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.084423", "ticker_sentiment_score": "0.008282", "ticker_sentiment_label": "Neutral"}]}, {"title": "EYLEA\u00ae HD  ( aflibercept )  Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA", "url": "https://www.globenewswire.com/news-release/2023/10/05/2755506/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Two-year-Results-from-Pivotal-PULSAR-Trial-in-Wet-Age-related-Macular-Degeneration-Presented-at-EURETINA.html", "time_published": "20231005T134300", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.076649, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.072964", "ticker_sentiment_score": "0.044662", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.014612", "ticker_sentiment_score": "0.12692", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014612", "ticker_sentiment_score": "0.040772", "ticker_sentiment_label": "Neutral"}]}, {"title": "EYLEA\u00ae HD  ( aflibercept )  Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35108562/eylea-hd-aflibercept-injection-8-mg-two-year-results-from-pivotal-pulsar-trial-in-wet-age-related-", "time_published": "20231005T134300", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.074073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.07292", "ticker_sentiment_score": "0.042608", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.014604", "ticker_sentiment_score": "0.126912", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014604", "ticker_sentiment_score": "0.039824", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's the Best Big Pharma Stock of the Decade so Far  ( and It's Not Even Close ) ", "url": "https://www.fool.com/investing/2023/10/05/heres-the-best-big-pharma-stock-of-the-decade-so-f/", "time_published": "20231005T095000", "authors": ["Keith Speights"], "summary": "This stock puts the \"big\" in big pharma after massive gains in recent years.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.257867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.391486", "ticker_sentiment_score": "0.447177", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.116348", "ticker_sentiment_score": "0.285979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.230235", "ticker_sentiment_score": "0.258954", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo", "url": "https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html", "time_published": "20231004T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.128467, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SYRS", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLTO", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.042655", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.051258", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.040696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.046141", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.10057", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "IUGNF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPHLF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teva Hooks Immunology Powerhouse Sanofi In $1.5 Billion Deal", "url": "https://www.investors.com/news/technology/teva-stock-dives-after-inking-deal-for-inflammation-drug/", "time_published": "20231004T144700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-tevapharmaceuticals-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.190416, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.049732", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049732", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.099271", "ticker_sentiment_score": "0.11034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.099271", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.148426", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.382193", "ticker_sentiment_score": "0.176752", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Intellia  ( NTLA ) , Regeneron Expand Deal for Gene-Editing Therapies", "url": "https://www.zacks.com/stock/news/2160105/intellia-ntla-regeneron-expand-deal-for-gene-editing-therapies", "time_published": "20231004T132700", "authors": ["Zacks Equity Research"], "summary": "Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026584, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANIK", "relevance_score": "0.217508", "ticker_sentiment_score": "0.08076", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.354572", "ticker_sentiment_score": "-0.068202", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.2872", "ticker_sentiment_score": "0.339345", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.480536", "ticker_sentiment_score": "0.457195", "ticker_sentiment_label": "Bullish"}]}, {"title": "Public reimbursement for biosimilar BYOOVIZ\u2122 to treat serious retinal disorders now secured in four provinces and two national benefits programs", "url": "https://www.newswire.ca/news-releases/public-reimbursement-for-biosimilar-byooviz-tm-to-treat-serious-retinal-disorders-now-secured-in-four-provinces-and-two-national-benefits-programs-817633984.html", "time_published": "20231004T110000", "authors": ["Biogen Canada"], "summary": "Public reimbursement for biosimilar BYOOVIZ\u2122 to treat serious retinal disorders now secured in four provinces and two ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2238276/Biogen_Canada_Public_reimbursement_for_biosimilar_BYOOVIZ__to_tr.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.338403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.171282", "ticker_sentiment_score": "0.263662", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.436009", "ticker_sentiment_score": "0.557652", "ticker_sentiment_label": "Bullish"}]}, {"title": "MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer - MAIA Biotechnology  ( AMEX:MAIA ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35066621/maia-secures-fda-clearance-of-ind-application-for-thio-for-non-small-cell-lung-cancer", "time_published": "20231003T172533", "authors": ["Nabaparna Bhattacharya"], "summary": "MAIA Biotechnology, Inc. MAIA announced that the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational New Drug application for THIO, a first-in-class telomere targeting agent for the treatment of non-small-cell-lung-cancer, or NSLC.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/maia.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.274587, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.012168", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/10/35067969/regeneron-pharmaceuticals-unusual-options-activity", "time_published": "20231003T160140", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.104183, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.802374", "ticker_sentiment_score": "0.228994", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron, Intellia to make gene editing therapies in expanded collaboration", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-intellia-therapeutics-expand-research-collaboration-make-gene-editing-2023-10-03/", "time_published": "20231003T111000", "authors": ["Reuters"], "summary": "Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=159", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.158543, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Intellia Therapeutics  ( NASDAQ:NTLA ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35055988/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-therapies-", "time_published": "20231003T110000", "authors": ["Globe Newswire"], "summary": "Collaboration combines Intellia's leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron's proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.131171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.085022", "ticker_sentiment_score": "0.065391", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.085022", "ticker_sentiment_score": "0.067506", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.017035", "ticker_sentiment_score": "0.043162", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases", "url": "https://www.globenewswire.com/news-release/2023/10/03/2753457/0/en/Regeneron-and-Intellia-Announce-Expanded-Research-Collaboration-to-Develop-CRISPR-Based-Therapies-for-the-Treatment-of-Neurological-and-Muscular-Diseases.html", "time_published": "20231003T110000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Collaboration combines Intellia's leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron's proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.138347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.069194", "ticker_sentiment_score": "0.0646", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.069194", "ticker_sentiment_score": "0.067648", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.017319", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases", "url": "https://www.globenewswire.com/news-release/2023/10/03/2753456/0/en/Regeneron-and-Intellia-Announce-Expanded-Research-Collaboration-to-Develop-CRISPR-Based-Therapies-for-the-Treatment-of-Neurological-and-Muscular-Diseases.html", "time_published": "20231003T110000", "authors": ["Intellia Therapeutics", "Inc."], "summary": "TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) and Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.138343, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.051961", "ticker_sentiment_score": "0.063974", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.069244", "ticker_sentiment_score": "0.067652", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.017331", "ticker_sentiment_score": "0.0451", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Split Watch: Is Regeneron Pharmaceuticals Next?", "url": "https://www.fool.com/investing/2023/09/30/stock-split-watch-is-regeneron-next/", "time_published": "20230930T093000", "authors": ["Adria Cimino"], "summary": "If the biotech does split its stock, it will be a first for the company.", "banner_image": "https://media.ycharts.com/charts/8370f5419ba358885daf9fea5a076936.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.210531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.054857", "ticker_sentiment_score": "0.010046", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.109455", "ticker_sentiment_score": "0.049699", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.054857", "ticker_sentiment_score": "0.010046", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054857", "ticker_sentiment_score": "0.045859", "ticker_sentiment_label": "Neutral"}]}, {"title": "Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma  ( FL )  and Diffuse Large B-cell Lymphoma  ( DLBCL )  Accepted for FDA Priority Review", "url": "https://www.globenewswire.com/news-release/2023/09/29/2751977/0/en/Odronextamab-BLA-for-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma-FL-and-Diffuse-Large-B-cell-Lymphoma-DLBCL-Accepted-for-FDA-Priority-Review.html", "time_published": "20230929T123000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL - the two most common subtypes of non-Hodgkin lymphoma ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.129974, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.117948", "ticker_sentiment_score": "0.051846", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.023673", "ticker_sentiment_score": "0.049587", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023", "url": "https://www.globenewswire.com/news-release/2023/09/28/2751630/0/en/Regeneron-to-Report-Third-Quarter-2023-Financial-and-Operating-Results-and-Host-Conference-Call-and-Webcast-on-November-2-2023.html", "time_published": "20230928T200500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Sept. 28, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.124909, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.25168", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Improving Market Leadership: Regeneron Pharmaceuticals Earns 85 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-regeneron-pharmaceuticals-earns-85-rs-rating/", "time_published": "20230927T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Stocks Showing Improving Market Leadership: Regeneron ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.303646, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.625937", "ticker_sentiment_score": "-0.081122", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: What To Do As Stocks Sell Off; Meta's AI Push In Focus", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-correction-intensifies-what-to-do-meta-ai-push-in-focus/", "time_published": "20230926T204900", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Futures: What To Do As Stocks Sell Off. Meta's AI Push In Focus Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/ETFSTRAT-bear-101119-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.019374, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.083561", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.144102", "ticker_sentiment_score": "0.048146", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.086765", "ticker_sentiment_score": "-0.088829", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOD", "relevance_score": "0.115509", "ticker_sentiment_score": "-0.040447", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFL", "relevance_score": "0.115509", "ticker_sentiment_score": "0.098349", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.144102", "ticker_sentiment_score": "0.105294", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.028972", "ticker_sentiment_score": "-0.109086", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.144102", "ticker_sentiment_score": "-0.10917", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.144102", "ticker_sentiment_score": "0.039605", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.028972", "ticker_sentiment_score": "0.216761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FDX", "relevance_score": "0.144102", "ticker_sentiment_score": "-0.051198", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.086765", "ticker_sentiment_score": "0.103975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.086765", "ticker_sentiment_score": "-0.019185", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Accepts Sanofi's  ( SNY )  sBLA for Dupixent in Pediatric EoE", "url": "https://www.zacks.com/stock/news/2155380/fda-accepts-sanofis-sny-sbla-for-dupixent-in-pediatric-eoe", "time_published": "20230926T121100", "authors": ["Zacks Equity Research"], "summary": "If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187007, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.204647", "ticker_sentiment_score": "0.218257", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.270523", "ticker_sentiment_score": "0.083242", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.6584", "ticker_sentiment_score": "0.311361", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review", "url": "https://www.globenewswire.com/news-release/2023/09/26/2749151/0/en/Press-Release-Dupixent-dupilumab-sBLA-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1-to-11-accepted-for-FDA-Priority-Review.html", "time_published": "20230926T053000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review \u2022 If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.069908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.032164", "ticker_sentiment_score": "0.043115", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.128135", "ticker_sentiment_score": "0.029038", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review", "url": "https://www.benzinga.com/pressreleases/23/09/g34889029/press-release-dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1", "time_published": "20230926T053000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.062527, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.031446", "ticker_sentiment_score": "0.041974", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.171651", "ticker_sentiment_score": "0.041775", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  sBLA for Treatment of Eosinophilic Esophagitis  ( EoE )  in Children Aged 1 to 11 Accepted for FDA Priority Review", "url": "https://www.globenewswire.com/news-release/2023/09/26/2749147/0/en/Dupixent-dupilumab-sBLA-for-Treatment-of-Eosinophilic-Esophagitis-EoE-in-Children-Aged-1-to-11-Accepted-for-FDA-Priority-Review.html", "time_published": "20230926T052900", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.041219, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.054162", "ticker_sentiment_score": "0.047", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.108076", "ticker_sentiment_score": "0.019085", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx Launches Evkeeza\u00ae  ( evinacumab for injection )  in Canada for the Treatment of Homozygous Familial Hypercholesterolemia  ( HoFH )  - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34882289/ultragenyx-launches-evkeeza-evinacumab-for-injection-in-canada-for-the-treatment-of-homozygous-fam", "time_published": "20230925T211321", "authors": ["Globe Newswire"], "summary": "TORONTO, Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza\u00ae ( evinacumab ) in Canada.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.100248, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.076847", "ticker_sentiment_score": "0.099641", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.076847", "ticker_sentiment_score": "0.013247", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultragenyx Launches Evkeeza\u00ae  ( evinacumab for injection )  in Canada for the Treatment of Homozygous Familial Hypercholesterolemia  ( HoFH ) ", "url": "https://www.globenewswire.com/news-release/2023/09/25/2749034/20739/en/Ultragenyx-Launches-Evkeeza-evinacumab-for-injection-in-Canada-for-the-Treatment-of-Homozygous-Familial-Hypercholesterolemia-HoFH.html", "time_published": "20230925T211300", "authors": ["Ultragenyx Pharmaceutical Inc."], "summary": "Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration ( FDA ) and European Commission ( EC ) to treat an ultrarare, inherited form of high cholesterol Evkeeza is a first-in-class medicine approved by Health Canada, the U.S.", "banner_image": "https://ml.globenewswire.com/Resource/Download/121a9bda-7a64-41f8-85e8-1693a2dfa977", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.088573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.077593", "ticker_sentiment_score": "0.105934", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.077593", "ticker_sentiment_score": "0.012251", "ticker_sentiment_label": "Neutral"}]}, {"title": "CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio", "url": "https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html", "time_published": "20230925T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0762, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SRNEQ", "relevance_score": "0.037504", "ticker_sentiment_score": "0.019103", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.05623", "ticker_sentiment_score": "0.056937", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLYYF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.057813", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.037504", "ticker_sentiment_score": "0.028556", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.130723", "ticker_sentiment_score": "0.064024", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.018757", "ticker_sentiment_score": "0.057813", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBIO", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.037504", "ticker_sentiment_score": "0.05738", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.037504", "ticker_sentiment_score": "0.029512", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "CASI", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOS", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.130723", "ticker_sentiment_score": "0.049466", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.037504", "ticker_sentiment_score": "0.05738", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.09358", "ticker_sentiment_score": "0.057751", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLO", "relevance_score": "0.05623", "ticker_sentiment_score": "0.045942", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.037504", "ticker_sentiment_score": "0.014356", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.037504", "ticker_sentiment_score": "0.029512", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: Investors Keeping a Close Eye on These 3 Biotech Stocks", "url": "https://stocknews.com/news/regn-incy-cort-dbtx-investors-keeping-a-close-eye-on-these-3-biotech-stocks/", "time_published": "20230925T152017", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is fueled by an increasing number of orphan drug formulations and increasing investment in advanced technologies. Given the industry's steady growth prospects, investors could consider quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Corcept Therapeutics ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.27927, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.309864", "ticker_sentiment_score": "0.340321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CORT", "relevance_score": "0.235062", "ticker_sentiment_score": "0.168826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.19677", "ticker_sentiment_score": "0.176242", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management", "url": "https://www.zacks.com/stock/news/2154908/the-zacks-analyst-blog-highlights-amazoncom-boeing-regeneron-boston-scientific-and-waste-management", "time_published": "20230925T130700", "authors": ["Zacks Equity Research"], "summary": "Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/427.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}], "overall_sentiment_score": 0.179659, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ERJ", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.244754", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.218161", "ticker_sentiment_score": "0.049508", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.146469", "ticker_sentiment_score": "0.137406", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.146469", "ticker_sentiment_score": "0.037354", "ticker_sentiment_label": "Neutral"}, {"ticker": "WM", "relevance_score": "0.146469", "ticker_sentiment_score": "0.037354", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.420316", "ticker_sentiment_score": "0.048548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34861912/regeneron-completes-acquisition-of-decibel-therapeutics-adding-promising-gene-therapy-programs-for", "time_published": "20230925T123445", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.18804, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.067095", "ticker_sentiment_score": "0.056431", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.04476", "ticker_sentiment_score": "0.055617", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMSQF", "relevance_score": "0.022389", "ticker_sentiment_score": "0.122734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss", "url": "https://www.globenewswire.com/news-release/2023/09/25/2748643/0/en/Regeneron-Completes-Acquisition-of-Decibel-Therapeutics-Adding-Promising-Gene-Therapy-Programs-for-Hearing-Loss.html", "time_published": "20230925T123400", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.199667, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.068371", "ticker_sentiment_score": "0.058553", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.045612", "ticker_sentiment_score": "0.057696", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMSQF", "relevance_score": "0.022815", "ticker_sentiment_score": "0.134113", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost", "url": "https://www.fool.com/investing/2023/09/20/this-recent-fda-approval-could-give-regenerons-top/", "time_published": "20230920T140700", "authors": ["David Jagielski"], "summary": "A higher-dose version of Eylea will help the company fight off competition and increase revenue.", "banner_image": "https://media.ycharts.com/charts/429547f1105606068e0b3665e93e81f6.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.224813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.10349", "ticker_sentiment_label": "Neutral"}]}, {"title": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte", "url": "https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html", "time_published": "20230918T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.109459, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLTO", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKUNF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.04824", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}]}, {"title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, RETA, VRTV, HCCI", "url": "https://www.benzinga.com/pressreleases/23/09/g34702887/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-reta-vrtv-hcci", "time_published": "20230918T205947", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.331688, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HCCI", "relevance_score": "0.266101", "ticker_sentiment_score": "0.213604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.067727", "ticker_sentiment_score": "0.119871", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.266101", "ticker_sentiment_score": "0.234832", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.266101", "ticker_sentiment_score": "0.237454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTV", "relevance_score": "0.266101", "ticker_sentiment_score": "0.21949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.120965", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/myopia-and-presbyopia-treatment-market-to-grow-by-usd-7-94-billion-from-2022-to-2027--asia-to-account-for-37-of-market-growth--technavio-301929564.html", "time_published": "20230918T041500", "authors": [], "summary": "Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.234998, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MTLZF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESLOF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALC", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BHC", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TOPCF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EVO", "relevance_score": "0.052801", "ticker_sentiment_score": "0.184679", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - GlaxoSmithKline, AstraZeneca, Sanofi, Roche, Amgen, Regeneron, Incyte, Areteia, Suzhou Connect, Cumberland, Pulmatrix", "url": "https://www.prnewswire.com/news-releases/asthma-market-is-predicted-to-exhibit-remarkable-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---glaxosmithkline-astrazeneca-sanofi-roche-amgen-regeneron-incyte-areteia-suzhou-connect-cumberland-pulma-301927336.html", "time_published": "20230914T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.116778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPIX", "relevance_score": "0.077677", "ticker_sentiment_score": "0.077029", "ticker_sentiment_label": "Neutral"}, {"ticker": "PULM", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.003692", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTX", "relevance_score": "0.05183", "ticker_sentiment_score": "0.092531", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKTX", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVLO", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.17998", "ticker_sentiment_score": "0.064093", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAPT", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFFP", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.025929", "ticker_sentiment_score": "0.003692", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.129099", "ticker_sentiment_score": "0.052198", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34582720/peering-into-regeneron-pharmaceuticalss-recent-short-interest", "time_published": "20230914T140038", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 9.4% since its last report. The company recently reported that it has 1.48 million shares sold short, which is 1.63% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, CELL, CCF, AGE", "url": "https://www.benzinga.com/pressreleases/23/09/g34500135/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-cell-ccf-age", "time_published": "20230912T180136", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.323042, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.068112", "ticker_sentiment_score": "0.127116", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.068112", "ticker_sentiment_score": "0.119922", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELL", "relevance_score": "0.267559", "ticker_sentiment_score": "0.250298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.267559", "ticker_sentiment_score": "0.235828", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "REGN: 3 Biotech Gainers to Consider", "url": "https://stocknews.com/news/regn-biib-regn-reta-3-biotech-gainers-to-consider/", "time_published": "20230911T164719", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Biogen Inc. ( BIIB ) , and United Therapeutics Corporation ( UTHR ) could be worth buying.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.216037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.265217", "ticker_sentiment_score": "0.381353", "ticker_sentiment_label": "Bullish"}, {"ticker": "DBTX", "relevance_score": "0.06001", "ticker_sentiment_score": "0.291226", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.089909", "ticker_sentiment_score": "0.064947", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.089909", "ticker_sentiment_score": "0.075774", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.236684", "ticker_sentiment_score": "0.142313", "ticker_sentiment_label": "Neutral"}]}, {"title": "Morgan Stanley says it's a lonely bull, recommending government bonds", "url": "https://www.marketwatch.com/story/morgan-stanley-says-its-a-lonely-bull-recommending-government-bonds-78004824", "time_published": "20230911T105500", "authors": ["Steve Goldstein"], "summary": "Here's why Morgan Stanley is persisting with its call to buy government bonds.", "banner_image": "https://images.mktw.net/im-849733?width=700&height=709", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": -0.062885, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APO", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.051912", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.086556", "ticker_sentiment_score": "0.071289", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.086556", "ticker_sentiment_score": "0.044313", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWNK", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.065406", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.086556", "ticker_sentiment_score": "-0.241989", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:JPY", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.072913", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.072913", "ticker_sentiment_label": "Neutral"}]}, {"title": "New to Investing? Here's How You Can Get Started With $500.", "url": "https://www.fool.com/investing/2023/09/10/new-to-investing-heres-how-you-can-get-started-wit/", "time_published": "20230910T090000", "authors": ["Adria Cimino"], "summary": "You don't have to invest a lot to start building a winning portfolio.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999941"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.308697, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.129017", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.129017", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.054483", "ticker_sentiment_score": "0.204993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.054483", "ticker_sentiment_score": "0.15606", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.054483", "ticker_sentiment_score": "0.15606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Unstoppable Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/09/3-unstoppable-growth-stocks-to-buy-right-now/", "time_published": "20230909T105500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "These healthcare stocks show no signs of slowing down.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.247559, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.285526", "ticker_sentiment_score": "0.177763", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.165598", "ticker_sentiment_score": "0.085992", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.165598", "ticker_sentiment_score": "0.085386", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041682", "ticker_sentiment_score": "0.244904", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Provides Update on Planned Chief Financial Officer Transition", "url": "https://www.globenewswire.com/news-release/2023/09/08/2740338/0/en/Regeneron-Provides-Update-on-Planned-Chief-Financial-Officer-Transition.html", "time_published": "20230908T204600", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Robert E. Landry to retire effective February 2024. Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role Robert E. Landry to retire effective February 2024.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.243089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.211806", "ticker_sentiment_score": "-0.008631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Provides Update on Planned Chief Financial Officer Transition - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34373268/regeneron-provides-update-on-planned-chief-financial-officer-transition", "time_published": "20230908T204600", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.236131, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.20698", "ticker_sentiment_score": "-0.008466", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Updates to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/09/08/2740337/0/en/Regeneron-Announces-Updates-to-Board-of-Directors.html", "time_published": "20230908T204500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.252962, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.045836", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.045836", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.130453", "ticker_sentiment_score": "0.047984", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.045836", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.045836", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Updates to Board of Directors - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34373255/regeneron-announces-updates-to-board-of-directors", "time_published": "20230908T204500", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron's Board of Directors effective September 8, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.246119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.045749", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.045749", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.128592", "ticker_sentiment_score": "0.046349", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.045749", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.045749", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/09/34369351/check-out-what-whales-are-doing-with-regn", "time_published": "20230908T190117", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.085276, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.895116", "ticker_sentiment_score": "0.14938", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.107495", "ticker_sentiment_score": "-0.132714", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.107495", "ticker_sentiment_score": "-0.132714", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in September", "url": "https://www.fool.com/investing/2023/09/08/2-top-biotech-stocks-to-buy-in-september/", "time_published": "20230908T135300", "authors": ["Prosper Junior Bakiny"], "summary": "There is rarely a bad time to buy stocks with massive upside potential.", "banner_image": "https://media.ycharts.com/charts/f058ce16f4e7ed1399492b8da1636e0c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.293448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.216707", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.109956", "ticker_sentiment_score": "0.216707", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.055109", "ticker_sentiment_score": "0.160116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, DBTX, DM, ZYNE - Desktop Metal  ( NYSE:DM ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34321972/shareholder-investigation-halper-sadeh-llc-investigates-sovo-dbtx-dm-zyne", "time_published": "20230907T143609", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 07, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sovos Brands, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.229217, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SOVO", "relevance_score": "0.194242", "ticker_sentiment_score": "0.117902", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.097854", "ticker_sentiment_score": "0.082326", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRMY", "relevance_score": "0.097854", "ticker_sentiment_score": "0.255129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DM", "relevance_score": "0.377142", "ticker_sentiment_score": "0.205491", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.097854", "ticker_sentiment_score": "0.167429", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSYS", "relevance_score": "0.194242", "ticker_sentiment_score": "0.122446", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZYNE", "relevance_score": "0.097854", "ticker_sentiment_score": "0.255129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.097854", "ticker_sentiment_score": "0.167429", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm - Desktop Metal  ( NYSE:DM ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34321471/moore-kuehn-encourages-sovo-dbtx-dm-and-zyne-investors-to-contact-law-firm", "time_published": "20230907T141504", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 07, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.223559, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.105141", "ticker_sentiment_score": "-0.025872", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOVO", "relevance_score": "0.105141", "ticker_sentiment_score": "0.209132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CPB", "relevance_score": "0.105141", "ticker_sentiment_score": "0.209132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HRMY", "relevance_score": "0.105141", "ticker_sentiment_score": "0.256105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DM", "relevance_score": "0.208464", "ticker_sentiment_score": "0.413111", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.105141", "ticker_sentiment_score": "0.264846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSYS", "relevance_score": "0.208464", "ticker_sentiment_score": "0.413111", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZYNE", "relevance_score": "0.105141", "ticker_sentiment_score": "0.256105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.105141", "ticker_sentiment_score": "0.264846", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2145173/should-you-invest-in-the-invesco-biotechnology-genome-pbe", "time_published": "20230906T102004", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default72.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.196183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.195287", "ticker_sentiment_score": "0.113137", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - NEWR, AMNB, DBTX, RETA", "url": "https://www.benzinga.com/pressreleases/23/09/g34257451/alert-the-m-a-class-action-firm-continues-investigating-the-merger-newr-amnb-dbtx-reta", "time_published": "20230905T234611", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.344643, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NEWR", "relevance_score": "0.266828", "ticker_sentiment_score": "0.241955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.135347", "ticker_sentiment_score": "0.197052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.266828", "ticker_sentiment_score": "0.237955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.161474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.067919", "ticker_sentiment_score": "0.119896", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.266828", "ticker_sentiment_score": "0.235329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.266828", "ticker_sentiment_score": "0.31425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.161474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.120992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Bausch & Lomb, Aldeyra, Vanda, Allakos, Regeneron, JW, Nanomerics, OKYO Pharma", "url": "https://www.prnewswire.com/news-releases/allergic-conjunctivitis-market-is-expected-to-showcase-a-significant-growth-by-2032-predicts-delveinsight--key-companies---bausch--lomb-aldeyra-vanda-allakos-regeneron-jw-nanomerics-okyo-pharma-301916685.html", "time_published": "20230904T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.093016, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLK", "relevance_score": "0.105141", "ticker_sentiment_score": "0.013332", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAPT", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMMLD", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.052685", "ticker_sentiment_score": "0.012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Gains 13% in 1 Month on FDA Nod For Eylea HD", "url": "https://www.zacks.com/stock/news/2143243/regeneron-regn-gains-13-in-1-month-on-fda-nod-for-eylea-hd", "time_published": "20230831T174300", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.199762, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.199463", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.113597", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.056943", "ticker_sentiment_score": "0.201995", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc.  ( Nasdaq - ACER ) , Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34142398/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-acer-therapeu", "time_published": "20230831T125433", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 31, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999355"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.261848, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACER", "relevance_score": "0.064973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZVRA", "relevance_score": "0.129516", "ticker_sentiment_score": "0.170361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOVO", "relevance_score": "0.064973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.193207", "ticker_sentiment_score": "0.255165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.193207", "ticker_sentiment_score": "0.059393", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTG", "relevance_score": "0.255641", "ticker_sentiment_score": "0.152225", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.189349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.064973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/34125693/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity", "time_published": "20230830T204549", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.127536, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.83872", "ticker_sentiment_score": "0.117595", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.184598", "ticker_sentiment_score": "-0.17771", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734798/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230830T201500", "authors": ["Alvotech"], "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.122774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.041586", "ticker_sentiment_score": "0.027392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.45704", "ticker_sentiment_score": "0.250081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734797/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230830T201500", "authors": ["Alvotech"], "summary": "REYKJAVIK, Iceland, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.122757, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.041442", "ticker_sentiment_score": "0.02738", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.455642", "ticker_sentiment_score": "0.249568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Allakos Appoints Neil Graham to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734781/0/en/Allakos-Appoints-Neil-Graham-to-its-Board-of-Directors.html", "time_published": "20230830T200500", "authors": ["Allakos Inc."], "summary": "SAN CARLOS, Calif., Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Allakos Inc. ( Nasdaq: ALLK ) , a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/58aeb59e-2de0-4f25-a39b-cd7e644f9fc1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.031547, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZURA", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.221004", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TLSA", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.221004", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASLN", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.221004", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALLK", "relevance_score": "0.831429", "ticker_sentiment_score": "0.033106", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.221004", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PMXSF", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.221004", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "10 growth stocks that are trading at bargain prices, including Delta and Cheniere Energy", "url": "https://www.marketwatch.com/story/10-growth-stocks-that-are-trading-at-bargain-prices-including-delta-and-cheniere-energy-1c407efd", "time_published": "20230830T161000", "authors": ["Philip van Doorn"], "summary": "These stocks trade at low P/E ratios, pass FTSE Russell's growth screens and are favored by analysts.", "banner_image": "https://images.mktw.net/im-844586/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.234314, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.113329", "ticker_sentiment_score": "0.177675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.113329", "ticker_sentiment_score": "0.177675", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34097085/shareholder-investigation-halper-sadeh-llc-investigates-dbtx-amed-reta-surf", "time_published": "20230829T163452", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128205, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SURF", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMED", "relevance_score": "0.255641", "ticker_sentiment_score": "0.157578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.129516", "ticker_sentiment_score": "0.091303", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.185732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.129516", "ticker_sentiment_score": "0.185732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.129516", "ticker_sentiment_score": "0.091303", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34095921/moore-kuehn-encourages-amed-dbtx-reta-and-surf-investors-to-contact-law-firm", "time_published": "20230829T154747", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.200602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.02614", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.213988", "ticker_sentiment_score": "0.311241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMED", "relevance_score": "0.213988", "ticker_sentiment_score": "0.311241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHRS", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca", "url": "https://www.zacks.com/stock/news/2141956/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-merck-novartis-and-astrazeneca", "time_published": "20230829T134500", "authors": ["Zacks Equity Research"], "summary": "Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.223165, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.100518", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.150278", "ticker_sentiment_score": "-0.032857", "ticker_sentiment_label": "Neutral"}]}, {"title": "Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy - Celularity  ( NASDAQ:CELU ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/34090241/small-cancer-therapy-player-celularity-to-provide-research-support-for-regenerons-therapy", "time_published": "20230829T134116", "authors": ["Vandana Singh"], "summary": "Celularity Inc CELU shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc REGN. The pact supports the research of Regeneron's allogeneic cell therapy candidates.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/29/aapharma_2.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.364341, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CELU", "relevance_score": "0.779232", "ticker_sentiment_score": "0.598606", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.459624", "ticker_sentiment_score": "0.61915", "ticker_sentiment_label": "Bullish"}]}, {"title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, CELL, ESTE, CPRI", "url": "https://www.benzinga.com/pressreleases/23/08/g34079898/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-cell-este-cpri", "time_published": "20230828T213427", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.346793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.16163", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TPR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.127207", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRKR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.127207", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRI", "relevance_score": "0.269776", "ticker_sentiment_score": "0.251887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.068698", "ticker_sentiment_score": "0.120002", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELL", "relevance_score": "0.269776", "ticker_sentiment_score": "0.251887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.269776", "ticker_sentiment_score": "0.237338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESTE", "relevance_score": "0.269776", "ticker_sentiment_score": "0.316831", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oncology Market's Huge Potential Puts These Stocks in Focus", "url": "https://www.zacks.com/stock/news/2141307/oncology-markets-huge-potential-puts-these-stocks-in-focus", "time_published": "20230828T123800", "authors": ["Sanghamitra Saha"], "summary": "The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/2078.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.230424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.107978", "ticker_sentiment_score": "0.080642", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.161349", "ticker_sentiment_score": "0.023487", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street Thinks This Tiny Biotech Company Could Soar Soon", "url": "https://www.fool.com/investing/2023/08/28/wall-street-thinks-this-tiny-biotech-company-could/", "time_published": "20230828T123000", "authors": ["George Budwell"], "summary": "An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745581%2Fresearcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.204223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.055621", "ticker_sentiment_score": "0.157909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.110973", "ticker_sentiment_score": "0.079156", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/34048020/check-out-what-whales-are-doing-with-regn", "time_published": "20230825T180105", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.132589, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.130889", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.102888", "ticker_sentiment_score": "0.230525", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.755492", "ticker_sentiment_score": "0.015699", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.130889", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inside Tema ETFs' New Oncology ETF  ( CANC ) ", "url": "https://www.zacks.com/stock/news/2141014/inside-tema-etfs-new-oncology-etf-canc", "time_published": "20230825T180000", "authors": ["Sanghamitra Saha"], "summary": "Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/1042.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.129037, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IVZ", "relevance_score": "0.074926", "ticker_sentiment_score": "0.058097", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.074926", "ticker_sentiment_score": "0.050822", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.074926", "ticker_sentiment_score": "0.050822", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics", "url": "https://www.zacks.com/stock/news/2140807/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-gilead-sciences-novavax-apellis-pharmaceuticals-and-fulcrum-therapeutics", "time_published": "20230825T131600", "authors": ["Zacks Equity Research"], "summary": "Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.148916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.10087", "ticker_sentiment_score": "0.038774", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.10087", "ticker_sentiment_score": "0.054348", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.200134", "ticker_sentiment_score": "0.040362", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "0.030389", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.10087", "ticker_sentiment_score": "0.059516", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.10087", "ticker_sentiment_score": "0.062715", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insmed Shows Market Leadership With Jump To 81 RS Rating", "url": "https://www.investors.com/ibd-data-stories/insmed-shows-market-leadership-with-jump-to-81-rs-rating/", "time_published": "20230825T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When building your watch list, look for stocks with an 80 or higher RS Rating. Insmed ( INSM ) now meets that criteria, with a jump from 75 to 81 Friday. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.343361, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KNSA", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.178459", "ticker_sentiment_score": "0.08235", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.501398", "ticker_sentiment_score": "0.345923", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amicus Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold", "url": "https://www.investors.com/ibd-data-stories/amicus-therapeutics-scores-relative-strength-rating-upgrade-hits-key-threshold/", "time_published": "20230825T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Amicus Therapeutics Scores Relative Strength Rating Upgrade. Hits ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.308953, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.343279", "ticker_sentiment_score": "0.646625", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Zynerba Pharmaceuticals, Inc.  ( Nasdaq - ZYNE ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34028240/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-sovos-brands-", "time_published": "20230824T161728", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 24, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.28623, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SOVO", "relevance_score": "0.06623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.196877", "ticker_sentiment_score": "0.258638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.196877", "ticker_sentiment_score": "0.060245", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTG", "relevance_score": "0.26042", "ticker_sentiment_score": "0.154469", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HRMY", "relevance_score": "0.132004", "ticker_sentiment_score": "0.241757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.132004", "ticker_sentiment_score": "0.19117", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZYNE", "relevance_score": "0.06623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.06623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More", "url": "https://www.zacks.com/stock/news/2140318/biotech-stock-roundup-regn-up-on-approval-apls-nvax-gain-on-updates-more", "time_published": "20230824T141500", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.153817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.071463", "ticker_sentiment_score": "0.075322", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.071463", "ticker_sentiment_score": "0.112486", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.17741", "ticker_sentiment_score": "0.058468", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.071463", "ticker_sentiment_score": "0.030591", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.071463", "ticker_sentiment_score": "0.143951", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.071463", "ticker_sentiment_score": "0.136884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Investor Conference Presentations", "url": "https://www.globenewswire.com/news-release/2023/08/23/2730718/0/en/Regeneron-Announces-Investor-Conference-Presentations.html", "time_published": "20230823T200500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "TARRYTOWN, N.Y., Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) will webcast management participation as follows: ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.104383, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.158519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.158519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Investor Conference Presentations - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34012324/regeneron-announces-investor-conference-presentations", "time_published": "20230823T200500", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN will webcast management participation as follows: \u2022 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 \u2022 Morgan Stanley 21st Annual Global Healthcare Conference at ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.092292, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.282234", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.143415", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.143415", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer", "url": "https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-departure-of-chief-financial-officer-laurie-stelzer-301908485.html", "time_published": "20230823T200000", "authors": ["Inc.", "Mirati Therapeutics"], "summary": "SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.\u00ae ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.", "banner_image": "https://mma.prnewswire.com/media/341355/Mirati_Tx_v2_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.112191, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.064015", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.364275", "ticker_sentiment_score": "0.21646", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top 5 Health Care Stocks That May Fall Off A Cliff - Praxis Precision Medicine  ( NASDAQ:PRAX ) , Capricor Therapeutics  ( NASDAQ:CAPR ) ", "url": "https://www.benzinga.com/news/23/08/34001545/top-5-health-care-stocks-that-may-fall-off-a-cliff", "time_published": "20230823T115845", "authors": ["Lisa Levin"], "summary": "The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/23/image36.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.264839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRAX", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.068507", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.329551", "ticker_sentiment_score": "0.102161", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPR", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.068507", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, DBTX, CPRI, AVID - Capri Holdings  ( NYSE:CPRI ) , Avid Technology  ( NASDAQ:AVID ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33998548/shareholder-investigation-halper-sadeh-llc-investigates-vrtv-dbtx-cpri-avid", "time_published": "20230823T081539", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.1378, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPRI", "relevance_score": "0.124809", "ticker_sentiment_score": "0.011865", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.124809", "ticker_sentiment_score": "0.182563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.124809", "ticker_sentiment_score": "0.182563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVID", "relevance_score": "0.124809", "ticker_sentiment_score": "0.15699", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTV", "relevance_score": "0.246582", "ticker_sentiment_score": "0.113074", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPR", "relevance_score": "0.124809", "ticker_sentiment_score": "0.011865", "ticker_sentiment_label": "Neutral"}]}, {"title": "Axsome Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/axsome-therapeutics-scores-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20230823T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Axsome Therapeutics Scores Relative Strength Rating Upgrade ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.359429, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.651499", "ticker_sentiment_score": "0.205413", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/08/33994166/regeneron-awarded-326m-government-contract-for-covid-19-antibody-therapy-development", "time_published": "20230822T204339", "authors": ["Adam Eckert"], "summary": "Regeneron Pharmaceuticals Inc REGN was awarded a government contract valued at up to $326 million on Tuesday. Here are the details.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/22/test-tube-5065426_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.228098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.498188", "ticker_sentiment_score": "0.651361", "ticker_sentiment_label": "Bullish"}]}, {"title": "US govt awards $1.4 bln for development of new COVID therapies, vaccines", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-govt-awards-14-bln-development-new-covid-therapies-vaccines-2023-08-22/", "time_published": "20230822T194500", "authors": ["Reuters"], "summary": "The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GOFRENRMTVPIXL4TZWNSJXPNM4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.032775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.401331", "ticker_sentiment_score": "-0.010895", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33991392/regeneron-announces-agreement-with-barda-supporting-development-of-next-generation-antibody-therap", "time_published": "20230822T181541", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Aug. 22, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.20818, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.156461", "ticker_sentiment_score": "0.134525", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention", "url": "https://www.globenewswire.com/news-release/2023/08/22/2729953/0/en/Regeneron-Announces-Agreement-with-BARDA-Supporting-Development-of-Next-Generation-Antibody-Therapy-for-COVID-19-Prevention.html", "time_published": "20230822T181500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Program is part of U.S. Government's 'Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody therapy Program is part of U.S. Government's 'Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.167308, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.102449", "ticker_sentiment_score": "0.065335", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025679", "ticker_sentiment_score": "0.048368", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm - Arco Platform  ( NASDAQ:ARCE ) , Avid Technology  ( NASDAQ:AVID ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33990599/moore-kuehn-encourages-dbtx-avid-cpri-and-arce-investors-to-contact-law-firm", "time_published": "20230822T173017", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 22, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.225867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.02614", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRI", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCE", "relevance_score": "0.107978", "ticker_sentiment_score": "0.20215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33989686/peering-into-regeneron-pharmaceuticalss-recent-short-interest", "time_published": "20230822T164520", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 6.52% since its last report. The company recently reported that it has 1.34 million shares sold short, which is 1.47% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Flashing Renewed Technical Strength: ACELYRIN", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-acelyrin/", "time_published": "20230822T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "ACELYRIN ( SLRN ) had its Relative Strength ( RS ) Rating upgraded from 87 to 91 Tuesday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.367086, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.338582", "ticker_sentiment_score": "0.129299", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.338582", "ticker_sentiment_score": "0.129299", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.618922", "ticker_sentiment_score": "0.600524", "ticker_sentiment_label": "Bullish"}]}, {"title": "Alkermes Clears Key Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/alkermes-clears-key-benchmark-hitting-80-plus-rs-rating-2/", "time_published": "20230822T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Alkermes ( ALKS ) , which had its Relative Strength ( RS ) Rating upgraded from 79 to 82 Tuesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.316438, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.468029", "ticker_sentiment_score": "0.236265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CELL, DBTX, CPRI, ESTE", "url": "https://www.benzinga.com/pressreleases/23/08/g33973966/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-cell-dbtx-cpri-este", "time_published": "20230821T213234", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.346793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.16163", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TPR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.127207", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRKR", "relevance_score": "0.068698", "ticker_sentiment_score": "0.127207", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRI", "relevance_score": "0.269776", "ticker_sentiment_score": "0.251887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.068698", "ticker_sentiment_score": "0.120002", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELL", "relevance_score": "0.269776", "ticker_sentiment_score": "0.251887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.269776", "ticker_sentiment_score": "0.237338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESTE", "relevance_score": "0.269776", "ticker_sentiment_score": "0.316831", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33967522/regenerons-crucial-eylea-hd-approval-a-shield-against-potential-biosimilar-competit", "time_published": "20230821T190431", "authors": ["Vandana Singh"], "summary": "Friday, the FDA approved Regeneron Pharmaceuticals Inc's REGN approved Eylea HD ( aflibercept ) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy ( DR ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/21/regn_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.338626, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.30569", "ticker_sentiment_score": "0.21245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.104228", "ticker_sentiment_score": "0.260211", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  Gets FDA Nod for Higher Dose of Eylea", "url": "https://www.zacks.com/stock/news/2138751/regeneron-regn-gets-fda-nod-for-higher-dose-of-eylea", "time_published": "20230821T152300", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.17076, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.167322", "ticker_sentiment_score": "0.046973", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.056143", "ticker_sentiment_score": "0.214983", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.167322", "ticker_sentiment_score": "0.122906", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33959971/fda-approves-regenerons-drug-for-ultra-rare-immune-disorder", "time_published": "20230821T141809", "authors": ["Vandana Singh"], "summary": "The FDA approved Regeneron Pharmaceuticals Inc's REGN Veopoz ( pozelimab-bbfg ) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/21/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0653, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.423843", "ticker_sentiment_score": "0.296755", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why This Regeneron Approval 'Could Not Come Soon Enough'", "url": "https://www.investors.com/news/technology/regn-stock-climbs-as-fda-approves-high-dose-eylea-why-the-approval-could-not-come-soon-enough/", "time_published": "20230821T140100", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Climbs As FDA Approves High-Dose Eylea. Why The ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-regeneron-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.205742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.008689", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's Eylea could return to growth after nod to high-dose version- analysts", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regenerons-eylea-could-return-growth-after-nod-high-dose-version-analysts-2023-08-21/", "time_published": "20230821T134100", "authors": ["Reuters"], "summary": "The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://graphics.reuters.com/REGENERON-RESEARCH/egvbmmxkmpq/US-sales-of-regeneron-s-eye-drug-eylea.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.207778, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.207571", "ticker_sentiment_score": "0.279815", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTLT", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.005657", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.069617", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Monday", "url": "https://www.cnbc.com/2023/08/21/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html", "time_published": "20230821T130637", "authors": ["Jim Cramer"], "summary": "Stocks edge up in premarket trading Monday, following three-consecutive weeks of losses, as the market looks to Nvidia's (NVDA) quarterly report.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107247053-1685079163512-gettyimages-1177538069-MOBILE_WORLD_CONGRESS.jpeg?v=1692623197&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.175159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.058903", "ticker_sentiment_score": "0.067987", "ticker_sentiment_label": "Neutral"}, {"ticker": "DE", "relevance_score": "0.117486", "ticker_sentiment_score": "0.028623", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.175433", "ticker_sentiment_score": "-0.020198", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.058903", "ticker_sentiment_score": "0.245053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PTON", "relevance_score": "0.117486", "ticker_sentiment_score": "0.076178", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.174511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.117486", "ticker_sentiment_score": "0.078557", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.117486", "ticker_sentiment_score": "0.1932", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.117486", "ticker_sentiment_score": "0.276597", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33959575/fda-approves-regeneron-pharmaceuticals-higher-dose-of-eylea-for-age-related-blindness", "time_published": "20230821T123748", "authors": ["Vandana Singh"], "summary": "The FDA approved Regeneron Pharmaceuticals Inc's REGN approved Eylea HD ( aflibercept ) Injection 8 mg for wet age-related macular degeneration ( wAMD ) , diabetic macular edema ( DME ) , and diabetic retinopathy ( DR ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/21/aapharma.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.138908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.431065", "ticker_sentiment_score": "0.259452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.295867", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Regeneron Pharmaceuticals Still a Top Growth Stock?", "url": "https://www.fool.com/investing/2023/08/21/is-regeneron-pharmaceuticals-still-a-top-growth-st/", "time_published": "20230821T103000", "authors": ["George Budwell"], "summary": "The biotech's focus on innovation could be a boon for shareholders.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744754%2Fhealthcare.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.258645, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.110462", "ticker_sentiment_score": "0.09317", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.055364", "ticker_sentiment_score": "-0.025015", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.110462", "ticker_sentiment_score": "0.191467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.055364", "ticker_sentiment_score": "0.140427", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/08/20/regeneron-pharmaceuticals-nasdaqregn-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20230820T052103", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Coverage Initiated ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.995921"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.301504, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ROST", "relevance_score": "0.046095", "ticker_sentiment_score": "0.096462", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFC", "relevance_score": "0.046095", "ticker_sentiment_score": "0.054492", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.046095", "ticker_sentiment_score": "0.054492", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.752347", "ticker_sentiment_score": "0.450465", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.046095", "ticker_sentiment_score": "0.054492", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNET", "relevance_score": "0.046095", "ticker_sentiment_score": "0.054492", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-regenerons-8-mg-dose-eye-disease-drug-eylea-2023-08-18/", "time_published": "20230818T232700", "authors": ["Reuters"], "summary": "US FDA approves Regeneron's 8-mg dose of eye disease drug ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/76SMXR5NUNLEZJWAJFJBYI6BBE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.099038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.468029", "ticker_sentiment_score": "0.274517", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EYLEA HD  ( aflibercept )  Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration  ( wAMD ) , Diabetic Macular Edema  ( DME )  and Diabetic Retinopathy  ( DR )  - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33928076/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macular-degen", "time_published": "20230818T223500", "authors": ["Globe Newswire"], "summary": "Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA\u00ae HD demonstrated clinically equivalent vision gains to EYLEA ( aflibercept ) Injection 2 mg that were maintained with fewer injections TARRYTOWN, N.Y., Aug. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.100219, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.068384", "ticker_sentiment_score": "0.043345", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.013693", "ticker_sentiment_score": "0.126116", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.013693", "ticker_sentiment_score": "0.039556", "ticker_sentiment_label": "Neutral"}]}, {"title": "EYLEA HD  ( aflibercept )  Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration  ( wAMD ) , Diabetic Macular Edema  ( DME )  and Diabetic Retinopathy  ( DR ) ", "url": "https://www.globenewswire.com/news-release/2023/08/18/2728276/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Approved-by-FDA-for-Treatment-of-Wet-Age-related-Macular-Degeneration-wAMD-Diabetic-Macular-Edema-DME-and-Diabetic-Retinopathy-DR.html", "time_published": "20230818T223500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA\u00ae HD demonstrated clinically equivalent vision gains to EYLEA ( aflibercept ) Injection 2 mg that were maintained with fewer injections ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.102831, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.067804", "ticker_sentiment_score": "0.046358", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.013577", "ticker_sentiment_score": "0.126013", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.013577", "ticker_sentiment_score": "0.040461", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA approves Regeneron's ultra-rare blood disease drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-regenerons-ultra-rare-blood-disease-drug-2023-08-18/", "time_published": "20230818T180500", "authors": ["Reuters"], "summary": "The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/WGUWEQZMQFOL5BWWI7EQVGM5SY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.156581, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.485711", "ticker_sentiment_score": "0.311891", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Veopoz\u2122  ( pozelimab-bbfg )  Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33920844/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-ch", "time_published": "20230818T174319", "authors": ["Globe Newswire"], "summary": "Approval represents 10th FDA-approved medicine invented by Regeneron TARRYTOWN, N.Y., Aug. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.01706, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.079656", "ticker_sentiment_score": "0.037965", "ticker_sentiment_label": "Neutral"}]}, {"title": "Veopoz\u2122  ( pozelimab-bbfg )  Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease", "url": "https://www.globenewswire.com/news-release/2023/08/18/2728227/0/en/Veopoz-pozelimab-bbfg-Receives-FDA-Approval-as-the-First-Treatment-for-Children-and-Adults-with-CHAPLE-Disease.html", "time_published": "20230818T174300", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.021812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.066672", "ticker_sentiment_score": "0.051303", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.013349", "ticker_sentiment_score": "0.047138", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's  ( REGN )  Application for Blood Cancer Drug Accepted", "url": "https://www.zacks.com/stock/news/2138298/regenerons-regn-application-for-blood-cancer-drug-accepted", "time_published": "20230818T162000", "authors": ["Zacks Equity Research"], "summary": "Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default20.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.076841, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.032244", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.169676", "ticker_sentiment_score": "-0.001422", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.169676", "ticker_sentiment_score": "0.065321", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.169676", "ticker_sentiment_score": "0.132835", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug", "url": "https://www.zacks.com/stock/news/2138154/pharma-stock-roundup-fda-okays-pfe-jnj-drugs-eu-approves-abbvs-migraine-drug", "time_published": "20230818T153800", "authors": ["Kinjel Shah"], "summary": "FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.161528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.134806", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.110209", "ticker_sentiment_score": "0.075832", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.036988", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/08/18/2-biotech-stocks-that-could-make-you-richer/", "time_published": "20230818T140000", "authors": ["Prosper Junior Bakiny"], "summary": "Neither is performing particularly well this year compared to the broader market, but don't let that chase you away.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743922%2Fexcited-investor-looks-at-financial-charts-on-computer.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.214382, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.320081", "ticker_sentiment_score": "0.11899", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.046999", "ticker_sentiment_score": "-0.015826", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.483229", "ticker_sentiment_score": "0.350401", "ticker_sentiment_label": "Bullish"}]}, {"title": "Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33893875/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsedrefractory-follicular-lymphom", "time_published": "20230817T123011", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.108929, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.208914", "ticker_sentiment_score": "0.023548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "url": "https://www.globenewswire.com/news-release/2023/08/17/2727249/0/en/Odronextamab-Receives-EMA-Filing-Acceptance-for-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma-and-Diffuse-Large-B-cell-Lymphoma.html", "time_published": "20230817T123000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "TARRYTOWN, N.Y., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the European Medicines Agency ( EMA ) has accepted for review the Marketing Authorization Application ( MAA ) for odronextamab to treat adult patients with ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.123073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.127321", "ticker_sentiment_score": "0.053798", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025569", "ticker_sentiment_score": "0.050097", "ticker_sentiment_label": "Neutral"}]}, {"title": "Macular Degeneration Treatment Market to Expand USD 21.1 Bn by 2031, Registering at a CAGR of 8.8% | Exclusive Report by Transparency Market Research", "url": "https://www.benzinga.com/pressreleases/23/08/g33892714/macular-degeneration-treatment-market-to-expand-usd-21-1-bn-by-2031-registering-at-a-cagr-of-8-8-e", "time_published": "20230817T113000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global macular degeneration treatment market is projected to exceed US$ 21.1 Bn by 2031, up from US$ 9.0 Bn in 2021.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.120581, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.026846", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.026846", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.026846", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.026846", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.026846", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others Are In Buy Zones", "url": "https://www.investors.com/research/ibd-stock-screener-includes-meta-tesla-other-big-techs-but-these-others-are-in-buy-zones/", "time_published": "20230816T173900", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-Amazon-doorstep-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.917436"}], "overall_sentiment_score": 0.242434, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.053271", "ticker_sentiment_score": "0.186739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.210731", "ticker_sentiment_score": "0.219949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.158868", "ticker_sentiment_score": "0.086464", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.158868", "ticker_sentiment_score": "0.130202", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.053271", "ticker_sentiment_score": "0.206771", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADBE", "relevance_score": "0.158868", "ticker_sentiment_score": "0.11485", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHG", "relevance_score": "0.053271", "ticker_sentiment_score": "0.171717", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.158868", "ticker_sentiment_score": "0.215904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.158868", "ticker_sentiment_score": "0.193519", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "\"Motley Fool Money\" Mailbag: Commercial Real Estate, Personal Finance, and International Investing", "url": "https://www.fool.com/investing/2023/08/16/mailbag-commercial-real-estate-personal-finance-an/", "time_published": "20230816T092200", "authors": ["Motley Fool Staff"], "summary": "We answer some of the questions you've emailed us at podcasts@fool.com. We've also got a listener hotline! Leave us a voice mail with your question at 703-254-1445.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Economy - Macro", "relevance_score": "0.998626"}], "overall_sentiment_score": 0.136112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IBKR", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.027534", "ticker_sentiment_label": "Neutral"}, {"ticker": "KN", "relevance_score": "0.014816", "ticker_sentiment_score": "0.018437", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.022222", "ticker_sentiment_score": "0.07253", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.030606", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.030606", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.030606", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPH", "relevance_score": "0.073978", "ticker_sentiment_score": "0.032583", "ticker_sentiment_label": "Neutral"}, {"ticker": "FREQ", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.00251", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.007408", "ticker_sentiment_score": "0.092675", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.00251", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.007408", "ticker_sentiment_score": "-0.00251", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWWBF", "relevance_score": "0.051822", "ticker_sentiment_score": "0.031994", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:AUD", "relevance_score": "0.007408", "ticker_sentiment_score": "0.016637", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.022222", "ticker_sentiment_score": "0.117907", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33863985/100-invested-in-this-stock-20-years-ago-would-be-worth-5-400-today", "time_published": "20230815T173019", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.59% on an annualized basis producing an average annual return of 22.34%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.68 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica  ( Nasdaq - SOLO ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33860518/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-electrameccan", "time_published": "20230815T143711", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 15, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.684621"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.202495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.172097", "ticker_sentiment_score": "0.223988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.255641", "ticker_sentiment_score": "0.074053", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTG", "relevance_score": "0.33628", "ticker_sentiment_score": "0.188135", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept", "url": "https://www.globenewswire.com/news-release/2023/08/15/2725167/0/en/Sandoz-announces-positive-results-from-Mylight-Phase-lll-study-for-biosimilar-aflibercept.html", "time_published": "20230815T051500", "authors": ["Novartis Pharma AG"], "summary": "Basel, August 15, 2023 - Sandoz, a global leader in off-patent medicines, today releases positive results from the MYLIGHT Phase III confirmatory efficacy and safety study for its biosimilar aflibercept, for patients living with wet macular degeneration - a key development in its efforts to ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/d2955638-e1e1-4d2b-8341-7d4a492754be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.205898, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.029876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.029876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/33840559/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230814T174631", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.06636, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.898236", "ticker_sentiment_score": "0.100063", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.133117", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.133117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vivek Ramaswamy-Founded Biotech Reports Steep Losses, Light Sales", "url": "https://www.investors.com/news/technology/roiv-stock-roivant-earnings-q2-2023/", "time_published": "20230814T110000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "ROIV Stock, A Top Biotech Stock, Misses On Both Sales And Losses Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-DrugsPills-14-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.098224, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.140896", "ticker_sentiment_score": "0.128011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.522333", "ticker_sentiment_score": "-0.092003", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.070725", "ticker_sentiment_score": "-0.056883", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.103977", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating", "url": "https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-shows-rising-price-performance-with-jump-to-82-rs-rating/", "time_published": "20230814T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Monday, Regeneron Pharmaceuticals ( REGN ) got an upgrade to its Relative Strength ( RS ) Rating, from 74 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.344683, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.518022", "ticker_sentiment_score": "0.261692", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG - Computer Task Gr  ( NASDAQ:CTG ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33791951/lifshitz-law-pllc-announces-investigations-of-wmc-mitt-dbtx-and-ctg", "time_published": "20230813T001700", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 12, 2023 ( GLOBE NEWSWIRE ) -- Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.187492, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MITT", "relevance_score": "0.397517", "ticker_sentiment_score": "0.155211", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.082963", "ticker_sentiment_score": "0.139129", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/08/12/regeneron-pharmaceuticals-nasdaqregn-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230812T054051", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research report issued to clients and investors on Saturday.", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.294058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.76367", "ticker_sentiment_score": "0.466694", "ticker_sentiment_label": "Bullish"}, {"ticker": "TFC", "relevance_score": "0.04497", "ticker_sentiment_score": "0.037166", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.04497", "ticker_sentiment_score": "0.037166", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, DBTX - Computer Task Gr  ( NASDAQ:CTG ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33754883/shareholder-investigation-halper-sadeh-llc-investigates-ctg-dbtx", "time_published": "20230811T161137", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 11, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Computer Task Group, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.131236, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.152499", "ticker_sentiment_score": "0.202868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.152499", "ticker_sentiment_score": "0.202868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTG", "relevance_score": "0.299478", "ticker_sentiment_score": "0.155597", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "'s 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet - Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33750159/benzingas-stock-whisper-index-5-stocks-investors-are-secretly-monitoring-but-not-talking-about-ye", "time_published": "20230811T145457", "authors": ["Chris Katje"], "summary": "Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/11/stock_whisper_index_logo_6_copy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.19219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XFOR", "relevance_score": "0.122581", "ticker_sentiment_score": "-0.021855", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNI", "relevance_score": "0.242285", "ticker_sentiment_score": "0.080676", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122581", "ticker_sentiment_score": "0.302153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.122581", "ticker_sentiment_score": "0.302153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORGN", "relevance_score": "0.122581", "ticker_sentiment_score": "-0.103341", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.242285", "ticker_sentiment_score": "0.115057", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News", "url": "https://www.zacks.com/stock/news/2135802/biotech-stock-roundup-sage-grtx-plunge-on-setback-regn-to-buy-dbtx-more-news", "time_published": "20230811T143400", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.104054, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.069869", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.039878", "ticker_sentiment_score": "-0.028661", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTX", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.033262", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.041673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/08/11/2723474/0/en/Decibel-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html", "time_published": "20230811T114500", "authors": ["Inc.", "Decibel Therapeutics"], "summary": "- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities. anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/83689706-9e23-448c-9c5e-fa03a8df7d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.185664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.152018", "ticker_sentiment_score": "0.09331", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.101689", "ticker_sentiment_score": "0.121334", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33713936/regenerons-aflibercept-8mg-shows-sustained-vision-gains-at-two-years", "time_published": "20230810T163157", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN announced two-year ( 96 weeks ) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration ( wAMD ) . Among those who completed the two-year follow-up: 88% were on a \u226512-week dosing ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/10/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.030121, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.392948", "ticker_sentiment_score": "-0.04595", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  to Buy Decibel, Gains on Hearing Loss Therapies", "url": "https://www.zacks.com/stock/news/2135290/regeneron-regn-to-buy-decibel-gains-on-hearing-loss-therapies", "time_published": "20230810T160300", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/845.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.127681, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.196877", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.132004", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.196877", "ticker_sentiment_score": "0.14785", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/33713203/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230810T153108", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.145857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.845242", "ticker_sentiment_score": "0.189044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.09439", "ticker_sentiment_score": "-0.12791", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.09439", "ticker_sentiment_score": "-0.12791", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Biotech Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/08/10/3-top-biotech-stocks-defying-the-bear-market/", "time_published": "20230810T092100", "authors": ["Jim Halley"], "summary": "Biotech is still booming, if you pick the right biotech stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.13342, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.125025", "ticker_sentiment_score": "0.159439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.083541", "ticker_sentiment_score": "0.079729", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.325208", "ticker_sentiment_score": "0.23977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTLT", "relevance_score": "0.041828", "ticker_sentiment_score": "-0.016836", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.083541", "ticker_sentiment_score": "0.146184", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041828", "ticker_sentiment_score": "-0.036768", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Trying To Close In On Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-trying-to-close-in-on-key-technical-benchmark/", "time_published": "20230810T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Thursday, Regeneron Pharmaceuticals ( REGN ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 68 to 74. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.384273, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.827318", "ticker_sentiment_score": "0.551522", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Generalized Myasthenia Gravis Market is Expected to Expand by 2032, Assesses DelveInsight | Key Companies - Alexion, Argenx, UCB, Horizon, Roche, Janssen Bristol Myers Squibb, Biogen Pfizer, Novartis, Sanofi, Takeda", "url": "https://www.prnewswire.com/news-releases/generalized-myasthenia-gravis-market-is-expected-to-expand-by-2032-assesses-delveinsight--key-companies---alexion-argenx-ucb-horizon-roche-janssen-bristol-myers-squibb-biogen-pfizer-novartis-sanofi-takeda-301896552.html", "time_published": "20230809T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Generalized Myasthenia Gravis Market is Expected to Expand by 2032, Assesses DelveInsight | Key Companies ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.216508, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMVT", "relevance_score": "0.026503", "ticker_sentiment_score": "0.099064", "ticker_sentiment_label": "Neutral"}, {"ticker": "CABA", "relevance_score": "0.052977", "ticker_sentiment_score": "0.014903", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGCF", "relevance_score": "0.026503", "ticker_sentiment_score": "0.099064", "ticker_sentiment_label": "Neutral"}, {"ticker": "RLYB", "relevance_score": "0.052977", "ticker_sentiment_score": "0.014903", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.026503", "ticker_sentiment_score": "0.099064", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.026503", "ticker_sentiment_score": "0.099064", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.052977", "ticker_sentiment_score": "0.014903", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.074093", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.026503", "ticker_sentiment_score": "0.099064", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.052977", "ticker_sentiment_score": "0.014903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.074093", "ticker_sentiment_label": "Neutral"}]}, {"title": "Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/m-a/23/08/33670770/health-care-company-regeneron-pharmaceuticals-announces-acquisition-of-decibel-therapeutics", "time_published": "20230809T151006", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has announced an acquisition of Decibel Therapeutics DBTX that is expected to be completed in Q3 of 2023. Under the terms of the agreement, Regeneron Pharmaceuticals has agreed to give Decibel Therapeutics $213.00 million in cash in exchange for DBTX stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.102356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.492659", "ticker_sentiment_score": "-0.20842", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DBTX", "relevance_score": "0.592742", "ticker_sentiment_score": "0.532617", "ticker_sentiment_label": "Bullish"}]}, {"title": "DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals - Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33667486/dbtx-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-decibel-therapeutics", "time_published": "20230809T133123", "authors": ["Globe Newswire"], "summary": "MONSEY, N.Y., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right ( \"CVR\" ) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.232736, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.112532", "ticker_sentiment_score": "0.233034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.222838", "ticker_sentiment_score": "0.347618", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Decibel Therapeutics Stock Soars on Acquisition Deal - The Details - Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details", "time_published": "20230809T132414", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN has agreed to acquire Decibel Therapeutics Inc DBTX at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel's lead investigational ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/09/dbtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.145291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.368773", "ticker_sentiment_score": "0.674689", "ticker_sentiment_label": "Bullish"}, {"ticker": "DBTX", "relevance_score": "0.528475", "ticker_sentiment_score": "0.695937", "ticker_sentiment_label": "Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33666954/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-computer-task", "time_published": "20230809T131312", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.21835, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.207571", "ticker_sentiment_score": "0.255914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.306963", "ticker_sentiment_score": "0.085664", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTG", "relevance_score": "0.401331", "ticker_sentiment_score": "0.213415", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33660744/regeneron-to-acquire-decibel-therapeutics-strengthening-gene-therapy-and-hearing-loss-programs", "time_published": "20230809T113053", "authors": ["Globe Newswire"], "summary": "Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Decibel Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.999994"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999696"}], "overall_sentiment_score": 0.20185, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05439", "ticker_sentiment_score": "0.06101", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.05439", "ticker_sentiment_score": "0.067004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded by StockNews.com to \"Strong-Buy\"", "url": "https://www.defenseworld.net/2023/08/08/regeneron-pharmaceuticals-nasdaqregn-upgraded-by-stocknews-com-to-strong-buy.html", "time_published": "20230808T101439", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Regeneron Pharmaceuticals ( NASDAQ:REGN - Free Report ) from a buy rating to a strong-buy rating in a research report report published on Friday morning. REGN has been the topic of a number of other reports. Robert W.", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.283353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.771638", "ticker_sentiment_score": "0.452932", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.045743", "ticker_sentiment_score": "0.036452", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNET", "relevance_score": "0.045743", "ticker_sentiment_score": "0.036452", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/08/07/2719502/0/en/BioNTech-Announces-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html", "time_published": "20230807T100000", "authors": ["BioNTech SE"], "summary": "Conference call and webcast scheduled for August 7, 2023, at 8:00 am EDT ( 2:00 pm CEST ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9e2e00e-f790-4d54-a01f-4c85716b01bd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.204615, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOSUF", "relevance_score": "0.00987", "ticker_sentiment_score": "0.0068", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.00987", "ticker_sentiment_score": "-0.050379", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.00987", "ticker_sentiment_score": "0.0068", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.098456", "ticker_sentiment_score": "0.110349", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.334978", "ticker_sentiment_score": "0.230952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.00987", "ticker_sentiment_score": "0.0068", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Upgrades Regeneron Pharmaceuticals  ( NASDAQ:REGN )  to \"Strong-Buy\"", "url": "https://www.defenseworld.net/2023/08/06/stocknews-com-upgrades-regeneron-pharmaceuticals-nasdaqregn-to-strong-buy.html", "time_published": "20230806T060441", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report issued on Friday.", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.273494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBCPF", "relevance_score": "0.047092", "ticker_sentiment_score": "0.057431", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.785083", "ticker_sentiment_score": "0.440703", "ticker_sentiment_label": "Bullish"}, {"ticker": "WFC", "relevance_score": "0.047092", "ticker_sentiment_score": "0.057431", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.047092", "ticker_sentiment_score": "0.057431", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNET", "relevance_score": "0.047092", "ticker_sentiment_score": "0.057431", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33578514/regn-analyzing-regeneron-pharmaceuticalss-short-interest", "time_published": "20230804T164529", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 16.95% since its last report. The company recently reported that it has 1.27 million shares sold short, which is 1.38% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alnylam  ( ALNY )  Q2 Loss Wider Than Expected, Revenues Miss", "url": "https://www.zacks.com/stock/news/2132776/alnylam-alny-q2-loss-wider-than-expected-revenues-miss", "time_published": "20230804T152400", "authors": ["Zacks Equity Research"], "summary": "Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.148403, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.233556", "ticker_sentiment_score": "0.160761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.067632", "ticker_sentiment_score": "-0.023153", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.067632", "ticker_sentiment_score": "0.145477", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Under Pressure As Yields Soar: Weekly Review", "url": "https://www.investors.com/news/market-rally-under-pressure-as-yields-soar-amazon-elf-caterpillar-are-earnings-winners/", "time_published": "20230804T145100", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally came under pressure amid surging Treasury yields, fueled by a U.S. credit-rating downgrade as well, swelling Treasury issuance and improving U.S. economic growth. But yields pared gains following a mixed jobs report. Apple ( AAPL ) and Amazon ( AMZN ) capped a huge week of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/A1MAIN-bullsbears-100220-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.022066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.081111", "ticker_sentiment_score": "0.007297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.081111", "ticker_sentiment_score": "0.105986", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.04872", "ticker_sentiment_score": "0.015992", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.081111", "ticker_sentiment_score": "0.166261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.108704", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.064929", "ticker_sentiment_score": "0.132381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.040515", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "HWM", "relevance_score": "0.032491", "ticker_sentiment_score": "0.266242", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKNG", "relevance_score": "0.032491", "ticker_sentiment_score": "0.206139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.090092", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.081111", "ticker_sentiment_score": "-0.030628", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.032491", "ticker_sentiment_score": "0.13877", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.064929", "ticker_sentiment_score": "0.066645", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.081111", "ticker_sentiment_score": "0.023152", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNA", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.235891", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXPE", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNBR", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.198779", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGM", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLYS", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.108", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.010001", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.064929", "ticker_sentiment_score": "0.08922", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.065997", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.203852", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SQ", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.118638", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.016249", "ticker_sentiment_score": "-0.062612", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.121934", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.016249", "ticker_sentiment_score": "0.067967", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.032491", "ticker_sentiment_score": "0.023975", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SITM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.237782", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NIO", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.032491", "ticker_sentiment_score": "0.170055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GNRC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.23063", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.078464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.097259", "ticker_sentiment_score": "0.119103", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia  ( NTLA )  Misses on Q2 Earnings, Gives Pipeline Update", "url": "https://www.zacks.com/stock/news/2132773/intellia-ntla-misses-on-q2-earnings-gives-pipeline-update", "time_published": "20230804T141900", "authors": ["Zacks Equity Research"], "summary": "Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.11149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.244723", "ticker_sentiment_score": "0.25911", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADCT", "relevance_score": "0.184834", "ticker_sentiment_score": "-0.02297", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.839263", "ticker_sentiment_score": "0.254798", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ultragenyx  ( RARE )  Q2 Loss Wider Than Expected, Revenues Beat", "url": "https://www.zacks.com/stock/news/2132649/ultragenyx-rare-q2-loss-wider-than-expected-revenues-beat", "time_published": "20230804T121200", "authors": ["Zacks Equity Research"], "summary": "Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.10869, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADCT", "relevance_score": "0.219147", "ticker_sentiment_score": "0.036594", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.036983", "ticker_sentiment_score": "0.061539", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.073886", "ticker_sentiment_score": "0.114989", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.036983", "ticker_sentiment_score": "0.061539", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.323549", "ticker_sentiment_score": "0.111672", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.073886", "ticker_sentiment_score": "0.133203", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS", "url": "https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-financial-results-301893066.html", "time_published": "20230803T200100", "authors": ["Amgen"], "summary": "Positive Top-Line Results for LUMAKRAS\u00ae ( Sotorasib ) Plus Vectibix\u00ae ( Panitumumab ) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Aug. 3, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the second quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.118881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.014941", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.014941", "ticker_sentiment_score": "0.174477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.029876", "ticker_sentiment_score": "0.11085", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.014941", "ticker_sentiment_score": "0.094737", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Q2 Earnings & Sales Top, Eylea Sales Decline", "url": "https://www.zacks.com/stock/news/2132167/regeneron-regn-q2-earnings-sales-top-eylea-sales-decline", "time_published": "20230803T165300", "authors": ["Zacks Equity Research"], "summary": "Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.211765, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.22574", "ticker_sentiment_score": "0.27625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.045743", "ticker_sentiment_score": "0.069954", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.136629", "ticker_sentiment_score": "0.062995", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.26928", "ticker_sentiment_score": "0.26204", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Falls As Yields Surge; Warren Buffett Loads Up On Treasuries After Fitch Downgrade", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-yields-surge-warren-buffetts-top-holding-falls-on-earnings-as-buffett-loads-up-on-treasuries-amid-fitch-downgrade/", "time_published": "20230803T150800", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Falls As Yields Surge. Warren Buffett Loads Up On Treasuries After Fitch Downgrade Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.890401"}], "overall_sentiment_score": -0.089162, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.123948", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.17816", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COP", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.097821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.066414", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.11475", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUN", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.081699", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.123948", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.097821", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.132368", "ticker_sentiment_score": "0.028781", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.132368", "ticker_sentiment_score": "0.028781", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.132368", "ticker_sentiment_score": "0.028781", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.191299", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.132368", "ticker_sentiment_score": "0.231892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Regeneron Pharmaceuticals Moving Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33549371/why-is-regeneron-pharmaceuticals-moving-higher-today", "time_published": "20230803T143542", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Street estimate. Revenues increased 11% Y/Y to $3.16 billion, beating the consensus of $3.01 billion. Dupixent global net sales ( recorded by Sanofi ) increased 33% to $2.79 billion ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/03/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.401331", "ticker_sentiment_score": "-0.066489", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.27432", "ticker_sentiment_score": "0.029797", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.401331", "ticker_sentiment_score": "0.484263", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.139265", "ticker_sentiment_score": "0.126556", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Surmounts Its 200-Day Line On Solid Beat", "url": "https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q2-2023/", "time_published": "20230803T130400", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Surmounts Its 200-Day Line On Its Handy Second-Quarter Beat Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.232887, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.760593", "ticker_sentiment_score": "0.250735", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron expects FDA decision on high-dose eye drug this year, shares jump", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-pharma-beats-quarterly-profit-estimates-2023-08-03/", "time_published": "20230803T115000", "authors": ["Reuters"], "summary": "The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TUVSCCQOZBPTPFFOC5TQTF2ZDA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.130612, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.241684", "ticker_sentiment_score": "0.16134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.122269", "ticker_sentiment_score": "0.147221", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.122269", "ticker_sentiment_score": "-0.193865", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.122269", "ticker_sentiment_score": "0.052171", "ticker_sentiment_label": "Neutral"}]}, {"title": "Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Merck, Amgen, Ionis , BioMarin, AstraZeneca", "url": "https://www.prnewswire.com/news-releases/atherosclerosis-market-to-witness-growth-by-2032-estimates-delveinsight--leading-companies---csl-behring-novartis-merck-amgen-ionis--biomarin-astrazeneca-301891245.html", "time_published": "20230802T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.114748, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUMA", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.028868", "ticker_sentiment_score": "-0.085973", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.057698", "ticker_sentiment_score": "0.015995", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESPR", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNUGF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGCF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057698", "ticker_sentiment_score": "0.11102", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABIO", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.028868", "ticker_sentiment_score": "-0.085973", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHX", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "NAMS", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Biotech Stocks to Buy for August", "url": "https://stocknews.com/news/gild-regn-uthr-3-biotech-stocks-to-buy-for-august/", "time_published": "20230802T124337", "authors": ["StockNews.com Staff"], "summary": "The biotechnology industry has emerged at the forefront as a vital industry harboring potential for innovation, economic development, and enhanced healthcare deliverables.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/07/shutterstock_357740228-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.225061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.162255", "ticker_sentiment_score": "0.11428", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.162255", "ticker_sentiment_score": "-0.02238", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.292657", "ticker_sentiment_score": "0.140016", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nucor, Stifel And 3 Other Stocks Show Both Value And Growth", "url": "https://www.forbes.com/sites/johndorfman/2023/07/31/nucor-stifel-and-3-other-stocks-show-both-value-and-growth/", "time_published": "20230731T151156", "authors": ["John Dorfman"], "summary": "Value and growth, the two main schools of investing, don't have to be enemies. These stocks sell for less than 15 times per-share earnings and have grown their profits by at least 12% per year over the past five years.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64c73c14340993aecec6f9a3/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.132854, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMAT", "relevance_score": "0.109455", "ticker_sentiment_score": "0.068589", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.163539", "ticker_sentiment_score": "-0.04929", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLDR", "relevance_score": "0.054857", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.109455", "ticker_sentiment_score": "0.068589", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.109455", "ticker_sentiment_score": "0.183192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.054857", "ticker_sentiment_score": "0.166864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUE", "relevance_score": "0.21686", "ticker_sentiment_score": "0.124781", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLD", "relevance_score": "0.054857", "ticker_sentiment_score": "0.075823", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33464944/regeneron-pharma-says-fewer-aflibercept-injections-maintains-vision-anatomic-improvements-in-diab", "time_published": "20230731T134302", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year ( 96 weeks ) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to Eylea ( aflibercept ) injection, in diabetic macular edema ( DME ) patients.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/31/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.156903, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.34729", "ticker_sentiment_score": "0.09121", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.119235", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does Nvidia's AI for Biotech Make It a Buy?", "url": "https://www.fool.com/investing/2023/07/30/does-nvidias-ai-for-biotech-make-it-a-buy/", "time_published": "20230730T130000", "authors": ["Alex Carchidi"], "summary": "It's just starting to dip its toes into the biopharma waters.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741378%2Fcarefree-seniors-having-fun-on-rollercoaster-at-amusement-park.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.227454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.267559", "ticker_sentiment_score": "0.237075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RXRX", "relevance_score": "0.068112", "ticker_sentiment_score": "0.170691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SDGR", "relevance_score": "0.068112", "ticker_sentiment_score": "0.170691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.068112", "ticker_sentiment_score": "-0.038079", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.068112", "ticker_sentiment_score": "0.175726", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS", "url": "https://www.globenewswire.com/news-release/2023/07/29/2714510/0/en/Aflibercept-8-mg-Two-Year-Results-from-Pivotal-PHOTON-Trial-in-Diabetic-Macular-Edema-Presented-at-ASRS.html", "time_published": "20230729T182500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "89% and 84% of patients were maintained on \u226512- and \u226516-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.080728, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.059085", "ticker_sentiment_score": "0.054053", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.014784", "ticker_sentiment_score": "0.123426", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014784", "ticker_sentiment_score": "0.050403", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  to Report Q2 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2129606/regeneron-regn-to-report-q2-earnings-whats-in-store", "time_published": "20230728T164200", "authors": ["Zacks Equity Research"], "summary": "Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.173286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.119433", "ticker_sentiment_score": "-0.001144", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.236205", "ticker_sentiment_score": "0.26067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.079788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.039944", "ticker_sentiment_score": "0.036451", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.2741", "ticker_sentiment_score": "0.258934", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "P/E Ratio Insights for Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/07/33446204/pe-ratio-insights-for-regeneron-pharmaceuticals", "time_published": "20230728T161514", "authors": ["Benzinga Insights"], "summary": "In the current session, the stock is trading at $746.05, after a 0.19% spike. Over the past month, Regeneron Pharmaceuticals Inc. REGN stock increased by 3.83%, and in the past year, by 29.37%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": -0.044875, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.433523", "ticker_sentiment_score": "0.060612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director - Vaxxinity  ( NASDAQ:VAXX ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33431037/vaxxinity-appoints-peter-powchik-m-d-to-executive-vice-president-global-scientific-director", "time_published": "20230727T203036", "authors": ["Globe Newswire"], "summary": "Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 ( GLOBE NEWSWIRE ) -- Vaxxinity, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.21034, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.03448", "ticker_sentiment_score": "0.064032", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.612716", "ticker_sentiment_score": "0.316931", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director", "url": "https://www.globenewswire.com/news-release/2023/07/27/2712750/0/en/Vaxxinity-Appoints-Peter-Powchik-M-D-to-Executive-Vice-President-Global-Scientific-Director.html", "time_published": "20230727T203000", "authors": ["Inc.", "Vaxxinity"], "summary": "Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/212698a9-6cb8-4b60-93a6-954672dacad8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.214985, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.034933", "ticker_sentiment_score": "0.066095", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.618922", "ticker_sentiment_score": "0.321725", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33412284/roches-1h-earnings-decline-on-lower-covid-19-sales-cfo-says-late-stage-pipeline-has-gaps-that-nee", "time_published": "20230727T145825", "authors": ["Vandana Singh"], "summary": "Roche Holding AG RHHBY said sales for 1H 2023 dropped to CHF 30.62 billion from CHF 33.9 billion in the same period last year, reflecting the expected tapering of demand for COVID-19 tests that was booming during the pandemic.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/27/roche.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.112542, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.232439", "ticker_sentiment_score": "-0.151203", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33393415/novo-nordisks-obesity-drug-saxenda-not-included-in-whos-essential-drug-list", "time_published": "20230726T142405", "authors": ["Vandana Singh"], "summary": "The World Health Organization ( WHO ) published the new editions of the Model Lists of Essential Medicines ( EML ) and Essential Medicines for Children ( EMLc ) , which include important new medicines for multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions, among ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/26/saxenda-_liraglutida.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.083479, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.232439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.232439", "ticker_sentiment_score": "0.11475", "ticker_sentiment_label": "Neutral"}]}, {"title": "Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/", "time_published": "20230726T120200", "authors": ["Jennifer Rigby"], "summary": "LONDON, July 26 ( Reuters ) - Obesity drugs will not be included in the World Health Organization's ( WHO ) latest essential medicines list, but treatments for diseases including Ebola and multiple sclerosis will, according to documents published by the U.N. agency.", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/c6ac2f51-88d8-488a-98b5-60ee0922dc09.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.102296, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.077094", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should First Trust NASDAQ-100 Equal Weighted ETF  ( QQEW )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2127493/should-first-trust-nasdaq-100-equal-weighted-etf-qqew-be-on-your-investing-radar", "time_published": "20230726T102008", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266396, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LCID", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.116914", "ticker_sentiment_score": "0.101724", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?", "url": "https://www.zacks.com/stock/news/2127499/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt", "time_published": "20230726T102007", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default341.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}], "overall_sentiment_score": 0.157209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.134214", "ticker_sentiment_score": "0.071398", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.134214", "ticker_sentiment_score": "0.071398", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.134214", "ticker_sentiment_score": "0.071398", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33376698/regeneron-pharmaceuticals-investigated-by-block-leviton-for-potential-securities-law-violations-in", "time_published": "20230725T190401", "authors": ["Globe Newswire"], "summary": "BOSTON, July 25, 2023 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. REGN for potential securities law violations. Investors who have lost money in their Regeneron Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.101373, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.541149", "ticker_sentiment_score": "-0.243446", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CTLT", "relevance_score": "0.098255", "ticker_sentiment_score": "0.059931", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution", "url": "https://www.globenewswire.com/news-release/2023/07/25/2710316/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html", "time_published": "20230725T113000", "authors": ["Ltd.", "Kiniksa Pharmaceuticals"], "summary": "- ARCALYST\u00ae ( rilonacept ) Q2 2023 net product revenue of $54.5 million -- ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint -- KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 -- Cash reserves now ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d9c74849-9de0-4f1f-807c-990609944292", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999921"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.021716, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.019879", "ticker_sentiment_score": "-0.168969", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KNSA", "relevance_score": "0.039745", "ticker_sentiment_score": "0.040407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company", "url": "https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html", "time_published": "20230724T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.105653, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDYA", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "GALT", "relevance_score": "0.02692", "ticker_sentiment_score": "0.033392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.05381", "ticker_sentiment_score": "0.031999", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.080638", "ticker_sentiment_score": "0.047754", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.080638", "ticker_sentiment_score": "0.047754", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.05381", "ticker_sentiment_score": "0.031999", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.02692", "ticker_sentiment_score": "0.029117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors", "url": "https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-appointment-of-robert-lisicki-to-board-of-directors-301883700.html", "time_published": "20230724T130000", "authors": ["Cadrenal Therapeutics", "Inc."], "summary": "PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ( \"Cadrenal\" or the \"Company\" ) ( Nasdaq: CVKD ) , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant ( blood thinner ) for certain rare medical conditions, today ...", "banner_image": "https://mma.prnewswire.com/media/1986995/CADRENAL_THERAPEUTICS_LOGO_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.173838, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.054483", "ticker_sentiment_score": "-0.049075", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.054483", "ticker_sentiment_score": "0.100788", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVKD", "relevance_score": "0.267413", "ticker_sentiment_score": "0.130961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech wins fail to move stock indicators ahead of earnings", "url": "https://www.financialexpress.com/healthcare/news-healthcare/biotech-wins-fail-to-move-stock-indicators-ahead-of-earnings/3184760/", "time_published": "20230724T103525", "authors": ["Bloomberg"], "summary": "Biotech has had a pretty good year between a flurry of deals and approvals of new drugs for vexing diseases such as Alzheimer's. Yet that isn't showing up in stock performance. Two closely watched indicators lag far behind the overall market.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/pathology-rp.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.114137", "ticker_sentiment_score": "0.0994", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRPH", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOSS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.085371", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVRO", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.144975", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2125862/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230724T102008", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.282717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061159", "ticker_sentiment_score": "0.109012", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is First Trust NYSE Arca Biotechnology ETF  ( FBT )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2125864/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now", "time_published": "20230724T102007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.253666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/07/33289402/looking-into-regeneron-pharmaceuticalss-recent-short-interest", "time_published": "20230719T170034", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has fallen 11.28% since its last report. The company recently reported that it has 1.08 million shares sold short, which is 1.18% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer", "url": "https://www.globenewswire.com/news-release/2023/07/19/2707172/0/en/Autolus-Therapeutics-announces-appointment-of-Robert-F-Dolski-as-Chief-Financial-Officer.html", "time_published": "20230719T110000", "authors": ["Autolus Inc."], "summary": "- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/680b5e1a-9aba-4e38-b280-e43036561ef1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.079382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUTL", "relevance_score": "0.049526", "ticker_sentiment_score": "0.080276", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.024775", "ticker_sentiment_score": "0.063853", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.087686", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2123401/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230719T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default167.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.164146, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068896", "ticker_sentiment_score": "0.034085", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023", "url": "https://www.globenewswire.com/news-release/2023/07/18/2705178/0/en/Kiniksa-Pharmaceuticals-to-Report-Second-Quarter-2023-Financial-Results-on-July-25-2023.html", "time_published": "20230718T200100", "authors": ["Kiniksa Pharmaceuticals", "Ltd."], "summary": "HAMILTON, Bermuda, July 18, 2023 ( GLOBE NEWSWIRE ) -- Kiniksa Pharmaceuticals, Ltd. ( Nasdaq: KNSA ) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d9c74849-9de0-4f1f-807c-990609944292", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.193394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.183895", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's in Store for Thermo Fisher  ( TMO )  in Q2 Earnings?", "url": "https://www.zacks.com/stock/news/2123161/whats-in-store-for-thermo-fisher-tmo-in-q2-earnings", "time_published": "20230718T152300", "authors": ["Zacks Investment Research"], "summary": "Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/1473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.216138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.112532", "ticker_sentiment_score": "0.121519", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.075161", "ticker_sentiment_score": "0.075691", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.037622", "ticker_sentiment_score": "0.113424", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADUS", "relevance_score": "0.075161", "ticker_sentiment_score": "0.077713", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.258743", "ticker_sentiment_score": "0.203607", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/07/33255457/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230717T194603", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.122882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.825367", "ticker_sentiment_score": "0.024317", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.132914", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars - Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33247048/alnylam-says-single-injection-of-rnai-therapy-cuts-alzheimers-linked-proteins-by-65-stock-soars", "time_published": "20230717T141827", "authors": ["Vandana Singh"], "summary": "Alnylam Pharmaceuticals Inc ALNY announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and cerebral amyloid angiopathy ( CAA ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/17/alny.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.082914, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.355588", "ticker_sentiment_score": "0.119661", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.125582", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alnylam  ( ALNY )  Posts Upbeat Data From Alzheimer's Disease Study", "url": "https://www.zacks.com/stock/news/2122141/alnylam-alny-posts-upbeat-data-from-alzheimers-disease-study", "time_published": "20230717T140600", "authors": ["Zacks Investment Research"], "summary": "Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.059575, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.337811", "ticker_sentiment_score": "0.067201", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.337811", "ticker_sentiment_score": "0.048918", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIX", "relevance_score": "0.2842", "ticker_sentiment_score": "0.078348", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.172919", "ticker_sentiment_score": "0.087479", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023", "url": "https://www.globenewswire.com/news-release/2023/07/17/2705178/0/en/Kiniksa-Pharmaceuticals-to-Report-Second-Quarter-2023-Financial-Results-on-July-25-2023.html", "time_published": "20230717T120000", "authors": ["Kiniksa Pharmaceuticals", "Ltd."], "summary": "HAMILTON, Bermuda, July 17, 2023 ( GLOBE NEWSWIRE ) -- Kiniksa Pharmaceuticals, Ltd. ( Nasdaq: KNSA ) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d9c74849-9de0-4f1f-807c-990609944292", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.193394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.183895", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fibrodysplasia Ossificans Progressiva Pipeline Research 2023: Focus on 5+ Companies and 7+ Pipeline Drugs - Analysis of the Advancements and Potential Breakthroughs", "url": "https://www.prnewswire.com/news-releases/fibrodysplasia-ossificans-progressiva-pipeline-research-2023-focus-on-5-companies-and-7-pipeline-drugs---analysis-of-the-advancements-and-potential-breakthroughs-301877547.html", "time_published": "20230715T003000", "authors": ["Research and Markets"], "summary": "Fibrodysplasia Ossificans Progressiva Pipeline Research 2023: Focus on 5+ Companies and 7+ Pipeline Drugs ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.171869, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.074926", "ticker_sentiment_score": "0.063543", "ticker_sentiment_label": "Neutral"}]}, {"title": "UnitedHealth Group  ( UNH )  Q2 Earnings Beat, Boosts '23 EPS View", "url": "https://www.zacks.com/stock/news/2121564/unitedhealth-group-unh-q2-earnings-beat-boosts-23-eps-view", "time_published": "20230714T160000", "authors": ["Zacks Investment Research"], "summary": "UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.999974"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.19489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.107743", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.078482", "ticker_sentiment_score": "0.076026", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.412093", "ticker_sentiment_score": "0.274575", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADUS", "relevance_score": "0.078482", "ticker_sentiment_score": "0.097376", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Editing Market worth $10.6 billion | MarketsandMarkets", "url": "https://www.prnewswire.com/news-releases/gene-editing-market-worth-10-6-billion--marketsandmarkets-301877363.html", "time_published": "20230714T141500", "authors": ["MarketsandMarkets"], "summary": "CHICAGO, July 14, 2023 /PRNewswire/ -- In the near future, the gene editing industry holds immense promise in revolutionizing healthcare and addressing genetic disorders.", "banner_image": "https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.361016, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGMO", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "A", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.023957", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DTIL", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.047892", "ticker_sentiment_score": "0.165754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.023957", "ticker_sentiment_score": "0.153382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors", "url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-301874728.html", "time_published": "20230711T200500", "authors": ["Inc.", "Neurocrine Biosciences"], "summary": "SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX ) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.", "banner_image": "https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.047229, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRU", "relevance_score": "0.07913", "ticker_sentiment_score": "0.032424", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHW", "relevance_score": "0.07913", "ticker_sentiment_score": "0.032424", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.308891", "ticker_sentiment_score": "-0.011001", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.380591", "ticker_sentiment_score": "0.098216", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.07913", "ticker_sentiment_score": "0.057942", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.07913", "ticker_sentiment_score": "0.032424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.07913", "ticker_sentiment_score": "0.032424", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN", "url": "https://www.benzinga.com/pressreleases/23/07/g33158526/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-regeneron-pharm", "time_published": "20230709T165951", "authors": ["Globe Newswire"], "summary": "NEW YORK, July 09, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ( \"Regeneron\" or the \"Company\" ) REGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.002423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.275867", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/07/33150473/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity", "time_published": "20230707T164917", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.135986, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.834422", "ticker_sentiment_score": "0.323772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.100308", "ticker_sentiment_score": "-0.12993", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1 Billion Deal For Moderna To Expand Product Pipeline In China - Gilead Sciences  ( NASDAQ:GILD ) , Moderna  ( NASDAQ:MRNA ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33145546/1-billion-deal-for-moderna-to-expand-product-pipeline-in-china", "time_published": "20230707T124517", "authors": ["MarketBeat"], "summary": "The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/moderna_logo.svg_.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": -0.012008, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.402941", "ticker_sentiment_score": "-0.088447", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.157141", "ticker_sentiment_score": "-0.041704", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.157141", "ticker_sentiment_score": "-0.041704", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Cathie Wood Stock That Could Double Your Money", "url": "https://www.fool.com/investing/2023/07/06/1-cathie-wood-stock-that-could-double-your-money/", "time_published": "20230706T133000", "authors": ["George Budwell"], "summary": "This gene-editing pioneer stands out as a top growth stock to buy right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738729%2Fbiotech-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.251524, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.055492", "ticker_sentiment_score": "0.108864", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.219312", "ticker_sentiment_score": "0.166139", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday - Amedisys  ( NASDAQ:AMED ) , ArcBest  ( NASDAQ:ARCB ) ", "url": "https://www.benzinga.com/news/23/07/33131758/meta-platforms-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday", "time_published": "20230706T124335", "authors": ["Lisa Levin"], "summary": "Morgan Stanley cut the price target for ArcBest Corporation ARCB from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday. Truist Securities increased the price target for Owens Corning OC from $105 to $135.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/06/meta_platforms_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999966"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.102958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.285526", "ticker_sentiment_score": "0.084807", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.192694", "ticker_sentiment_score": "0.224212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.03929", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.236249", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GS", "relevance_score": "0.192694", "ticker_sentiment_score": "0.062307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWA", "relevance_score": "0.285526", "ticker_sentiment_score": "0.052481", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCB", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.316512", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PTGX", "relevance_score": "0.285526", "ticker_sentiment_score": "0.47315", "ticker_sentiment_label": "Bullish"}, {"ticker": "OC", "relevance_score": "0.285526", "ticker_sentiment_score": "0.311403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMED", "relevance_score": "0.285526", "ticker_sentiment_score": "0.270211", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMA", "relevance_score": "0.285526", "ticker_sentiment_score": "0.017919", "ticker_sentiment_label": "Neutral"}, {"ticker": "CME", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.055932", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.185683", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Is Regeneron's Stock in Trouble After This FDA Rejection?", "url": "https://www.fool.com/investing/2023/07/06/is-regenerons-stock-in-trouble-after-this-fda-reje/", "time_published": "20230706T115000", "authors": ["David Jagielski"], "summary": "The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue.", "banner_image": "https://media.ycharts.com/charts/bfcfb846fd655934de649bfde3215f17.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.043751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.043867", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight", "url": "https://www.prnewswire.com/news-releases/prostate-cancer-global-market-to-witness-upsurge-in-growth-at-a-cagr-of-5-by-2028--delveinsight-301869890.html", "time_published": "20230705T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The prostate cancer market is anticipated to propel owing to the increasing incidence of prostate cancer around the world, the rising number of risk factors for prostate cancer, growing technological advancements in prostate cancer diagnostics, government, and non-government awareness ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.291039, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.125637", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.051647", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.051647", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.09511", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCON", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.051647", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.054055", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.045078", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORINY", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.051647", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.131624", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.051647", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.06205", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYPHF", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPIX", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERU", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.15097", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.093078", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Loses 13% in Three Months: What Lies Ahead?", "url": "https://www.zacks.com/stock/news/2116853/regeneron-regn-loses-13-in-three-months-what-lies-ahead", "time_published": "20230705T115800", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203615, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.188505", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAYZF", "relevance_score": "0.067536", "ticker_sentiment_score": "0.202833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.200688", "ticker_sentiment_score": "0.20077", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight", "url": "https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html", "time_published": "20230703T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.081483", "ticker_sentiment_score": "0.144952", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBPH", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRIS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.040795", "ticker_sentiment_score": "0.06675", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.020404", "ticker_sentiment_score": "0.003677", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELDN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.020404", "ticker_sentiment_score": "0.130751", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.081483", "ticker_sentiment_score": "0.105903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABUS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.040795", "ticker_sentiment_score": "0.032589", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.061159", "ticker_sentiment_score": "0.058024", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMMT", "relevance_score": "0.020404", "ticker_sentiment_score": "0.167562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCUS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCON", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.040795", "ticker_sentiment_score": "0.126795", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASCLF", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.020404", "ticker_sentiment_score": "0.202125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHIO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.081483", "ticker_sentiment_score": "0.048837", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040795", "ticker_sentiment_score": "0.143852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/07/33100708/check-out-what-whales-are-doing-with-regn", "time_published": "20230703T183259", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 15 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.127168, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.108466", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.78028", "ticker_sentiment_score": "0.090724", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/07/33096690/looking-into-regeneron-pharmaceuticalss-recent-short-interest", "time_published": "20230703T134606", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 7.26% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.33% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2115804/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe", "time_published": "20230703T102009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.236458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.253646", "ticker_sentiment_score": "0.156677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33084292/regeneron-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses", "time_published": "20230630T193317", "authors": ["Globe Newswire"], "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2023 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc. ( \"Regeneron\" or \"the Company\" ) REGNinvestors that the law firm has initiated an investigation ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.126119", "ticker_sentiment_score": "0.035373", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33083753/regn-shareholder-news-johnson-fistel-encourages-regeneron-pharmaceuticals-shareholders-with-losses", "time_published": "20230630T184943", "authors": ["Globe Newswire"], "summary": "SAN DIEGO, June 30, 2023 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Regeneron Pharmaceuticals, Inc. ( \"Regeneron\" or \"the Company\" ) REGN, any of its executive officers or others violated securities laws by ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.089156, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.288893", "ticker_sentiment_score": "-0.125235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Roars Back Toward Highs: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-roars-back-toward-highs-carnival-delta-micron-nvidia-in-focus/", "time_published": "20230630T174800", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally ran toward 2023 highs again with broad-based gains, as many of the major indexes rebound from or near their 21-day moving averages. A number of stocks flashed buy signals, either from traditional breakouts or from pullbacks or early entries.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/KPBLOG01-022916-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.036714, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.027103", "ticker_sentiment_score": "0.056744", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.214225", "ticker_sentiment_score": "0.050157", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.054175", "ticker_sentiment_score": "0.060008", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTAI", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.108088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.134892", "ticker_sentiment_score": "0.053234", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.108088", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLTX", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.108088", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.213002", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FGEN", "relevance_score": "0.081184", "ticker_sentiment_score": "-0.112409", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.081184", "ticker_sentiment_score": "0.062078", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.081184", "ticker_sentiment_score": "0.064969", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.1081", "ticker_sentiment_score": "0.042", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIS", "relevance_score": "0.054175", "ticker_sentiment_score": "0.048179", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.054175", "ticker_sentiment_score": "0.043954", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.1081", "ticker_sentiment_score": "-0.120334", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKLA", "relevance_score": "0.081184", "ticker_sentiment_score": "-0.110643", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.1081", "ticker_sentiment_score": "-0.046751", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.134892", "ticker_sentiment_score": "0.023747", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOR", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.135257", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.108088", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIDE", "relevance_score": "0.081184", "ticker_sentiment_score": "-0.110643", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGTX", "relevance_score": "0.054175", "ticker_sentiment_score": "-0.108088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Pharmaceuticals Stock Dipped This Week", "url": "https://www.fool.com/investing/2023/06/29/why-regeneron-pharmaceuticals-stock-dipped-this-we/", "time_published": "20230629T180419", "authors": ["George Budwell"], "summary": "A key regulatory setback is weighing on the biotech's stock.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737733%2Ftesla.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.029633, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.268294", "ticker_sentiment_score": "-0.033506", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.020474", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Will Amgen Buy Next?", "url": "https://www.fool.com/investing/2023/06/29/what-will-amgen-buy-next/", "time_published": "20230629T164500", "authors": ["George Budwell"], "summary": "The biotech could pursue these two budget-friendly targets.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738041%2Fmna.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.074103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.43816", "ticker_sentiment_score": "0.233553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.131643", "ticker_sentiment_score": "0.126483", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.196344", "ticker_sentiment_score": "0.299473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.380978", "ticker_sentiment_score": "0.206762", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Catalent's  ( CTLT )  Facility Snag Linked to Regeneron's Eylea CRL", "url": "https://www.zacks.com/stock/news/2114846/catalents-ctlt-facility-snag-linked-to-regenerons-eylea-crl", "time_published": "20230629T133800", "authors": ["Zacks Investment Research"], "summary": "Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.045822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTLT", "relevance_score": "0.540042", "ticker_sentiment_score": "-0.178227", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.058903", "ticker_sentiment_score": "0.021012", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.159001", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WST", "relevance_score": "0.175433", "ticker_sentiment_score": "0.084112", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRAY", "relevance_score": "0.175433", "ticker_sentiment_score": "0.137669", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.023014", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.176046", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DHR", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.093993", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks", "url": "https://www.zacks.com/stock/news/2114560/the-zacks-analyst-blog-highlights-texas-instruments-regeneron-pharmaceuticals-micron-technology-fedex-and-arista-networks", "time_published": "20230629T090000", "authors": ["Zacks Investment Research"], "summary": "Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/83/1947.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MU", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.70749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Catalent Stock Flopped Today", "url": "https://www.fool.com/investing/2023/06/28/why-catalent-stock-flopped-today/", "time_published": "20230628T224000", "authors": ["Eric Volkman"], "summary": "The company takes the fall for a failed drug application.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737733%2Ftesla.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009661, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.295867", "ticker_sentiment_score": "0.011551", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.657566", "ticker_sentiment_score": "0.022502", "ticker_sentiment_label": "Neutral"}]}, {"title": "Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio", "url": "https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html", "time_published": "20230628T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.090361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KOD", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.087948", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTLK", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.055936", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSD", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.087948", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.051663", "ticker_sentiment_score": "0.002", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISEE", "relevance_score": "0.051663", "ticker_sentiment_score": "0.002", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.025845", "ticker_sentiment_score": "0.007551", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANNX", "relevance_score": "0.077426", "ticker_sentiment_score": "-0.01029", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.051663", "ticker_sentiment_score": "0.002", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.055936", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPT", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.087948", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077426", "ticker_sentiment_score": "-0.075581", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGM", "relevance_score": "0.077426", "ticker_sentiment_score": "0.00206", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.055936", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.087948", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Stock Is Trading Lower Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/06/33049479/why-regeneron-stock-is-trading-lower-today", "time_published": "20230628T195322", "authors": ["Ryan Gustafson"], "summary": "Regeneron Pharmaceuticals, Inc. REGN shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter ( CRL ) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/28/medications-1853400_12801.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.021585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.18967", "ticker_sentiment_score": "-0.114339", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.969227", "ticker_sentiment_score": "-0.123899", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.18967", "ticker_sentiment_score": "-0.295606", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology", "url": "https://www.zacks.com/research-daily/2114238/top-analyst-reports-for-texas-instruments-regeneron-micron-technology", "time_published": "20230628T155300", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.233731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MU", "relevance_score": "0.31006", "ticker_sentiment_score": "0.223424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANET", "relevance_score": "0.126784", "ticker_sentiment_score": "0.118819", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.118819", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.250386", "ticker_sentiment_score": "0.189446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.126784", "ticker_sentiment_score": "0.118819", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.126784", "ticker_sentiment_score": "0.118819", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:AMD", "relevance_score": "0.063594", "ticker_sentiment_score": "0.099551", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/06/33043055/check-out-what-whales-are-doing-with-regn", "time_published": "20230628T135110", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.084862, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.099066", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.7868", "ticker_sentiment_score": "0.184525", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.099066", "ticker_sentiment_score": "-0.129485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday - American States Water  ( NYSE:AWR ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/06/33039749/amazon-com-to-rally-over-16-here-are-10-other-analyst-forecasts-for-wednesday", "time_published": "20230628T115301", "authors": ["Lisa Levin"], "summary": "Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. WBA from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2% to $28.59 in pre-market trading. Canaccord Genuity cut the price target for Regeneron Pharmaceuticals, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/28/amazon_-logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.144552, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAIA", "relevance_score": "0.179788", "ticker_sentiment_score": "0.209196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNOW", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.018233", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.090474", "ticker_sentiment_score": "0.036268", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLD", "relevance_score": "0.266828", "ticker_sentiment_score": "0.252348", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCORF", "relevance_score": "0.179788", "ticker_sentiment_score": "-0.11771", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.350564", "ticker_sentiment_score": "0.089722", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.179788", "ticker_sentiment_score": "-0.112971", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCI", "relevance_score": "0.266828", "ticker_sentiment_score": "0.496066", "ticker_sentiment_label": "Bullish"}, {"ticker": "PINS", "relevance_score": "0.266828", "ticker_sentiment_score": "0.280887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWR", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.15993", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.159547", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMS", "relevance_score": "0.179788", "ticker_sentiment_score": "0.051415", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.266828", "ticker_sentiment_score": "0.114412", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.179788", "ticker_sentiment_score": "0.178695", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  Gets CRL for Aflibercept 8 mg Drug, Shares Fall", "url": "https://www.zacks.com/stock/news/2114010/regeneron-regn-gets-crl-for-aflibercept-8-mg-drug-shares-fall", "time_published": "20230628T101300", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/1887.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.180013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.276909", "ticker_sentiment_score": "0.041876", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.276909", "ticker_sentiment_score": "0.072657", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.320676", "ticker_sentiment_score": "0.309563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.047092", "ticker_sentiment_score": "0.234638", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027; North America will account for 44% of market growth - Technavio", "url": "https://www.prnewswire.com/news-releases/ophthalmology-therapeutics-market-size-to-increase-by-usd-15-72-billion-from-2022-to-2027-north-america-will-account-for-44-of-market-growth---technavio-301864687.html", "time_published": "20230628T011500", "authors": ["Technavio"], "summary": "Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027. North America will ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2140796/Technavio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.133515, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNPHF", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OCUL", "relevance_score": "0.026013", "ticker_sentiment_score": "0.191762", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Regeneron Stock Is Falling Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/23/06/33032909/why-regeneron-stock-is-falling-today", "time_published": "20230627T195304", "authors": ["Ryan Gustafson"], "summary": "Regeneron Pharmaceuticals, Inc. REGN shares fell after the FDA issued a Complete Response Letter ( CRL ) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/27/medications-257336_1280.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.196004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.783955", "ticker_sentiment_score": "0.224293", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Crumbles After FDA Rejects Its Next Blockbuster Contender", "url": "https://www.investors.com/news/technology/regn-stock-crumbles-after-the-fda-rejects-its-next-possible-blockbuster/", "time_published": "20230627T195000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Crumbles After The FDA Rejects Its Next Possible ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.127428, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.582526", "ticker_sentiment_score": "-0.320479", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FGEN", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.366088", "ticker_sentiment_label": "Bearish"}]}, {"title": "US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-regeneron-high-dose-eylea-2023-06-27/", "time_published": "20230627T185900", "authors": ["Reuters"], "summary": "US FDA declines to approve ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TUVSCCQOZBPTPFFOC5TQTF2ZDA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.026805", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema", "url": "https://www.globenewswire.com/news-release/2023/06/27/2695733/0/en/Two-year-Results-for-Aflibercept-8-mg-from-Pivotal-PHOTON-Trial-Demonstrate-Durable-Vision-Gains-at-Extended-Dosing-Intervals-in-Diabetic-Macular-Edema.html", "time_published": "20230627T184600", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "89% of all aflibercept 8 mg patients maintained \u226512-week dosing intervals through two years ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.094833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.054857", "ticker_sentiment_score": "0.048", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.013724", "ticker_sentiment_score": "0.12252", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.013724", "ticker_sentiment_score": "0.050015", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Issues Complete Response Letter  ( CRL )  for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33032072/fda-issues-complete-response-letter-crl-for-aflibercept-8-mg-biologics-license-application-solely-", "time_published": "20230627T184500", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., June 27, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.115871, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.24289", "ticker_sentiment_score": "0.015121", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.082111", "ticker_sentiment_score": "0.125613", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Issues Complete Response Letter  ( CRL )  for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler", "url": "https://www.globenewswire.com/news-release/2023/06/27/2695732/0/en/FDA-Issues-Complete-Response-Letter-CRL-for-Aflibercept-8-mg-Biologics-License-Application-Solely-Due-to-an-Ongoing-Review-of-Inspection-Findings-at-a-Third-party-Filler.html", "time_published": "20230627T184500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.130015, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.115094", "ticker_sentiment_score": "0.05356", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.117445", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028868", "ticker_sentiment_score": "0.054669", "ticker_sentiment_label": "Neutral"}]}, {"title": "Questex's Fierce Clinical Summit Returns to Discuss All Things Clinical, Brings the Clinical Research and Trial Management Ecosystem Together September 26-28 in Philadelphia", "url": "https://www.benzinga.com/pressreleases/23/06/g33025104/questexs-fierce-clinical-summit-returns-to-discuss-all-things-clinical-brings-the-clinical-researc", "time_published": "20230627T140000", "authors": ["Globe Newswire"], "summary": "NEW YORK, June 27, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Pharma today announces the Fierce Clinical Summit will take place September 26-28 in Philadelphia. The Summit is Fierce Pharma's flagship event for the clinical research and trial management ecosystem.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149331, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.044885", "ticker_sentiment_score": "0.252998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FIXX", "relevance_score": "0.044885", "ticker_sentiment_score": "-0.33136", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.13409", "ticker_sentiment_score": "0.190137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.089629", "ticker_sentiment_score": "0.137946", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.044885", "ticker_sentiment_score": "-0.045099", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.044885", "ticker_sentiment_score": "0.252998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNCE", "relevance_score": "0.044885", "ticker_sentiment_score": "0.135942", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.044885", "ticker_sentiment_score": "0.191892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.044885", "ticker_sentiment_score": "-0.228931", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.044885", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "STTK", "relevance_score": "0.044885", "ticker_sentiment_score": "-0.298186", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain", "url": "https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html", "time_published": "20230626T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.062676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.041791", "ticker_sentiment_score": "0.070986", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.041791", "ticker_sentiment_score": "0.038751", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.062651", "ticker_sentiment_score": "0.023001", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.020903", "ticker_sentiment_score": "0.064977", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.020903", "ticker_sentiment_score": "0.063178", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.145521", "ticker_sentiment_score": "0.031689", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.266604", "ticker_sentiment_score": "0.085501", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.020903", "ticker_sentiment_score": "0.064977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKBO", "relevance_score": "0.041791", "ticker_sentiment_score": "0.038751", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.041791", "ticker_sentiment_score": "0.127136", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELDN", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062651", "ticker_sentiment_score": "0.067013", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.020903", "ticker_sentiment_score": "0.063178", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.062651", "ticker_sentiment_score": "0.023001", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.104228", "ticker_sentiment_score": "0.00218", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.083468", "ticker_sentiment_score": "0.037756", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.083468", "ticker_sentiment_score": "-0.023781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Lowered to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/06/23/regeneron-pharmaceuticals-nasdaqregn-lowered-to-buy-at-stocknews-com.html", "time_published": "20230623T081243", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Lowered to \"Buy\" at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.282598, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.097259", "ticker_sentiment_score": "0.189147", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.04872", "ticker_sentiment_score": "0.059307", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.04872", "ticker_sentiment_score": "0.116658", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRI", "relevance_score": "0.04872", "ticker_sentiment_score": "0.116658", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.04872", "ticker_sentiment_score": "0.059307", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.821115", "ticker_sentiment_score": "0.461679", "ticker_sentiment_label": "Bullish"}]}, {"title": "$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32977277/100-invested-in-this-stock-5-years-ago-would-be-worth-200-today", "time_published": "20230622T213159", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 9.01% on an annualized basis producing an average annual return of 18.97%. Currently, Regeneron Pharmaceuticals has a market capitalization of $85.55 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "VRTX: 3 Biotech Stocks With 'A' POWR Ratings", "url": "https://stocknews.com/news/vrtx-regn-uthr-crsp-3-biotech-stocks-with-a-powr-ratings/", "time_published": "20230622T170933", "authors": [], "summary": "The biotech industry shows solid growth, mainly driven by the influx of emerging and innovative technology and government-backed investments.", "banner_image": "https://stocknews.com/wp-content/uploads/2019/04/stock-photo-beautiful-young-woman-scientist-in-laboratory-working-young-female-scientist-doing-some-research-1083503930.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.277672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.33127", "ticker_sentiment_score": "0.275125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.075754", "ticker_sentiment_score": "-0.013247", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.260719", "ticker_sentiment_score": "0.174042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.150827", "ticker_sentiment_score": "0.043442", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/06/21/2-biotech-stocks-you-can-buy-and-hold-for-the-next/", "time_published": "20230621T122200", "authors": ["Jim Halley"], "summary": "Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736572%2Fgrowth-4.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999975"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.195269, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.08609", "ticker_sentiment_score": "0.130467", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.08609", "ticker_sentiment_score": "0.130467", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.08609", "ticker_sentiment_score": "0.077705", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period  ( 2019-2032 ) , Estimates DelveInsight", "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html", "time_published": "20230619T200000", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period ( 2019-2032 ) , Estimates ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.085849, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.026474", "ticker_sentiment_score": "-0.135106", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTPF", "relevance_score": "0.052918", "ticker_sentiment_score": "0.039778", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPPSF", "relevance_score": "0.026474", "ticker_sentiment_score": "0.032391", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.026474", "ticker_sentiment_score": "0.092467", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.026474", "ticker_sentiment_score": "0.037854", "ticker_sentiment_label": "Neutral"}, {"ticker": "EQ", "relevance_score": "0.026474", "ticker_sentiment_score": "0.001835", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.026474", "ticker_sentiment_score": "0.074709", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.026474", "ticker_sentiment_score": "0.032391", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.079304", "ticker_sentiment_score": "0.080311", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.026474", "ticker_sentiment_score": "0.074709", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:VND", "relevance_score": "0.026474", "ticker_sentiment_score": "0.032391", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Short-Squeeze Candidates That Could Go Parabolic", "url": "https://www.fool.com/investing/2023/06/15/2-short-squeeze-candidates-that-could-go-parabolic/", "time_published": "20230615T140000", "authors": ["George Budwell"], "summary": "Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.", "banner_image": "https://media.ycharts.com/charts/a0657495cf79028844cd868cd0773d0b.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.214709, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.050148", "ticker_sentiment_score": "0.212308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.198628", "ticker_sentiment_score": "0.228676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.050148", "ticker_sentiment_score": "0.212308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.149656", "ticker_sentiment_score": "0.167646", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.050148", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.100099", "ticker_sentiment_score": "0.077526", "ticker_sentiment_label": "Neutral"}]}, {"title": "EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 - EyePoint Pharmaceuticals  ( NASDAQ:EYPT ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32861319/eyepoints-eyp-1901-tipped-to-transform-wet-amd-market-analyst-predicts-potential-870m-sales-by-20", "time_published": "20230614T191432", "authors": ["Vandana Singh"], "summary": "JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc EYPT with a Buy rating and a $26 price target.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/14/eypt.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.271379, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYPT", "relevance_score": "0.490323", "ticker_sentiment_score": "0.452234", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.258351", "ticker_sentiment_score": "0.172124", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Stocks to Buy No Matter What Happens in June and Beyond", "url": "https://www.fool.com/investing/2023/06/14/2-stocks-to-buy-no-matter-what-happens-in-june-and/", "time_published": "20230614T140000", "authors": ["Prosper Junior Bakiny"], "summary": "A lot could go wrong in the next few months, but investors should largely ignore all that noise.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734671%2Ftwo-people-looking-at-a-computer-and-smiling.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.22103, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.05654", "ticker_sentiment_score": "0.324034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.521812", "ticker_sentiment_score": "0.37978", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.112797", "ticker_sentiment_score": "-0.04725", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.05654", "ticker_sentiment_score": "0.120932", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 2 Game-Changing Biotech Stocks, 1 to Sell Now", "url": "https://stocknews.com/news/gild-regn-ttnp-rcus-2-game-changing-biotech-stocks-1-to-sell-now/", "time_published": "20230612T152355", "authors": [], "summary": "Progress in the personalized medicines sector and the adoption of new avenues for biotechnology applications are boosting the biotech industry. However, concerns such as economic slowdowns and geopolitical risks might hamper its growth.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.150451, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.105759", "ticker_sentiment_score": "-0.078982", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.342329", "ticker_sentiment_score": "0.236632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.243585", "ticker_sentiment_score": "0.16252", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TTNP", "relevance_score": "0.209668", "ticker_sentiment_score": "0.110697", "ticker_sentiment_label": "Neutral"}]}, {"title": "Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure", "url": "https://www.prnewswire.com/news-releases/melanoma-market-to-witness-promising-growth-predicts-delveinsight--key-companies-to-watch---io-biotech-merck-eisai-regeneron-genentech-seagen-amgen-astellas-galectin-medimmune-aivita-linnaeus-checkmate-onkure-301846881.html", "time_published": "20230612T150000", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Melanoma Market to Witness Promising Growth, Predicts ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.079114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IDYA", "relevance_score": "0.019255", "ticker_sentiment_score": "0.056247", "ticker_sentiment_label": "Neutral"}, {"ticker": "GALT", "relevance_score": "0.057721", "ticker_sentiment_score": "0.049002", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.057721", "ticker_sentiment_score": "0.049002", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.019255", "ticker_sentiment_score": "0.05432", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.019255", "ticker_sentiment_score": "0.05432", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057721", "ticker_sentiment_score": "0.04696", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.076909", "ticker_sentiment_score": "0.054768", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTG", "relevance_score": "0.019255", "ticker_sentiment_score": "0.05432", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.038499", "ticker_sentiment_score": "0.050725", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTE", "relevance_score": "0.019255", "ticker_sentiment_score": "0.05432", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.038499", "ticker_sentiment_score": "0.050725", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.057721", "ticker_sentiment_score": "0.049002", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057721", "ticker_sentiment_score": "0.053018", "ticker_sentiment_label": "Neutral"}, {"ticker": "AURA", "relevance_score": "0.019255", "ticker_sentiment_score": "0.05432", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.038499", "ticker_sentiment_score": "0.050725", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.019255", "ticker_sentiment_score": "0.260485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKTR", "relevance_score": "0.038499", "ticker_sentiment_score": "0.035777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can This Gene-Editing Stock Deliver 10X Returns?", "url": "https://www.fool.com/investing/2023/06/08/can-this-gene-editing-stock-deliver-10x-returns/", "time_published": "20230608T153000", "authors": ["George Budwell"], "summary": "Buying shares of Intellia Therapeutics might be a smart move.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F735588%2Fgrowth-chart.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.197363, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.05749", "ticker_sentiment_score": "0.041119", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.386306", "ticker_sentiment_score": "0.150949", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32758841/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-10-years", "time_published": "20230607T140042", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.42% on an annualized basis producing an average annual return of 11.59%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.62 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2104843/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20230607T102006", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default320.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.26551, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.177584", "ticker_sentiment_score": "0.265381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "url": "https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark/", "time_published": "20230606T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Regeneron Pharmaceuticals Hits 80-Plus Relative Strength Rating ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.345285, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.470894", "ticker_sentiment_score": "0.201379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.", "url": "https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3", "time_published": "20230605T190500", "authors": ["Michael Brush"], "summary": "Big pharma will be looking to acquire companies with promsing new medicines.", "banner_image": "https://images.mktw.net/im-273079/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.682689"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.014455, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HZNP", "relevance_score": "0.097193", "ticker_sentiment_score": "0.031463", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.129342", "ticker_sentiment_score": "0.025247", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.064885", "ticker_sentiment_score": "-0.178347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.19295", "ticker_sentiment_score": "0.065446", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064885", "ticker_sentiment_score": "0.058044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For June 05 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/06/32722765/regeneron-pharmaceuticals-unusual-options-activity-for-june-05", "time_published": "20230605T190133", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.180027, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.722509", "ticker_sentiment_score": "0.308927", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32632128/regeneron-pharmaceuticals-unusual-options-activity", "time_published": "20230530T183059", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 12 strange trades.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.12952, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.784481", "ticker_sentiment_score": "0.090916", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight", "url": "https://www.prnewswire.com/news-releases/diabetic-retinopathy-clinical-trial-pipeline-space-brims-with-novel-emerging-therapies-with-over-50-key-companies-working-in-the-domain--delveinsight-301836337.html", "time_published": "20230529T150000", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.102329, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KOD", "relevance_score": "0.084275", "ticker_sentiment_score": "0.054596", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.084275", "ticker_sentiment_score": "0.04104", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.042196", "ticker_sentiment_score": "0.043678", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUP", "relevance_score": "0.084275", "ticker_sentiment_score": "0.098908", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.042196", "ticker_sentiment_score": "0.043678", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.042196", "ticker_sentiment_score": "0.045112", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUL", "relevance_score": "0.042196", "ticker_sentiment_score": "0.045112", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPT", "relevance_score": "0.021106", "ticker_sentiment_score": "0.002652", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRBO", "relevance_score": "0.042196", "ticker_sentiment_score": "0.043678", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYPT", "relevance_score": "0.063258", "ticker_sentiment_score": "0.047042", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.063258", "ticker_sentiment_score": "0.031047", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.021106", "ticker_sentiment_score": "0.002652", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.021106", "ticker_sentiment_score": "0.002652", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCGN", "relevance_score": "0.063258", "ticker_sentiment_score": "0.051042", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:VND", "relevance_score": "0.042196", "ticker_sentiment_score": "0.043678", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Posts Upbeat Data From Multiple Myeloma Study", "url": "https://www.zacks.com/stock/news/2100449/regeneron-regn-posts-upbeat-data-from-multiple-myeloma-study", "time_published": "20230526T150400", "authors": ["Zacks Investment Research"], "summary": "A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.142646, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.291182", "ticker_sentiment_score": "0.064985", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIP", "relevance_score": "0.336934", "ticker_sentiment_score": "0.214178", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.148121", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.244354", "ticker_sentiment_score": "-0.036953", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71% - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32590555/regeneron-reveals-updated-data-from-multiple-myeloma-study-showing-response-rate-of-71", "time_published": "20230526T104022", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN announced updated data from two Phase 2 expansion dose cohorts of linvoseltamab ( formerly REGN5458 ) in patients with heavily pre-treated, relapsed/refractory multiple myeloma.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/26/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.138228, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.40348", "ticker_sentiment_score": "0.163141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?", "url": "https://www.zacks.com/stock/news/2100032/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt", "time_published": "20230526T102005", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default20.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.138592, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Linvoseltamab  ( BCMAxCD3 )  Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma", "url": "https://www.globenewswire.com/news-release/2023/05/25/2676777/0/en/Updated-Linvoseltamab-BCMAxCD3-Data-from-Pivotal-Trial-Demonstrates-Early-Deep-and-Durable-Responses-in-Patients-with-Heavily-Pre-treated-Multiple-Myeloma.html", "time_published": "20230525T210500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.083606, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.046969", "ticker_sentiment_score": "0.048733", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.015664", "ticker_sentiment_score": "0.048953", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fianlimab  ( LAG-3 inhibitor )  Combined with Libtayo\u00ae  ( cemiplimab )  Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32585791/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-shows-clinically-meaningful-and-durable", "time_published": "20230525T210004", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., May 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced positive data from three independent cohorts evaluating an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo\u00ae ( cemiplimab ) in adults with advanced melanoma.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.036402, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.043918", "ticker_sentiment_score": "0.034726", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.010985", "ticker_sentiment_score": "0.050537", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For May 25 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32584357/regeneron-pharmaceuticals-unusual-options-activity-for-may-25", "time_published": "20230525T201926", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 16 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_10215.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.152718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.823417", "ticker_sentiment_score": "0.179594", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.107495", "ticker_sentiment_score": "-0.132714", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group", "url": "https://www.zacks.com/stock/news/2099438/the-zacks-analyst-blog-highlights-abbvie-intel-qualcomm-regeneron-and-cme-group", "time_published": "20230525T103800", "authors": ["Zacks Investment Research"], "summary": "AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/701.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CME", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Research Reports for AbbVie, Intel & Qualcomm", "url": "https://www.zacks.com/research-daily/2099100/top-research-reports-for-abbvie-intel-qualcomm", "time_published": "20230524T202600", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.185067, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CME", "relevance_score": "0.125789", "ticker_sentiment_score": "0.093205", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.365166", "ticker_sentiment_score": "0.199458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.125789", "ticker_sentiment_score": "0.093205", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.307731", "ticker_sentiment_score": "0.175846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.24847", "ticker_sentiment_score": "0.148935", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 4 Best Biotech Stocks According to POWR Ratings", "url": "https://stocknews.com/news/amgn-regn-uthr-vnda-4-best-biotech-stocks-according-to-powr-ratings/", "time_published": "20230523T143104", "authors": [], "summary": "The biotech industry has diversified and thrived, especially during the pandemic, owing to the advanced innovations and incessant efforts to curb the deadly virus. Moreover, the inelastic demand enjoyed by the industry makes it well-grounded to maintain its buoyancy in the upcoming times.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}], "overall_sentiment_score": 0.174501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TCRX", "relevance_score": "0.025139", "ticker_sentiment_score": "-0.054824", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.149966", "ticker_sentiment_score": "0.086737", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.247334", "ticker_sentiment_score": "0.09851", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.100308", "ticker_sentiment_score": "0.049217", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.149966", "ticker_sentiment_score": "0.010723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2098310/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230523T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999892"}], "overall_sentiment_score": 0.272138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061949", "ticker_sentiment_score": "0.11403", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should First Trust NASDAQ-100 Equal Weighted ETF  ( QQEW )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2098304/should-first-trust-nasdaq-100-equal-weighted-etf-qqew-be-on-your-investing-radar", "time_published": "20230523T102005", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.233315, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LCID", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.116914", "ticker_sentiment_score": "0.101724", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.116914", "ticker_sentiment_score": "0.060317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32520783/heres-how-much-100-invested-in-regeneron-pharmaceuticals-20-years-ago-would-be-worth-today", "time_published": "20230522T213303", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.78% on an annualized basis producing an average annual return of 22.45%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.45 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32508995/sanofi-regeneron-highlight-dupixent-data-say-drug-benefit-was-swift-sustained", "time_published": "20230522T155054", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY presented results from a Phase 3 study of Dupixent ( dupilumab ) in adults currently on maximal standard-of-care inhaled therapy ( triple therapy ) with uncontrolled chronic obstructive pulmonary disease ( COPD ) and evidence of type 2 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/22/sny-regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.093118, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.448842", "ticker_sentiment_score": "-0.104184", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.448842", "ticker_sentiment_score": "-0.104184", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32501095/dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultaneously-publishe", "time_published": "20230521T181851", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y. and PARIS, May 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.060345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.03746", "ticker_sentiment_score": "0.028366", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.112051", "ticker_sentiment_score": "0.001139", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine", "url": "https://www.globenewswire.com/news-release/2023/05/21/2672905/0/en/Dupixent-dupilumab-Late-breaking-Phase-3-COPD-Results-Presented-at-ATS-and-Simultaneously-Published-in-the-New-England-Journal-of-Medicine.html", "time_published": "20230521T181800", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.050796, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.035621", "ticker_sentiment_score": "0.02922", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.10658", "ticker_sentiment_score": "0.015656", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32501090/press-release-dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultane", "time_published": "20230521T181707", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.00483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025352", "ticker_sentiment_score": "0.037274", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.138754", "ticker_sentiment_score": "0.008849", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine", "url": "https://www.globenewswire.com/news-release/2023/05/21/2672904/0/en/Press-Release-Dupixent-dupilumab-late-breaking-Phase-3-COPD-results-presented-at-ATS-and-simultaneously-published-in-the-New-England-Journal-of-Medicine.html", "time_published": "20230521T181700", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025073", "ticker_sentiment_score": "0.037357", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.149578", "ticker_sentiment_score": "0.006631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio", "url": "https://www.prnewswire.com/news-releases/autoimmune-drugs-market-size-to-grow-by-usd-29-314-5-million-between-2022-and-2027-abbvie-inc-and-advacare-pharma-among-others-identified-as-key-vendors--technavio-301828870.html", "time_published": "20230519T231500", "authors": ["Technavio"], "summary": "Autoimmune Drugs Market size to grow by USD 29,314.5 million ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2080550/Technavio_Logo_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.200974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOALF", "relevance_score": "0.037622", "ticker_sentiment_score": "0.140333", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Faces Challenges as Eylea Sales Decline", "url": "https://www.zacks.com/stock/news/2097627/regeneron-regn-faces-challenges-as-eylea-sales-decline", "time_published": "20230519T174200", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.232236, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.142144", "ticker_sentiment_score": "-0.306968", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAYZF", "relevance_score": "0.071357", "ticker_sentiment_score": "0.204589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.211806", "ticker_sentiment_score": "0.210741", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32486814/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230519T144617", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.184226, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.766141", "ticker_sentiment_score": "0.344161", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is First Trust NYSE Arca Biotechnology ETF  ( FBT )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2097186/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now", "time_published": "20230519T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.244536, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.116348", "ticker_sentiment_score": "0.06132", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.116348", "ticker_sentiment_score": "0.06132", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.116348", "ticker_sentiment_score": "0.06132", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/05/19/2672401/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230519T090000", "authors": ["Alvotech"], "summary": "\u2022 Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 \u2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi\u00ae and Simponi Aria\u00ae ( golimumab ) initiated, marking the fifth internally developed portfolio ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.145891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.385137", "ticker_sentiment_score": "0.215528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.025087", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.012545", "ticker_sentiment_score": "0.051698", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ISK", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:SEK", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/05/19/2672402/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230519T090000", "authors": ["Alvotech"], "summary": "REYKJAVIK, Iceland, May 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.143537, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.384213", "ticker_sentiment_score": "0.212589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.025021", "ticker_sentiment_score": "0.0348", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.012512", "ticker_sentiment_score": "0.051684", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ISK", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:SEK", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation", "url": "https://www.globenewswire.com/news-release/2023/05/18/2672107/0/en/Regeneron-Applauds-Supreme-Court-s-Unanimous-Opinion-Striking-Down-Amgen-s-PCSK9-Patent-Claims-and-Supporting-Scientific-Innovation.html", "time_published": "20230518T154500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Decision ends nearly decade-long patent dispute related to ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.177741, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.056512", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.029256", "ticker_sentiment_score": "0.052074", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32470164/regeneron-applauds-supreme-courts-unanimous-opinion-striking-down-amgens-pcsk9-patent-claims-and-s", "time_published": "20230518T154500", "authors": ["Globe Newswire"], "summary": "Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent\u00ae ( alirocumab ) TARRYTOWN, N.Y., May 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.165956, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.113731", "ticker_sentiment_score": "0.053555", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.057011", "ticker_sentiment_score": "0.052012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top CEOs Earned Less In 2022 Compared To 2021: Discover Their Earnings And The Highest-Paid Leaders - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/05/32404282/top-ceos-earned-less-in-2022-compared-to-2021-discover-their-earnings-and-the-highest-paid-leaders", "time_published": "20230515T205722", "authors": ["Chris Katje"], "summary": "The issue of executive compensation remains a highly debated subject among shareholders of publicly traded corporations. This discussion is fueled by instances where job and cost reductions are implemented, while some executives continue to receive substantial rewards.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/15/sundar_pichai_flickr.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.064239, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.063594", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.063594", "ticker_sentiment_score": "0.297777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.126784", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.103373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.063594", "ticker_sentiment_score": "0.062024", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.103373", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.126784", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.063594", "ticker_sentiment_score": "0.297777", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/05/32400918/how-is-the-market-feeling-about-regeneron-pharmaceuticals", "time_published": "20230515T171545", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has risen 11.97% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 1.31% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/05/15/2668677/0/en/Decibel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Corporate-Update.html", "time_published": "20230515T114500", "authors": ["Inc.", "Decibel Therapeutics"], "summary": "- Initiated CHORD\u2122, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/83689706-9e23-448c-9c5e-fa03a8df7d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.092206, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.045012", "ticker_sentiment_score": "0.029736", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.089881", "ticker_sentiment_score": "0.11737", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2095065/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230515T102009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default205.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.191498, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069094", "ticker_sentiment_score": "0.03409", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}]}, {"title": "AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market - Meta Platforms  ( NASDAQ:META ) , NVIDIA  ( NASDAQ:NVDA ) , Apple  ( NASDAQ:AAPL ) , TJX Companies  ( NYSE:TJX ) , Monster Beverage  ( NASDAQ:MNST ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , QRAFT AI-Enhanced U.S. Large Cap Momentum ETF  ( ARCA:AMOM ) , Starbucks  ( NASDAQ:SBUX ) , Lowe's Companies  ( NYSE:LOW ) , O'Reilly Automotive  ( NASDAQ:ORLY ) , AutoZone  ( NYSE:AZO ) , Eli Lilly  ( NYSE:LLY ) , Home Depot  ( NYSE:HD ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Walmart  ( NYSE:WMT ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32366764/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-bre", "time_published": "20230512T151124", "authors": ["Shanthi Rexaline"], "summary": "Apple, Inc. AAPL is often touted as an all-weather stock but one exchange-traded fund, powered by artificial intelligence, has deemed it fit to dump its entire Apple holdings and switched its allegiance to a chipmaker. What Happened: QRAFT AI-Enhanced U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/artificial_intelligence_as_stock_picker.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.174621, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.249106", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.249106", "ticker_sentiment_score": "0.268016", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.572601", "ticker_sentiment_score": "0.201461", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORLY", "relevance_score": "0.249106", "ticker_sentiment_score": "-0.042508", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZO", "relevance_score": "0.249106", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.249106", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.249106", "ticker_sentiment_score": "0.194412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.249106", "ticker_sentiment_score": "0.194412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HD", "relevance_score": "0.249106", "ticker_sentiment_score": "-0.042508", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.249106", "ticker_sentiment_score": "0.194412", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CAGR of 5.6%, Red Biotechnology Market Expected to Surpass USD 609.6 Billion by 2031 - Exclusive Study by TMR", "url": "https://www.benzinga.com/pressreleases/23/05/g32362861/cagr-of-5-6-red-biotechnology-market-expected-to-surpass-usd-609-6-billion-by-2031-exclusive-study", "time_published": "20230512T123000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, May 12, 2023 ( GLOBE NEWSWIRE ) -- The global red biotechnology market size stood at USD 357.2 Bn in 2021 and is anticipated to surpass value of USD 609.6 Bn by 2031. The global industry is anticipated to expand at a CAGR of 5.6% between 2022 and 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.282507, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TAK", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices  ( AEMPS )  to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO - Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32360731/decibel-therapeutics-announces-approval-of-clinical-trial-application-by-the-spanish-agency-of-med", "time_published": "20230512T110000", "authors": ["Globe Newswire"], "summary": "BOSTON, May 12, 2023 ( GLOBE NEWSWIRE ) -- Decibel Therapeutics DBTX, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application ( CTA ) by the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.111111, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.037681", "ticker_sentiment_score": "0.107697", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.112709", "ticker_sentiment_score": "0.104898", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded to \"Strong-Buy\" by StockNews.com", "url": "https://www.defenseworld.net/2023/05/09/regeneron-pharmaceuticals-nasdaqregn-upgraded-to-strong-buy-by-stocknews-com.html", "time_published": "20230509T093055", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Upgraded to \"Strong ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.278419, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.047185", "ticker_sentiment_score": "0.058325", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.047185", "ticker_sentiment_score": "0.058325", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.047185", "ticker_sentiment_score": "0.058325", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENR", "relevance_score": "0.047185", "ticker_sentiment_score": "0.054425", "ticker_sentiment_label": "Neutral"}, {"ticker": "UVSP", "relevance_score": "0.094204", "ticker_sentiment_score": "0.215308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHGG", "relevance_score": "0.047185", "ticker_sentiment_score": "0.054425", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.047185", "ticker_sentiment_score": "0.054425", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.763362", "ticker_sentiment_score": "0.444403", "ticker_sentiment_label": "Bullish"}]}, {"title": "Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32274966/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity", "time_published": "20230508T204616", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.126559, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.846873", "ticker_sentiment_score": "0.303176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.094762", "ticker_sentiment_score": "-0.12803", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32240272/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-300-today", "time_published": "20230505T143022", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.49% on an annualized basis producing an average annual return of 11.18%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.95 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intellia  ( NTLA )  Beats on Q1 Earnings, Gives Pipeline Update", "url": "https://www.zacks.com/stock/news/2090934/intellia-ntla-beats-on-q1-earnings-gives-pipeline-update", "time_published": "20230505T131500", "authors": ["Zacks Investment Research"], "summary": "Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.124958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.261818", "ticker_sentiment_score": "0.170488", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OCUP", "relevance_score": "0.261818", "ticker_sentiment_score": "0.076416", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.261818", "ticker_sentiment_score": "0.272985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.78997", "ticker_sentiment_score": "0.257438", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ultragenyx  ( RARE )  Q1 Earnings and Revenues Miss Estimates", "url": "https://www.zacks.com/stock/news/2090844/ultragenyx-rare-q1-earnings-and-revenues-miss-estimates", "time_published": "20230505T122700", "authors": ["Zacks Investment Research"], "summary": "Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.078205, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.074812", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.046273", "ticker_sentiment_score": "0.037485", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.074812", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.183546", "ticker_sentiment_score": "-0.078597", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.09239", "ticker_sentiment_score": "0.137782", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.183546", "ticker_sentiment_score": "0.065692", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Off Heading Back To Day's Lows. Medical Diagnostics Stock Jumps 15% After Earnings.", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-off-lows-prostate-cancer-stock-jumps/", "time_published": "20230504T192700", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Off Lows Ahead Of Apple And Jobs. Prostate Cancer ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/Stock-MedicalDiagnostic-09-shut.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.999966"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.972476"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APO", "relevance_score": "0.08197", "ticker_sentiment_score": "0.05181", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.163078", "ticker_sentiment_score": "-0.176769", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WAL", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.028658", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.3142", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.041039", "ticker_sentiment_score": "0.01298", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.08197", "ticker_sentiment_score": "0.155347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHOP", "relevance_score": "0.08197", "ticker_sentiment_score": "0.013548", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNTH", "relevance_score": "0.08197", "ticker_sentiment_score": "0.164596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMA", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.3142", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARNC", "relevance_score": "0.122685", "ticker_sentiment_score": "0.042022", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.163078", "ticker_sentiment_score": "-0.077078", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.08197", "ticker_sentiment_score": "0.180021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.039639", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.041039", "ticker_sentiment_score": "0.148661", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Pharmaceuticals  ( REGN )  Shares Are Trading Lower Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32216673/why-regeneron-pharmaceuticals-shares-are-trading-lower-today", "time_published": "20230504T175024", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/04/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.092472, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.479683", "ticker_sentiment_score": "-0.078038", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.479683", "ticker_sentiment_score": "-0.098295", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Pharmaceuticals Stock Is Tanking Today", "url": "https://www.fool.com/investing/2023/05/04/why-regeneron-pharmaceuticals-stock-is-tanking-tod/", "time_published": "20230504T172355", "authors": ["George Budwell"], "summary": "Investors are worried about Eylea's falling sales.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F730934%2Fcleanroom.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.133697, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.145033", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.144275", "ticker_sentiment_score": "0.179424", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  Q1 Earnings & Sales Top, Eylea Sales Decline", "url": "https://www.zacks.com/stock/news/2090283/regeneron-regn-q1-earnings-sales-top-eylea-sales-decline", "time_published": "20230504T160300", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default172.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.255229, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.187463", "ticker_sentiment_score": "0.191405", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.047278", "ticker_sentiment_score": "0.121535", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.277958", "ticker_sentiment_score": "0.258959", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Dives As Competition Undercuts Its Biggest Moneymaker", "url": "https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q1-2023/", "time_published": "20230504T125000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "REGN Stock Dives As Competition Hammers Away At Eylea Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-regeneron-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.02671, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.779232", "ticker_sentiment_score": "0.091344", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/05/04/2661383/0/en/Intellia-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20230504T113000", "authors": ["Intellia Therapeutics", "Inc."], "summary": "CAMBRIDGE, Mass., May 04, 2023 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.161488, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.044496", "ticker_sentiment_score": "0.070367", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.693663", "ticker_sentiment_score": "0.298846", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron beats quarterly profit estimates", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-beats-quarterly-profit-estimates-eylea-strength-2023-05-04/", "time_published": "20230504T103900", "authors": ["Reuters"], "summary": "May 4 ( Reuters ) - Regeneron Pharmaceuticals Inc ( REGN.O ) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent. Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts' estimates of ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ODP5STQL2ZI27IZTIJTDAOIWMQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.339213, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.495015", "ticker_sentiment_score": "0.51181", "ticker_sentiment_label": "Bullish"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32196053/regeneron-pharmaceuticals-unusual-options-activity", "time_published": "20230503T191627", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_8470.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.198245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.753462", "ticker_sentiment_score": "0.375938", "ticker_sentiment_label": "Bullish"}]}, {"title": "Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More", "url": "https://www.zacks.com/stock/news/2089198/drug-biotech-stocks-q1-earnings-on-may-4-regn-zts-more", "time_published": "20230503T154600", "authors": ["Zacks Investment Research"], "summary": "Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/11325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.120979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZTS", "relevance_score": "0.281153", "ticker_sentiment_score": "0.176082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.235823", "ticker_sentiment_score": "0.042969", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.18967", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.281153", "ticker_sentiment_score": "0.070709", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.047844", "ticker_sentiment_score": "0.109472", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Earnings Season Could Be Great for Regeneron  ( REGN ) ", "url": "https://www.zacks.com/stock/news/2088882/why-earnings-season-could-be-great-for-regeneron-regn", "time_published": "20230503T123600", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default146.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.463498, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.812724", "ticker_sentiment_score": "0.693705", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/05/03/2660120/0/en/Cerevel-Therapeutics-Appoints-Ron-Renaud-as-President-and-Chief-Executive-Officer-and-Reports-First-Quarter-2023-Financial-Results.html", "time_published": "20230503T103000", "authors": ["Cerevel Therapeutics"], "summary": "Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023. Dr. Coles will continue as chairperson of the board ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a08b2b75-1208-494e-96a4-a7f98dc0328a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.187216, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.014541", "ticker_sentiment_score": "-0.024664", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.08708", "ticker_sentiment_score": "0.105061", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.014541", "ticker_sentiment_score": "0.053412", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.014541", "ticker_sentiment_score": "-0.024664", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.029078", "ticker_sentiment_score": "0.128117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2088704/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe", "time_published": "20230503T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.18305, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.194763", "ticker_sentiment_score": "0.124689", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution", "url": "https://www.globenewswire.com/news-release/2023/05/02/2659011/0/en/Kiniksa-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html", "time_published": "20230502T113000", "authors": ["Kiniksa Pharmaceuticals", "Ltd."], "summary": "- ARCALYST\u00ae ( rilonacept ) Q1 2023 net product revenue of $42.7 million -- ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint -- Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d9c74849-9de0-4f1f-807c-990609944292", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999822"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.024146, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.169486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KNSA", "relevance_score": "0.041216", "ticker_sentiment_score": "0.040619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32152354/regeneron-to-highlight-new-and-updated-clinical-data-at-asco-showcasing-breadth-of-cancer-research", "time_published": "20230502T110045", "authors": ["Globe Newswire"], "summary": "Oral presentations include interim results from pivotal trial of linvoseltamab ( BCMAxCD3 ) in relapsed/refractory multiple myeloma and three cohorts of fianlimab ( LAG-3 inhibitor ) combined with Libtayo\u00ae ( cemiplimab-rwlc ) in advanced melanoma", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.140601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.055837", "ticker_sentiment_score": "-0.098997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research", "url": "https://www.globenewswire.com/news-release/2023/05/02/2658982/0/en/Regeneron-to-Highlight-New-and-Updated-Clinical-Data-at-ASCO-Showcasing-Breadth-of-Cancer-Research.html", "time_published": "20230502T110000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Oral presentations include interim results from pivotal trial of linvoseltamab ( BCMAxCD3 ) in relapsed/refractory multiple myeloma and three cohorts of fianlimab ( LAG-3 inhibitor ) combined with Libtayo\u00ae ( cemiplimab-rwlc ) in advanced melanoma ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.070506, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.049706", "ticker_sentiment_score": "0.029966", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.012434", "ticker_sentiment_score": "0.052164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is a Beat on the Cards for Regeneron's  ( REGN )  Q1 Earnings?", "url": "https://www.zacks.com/stock/news/2087388/is-a-beat-on-the-cards-for-regenerons-regn-q1-earnings", "time_published": "20230501T120200", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.196493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.120834", "ticker_sentiment_score": "-0.001145", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.238913", "ticker_sentiment_score": "0.228333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.040416", "ticker_sentiment_score": "0.03649", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.277208", "ticker_sentiment_score": "0.244881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sports Medicine Devices Market to Witness 5.6% CAGR during 2021 - 2028, Reaching USD 13.85 Bn: TMR Study", "url": "https://www.benzinga.com/pressreleases/23/04/g32092403/sports-medicine-devices-market-to-witness-5-6-cagr-during-2021-2028-reaching-usd-13-85-bn-tmr-stud", "time_published": "20230428T193000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, April 29, 2023 ( GLOBE NEWSWIRE ) -- Increase in preference for minimally invasive surgeries and surge in adoption of arthroscopic surgery for the treatment of common sports injuries are propelling market growth.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.248694, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNPHF", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.077094", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.038592", "ticker_sentiment_score": "0.071758", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Charts Strategy May 1-5: Fed Policy, April Payrolls, Apple Earnings", "url": "https://www.investors.com/all-categories/stock-charts-action-plan-may-1-5-fed-policy-april-payrolls-apple-earnings/", "time_published": "20230428T171200", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Stock Charts Strategy May 1-5: Fed Policy, April Payrolls, Apple ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/04/stock-NYSE-exterior-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.07604, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.141448", "ticker_sentiment_score": "0.033036", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.047371", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.047371", "ticker_sentiment_score": "0.063101", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.047371", "ticker_sentiment_score": "0.017893", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.047371", "ticker_sentiment_score": "0.029001", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.071005", "ticker_sentiment_score": "0.089454", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLNT", "relevance_score": "0.047371", "ticker_sentiment_score": "0.131681", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.047371", "ticker_sentiment_score": "0.066605", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.047371", "ticker_sentiment_score": "0.111756", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTHM", "relevance_score": "0.023696", "ticker_sentiment_score": "0.041208", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047371", "ticker_sentiment_score": "-0.073673", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.071005", "ticker_sentiment_score": "0.068575", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.047371", "ticker_sentiment_score": "0.094847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.071005", "ticker_sentiment_score": "0.139848", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.071005", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.047371", "ticker_sentiment_score": "0.114742", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.071005", "ticker_sentiment_score": "-0.156309", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.047371", "ticker_sentiment_score": "0.066605", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.047371", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.047371", "ticker_sentiment_score": "-0.049249", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.023696", "ticker_sentiment_score": "-0.044381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Government Drug Price Curbs Could Sound A Death Knell For Industry", "url": "https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/", "time_published": "20230428T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-humira-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.024097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.11222", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.055277", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08123", "ticker_sentiment_score": "-0.011317", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.013561", "ticker_sentiment_score": "0.077066", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.027118", "ticker_sentiment_score": "0.05187", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.061364", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.027118", "ticker_sentiment_score": "0.052088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.064288", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067727", "ticker_sentiment_score": "0.005039", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054205", "ticker_sentiment_score": "-0.077946", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-first-quarter-financial-results/", "time_published": "20230427T204313", "authors": [], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121049, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.015675", "ticker_sentiment_score": "0.193262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNBWY", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031343", "ticker_sentiment_score": "0.109564", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVB", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.093836", "ticker_sentiment_score": "0.044844", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-first-quarter-financial-results-2659922399/", "time_published": "20230427T204313", "authors": [], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121049, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.015675", "ticker_sentiment_score": "0.193262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNBWY", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031343", "ticker_sentiment_score": "0.109564", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVB", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.093836", "ticker_sentiment_score": "0.044844", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-financial-results-301810090.html", "time_published": "20230427T200100", "authors": ["Amgen"], "summary": "THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.088516, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.006681", "ticker_sentiment_score": "0.182426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013361", "ticker_sentiment_score": "0.05887", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.013361", "ticker_sentiment_score": "0.099235", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week", "url": "https://stocknews.com/news/regn-biib-gild-vnda-a-prescription-for-success-check-out-this-strong-pharmaceutical-stock/", "time_published": "20230427T155446", "authors": [], "summary": "REGN: A Prescription for Success: Check Out This Strong ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.263793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.552443", "ticker_sentiment_score": "0.362894", "ticker_sentiment_label": "Bullish"}, {"ticker": "VNDA", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says - Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/04/32048648/alnylam-regeneron-partnered-alzheimers-candidates-initial-data-sounds-promising-analyst-says", "time_published": "20230427T155205", "authors": ["Vandana Singh"], "summary": "Alnylam Pharmaceuticals Inc ALNY and its partner Regeneron Pharmaceuticals Inc REGN announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/27/dementia-3051832_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.099029, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.38489", "ticker_sentiment_score": "0.248511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.38489", "ticker_sentiment_score": "0.248511", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial - SAB Biotherapeutics  ( NASDAQ:SABS ) ", "url": "https://www.benzinga.com/general/biotech/23/04/32004894/exclusive-sab-biotherapeutics-releases-topline-data-from-discontinued-covid-antibody-trial", "time_published": "20230426T120013", "authors": ["Vandana Singh"], "summary": "SAB Biotherapeutics Inc SABS has revealed topline results from the Phase 3 National Institutes of Health's ( NIH ) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at high risk for severe outcomes.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/26/sabs.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.038077, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.045143", "ticker_sentiment_label": "Neutral"}, {"ticker": "SABS", "relevance_score": "0.496915", "ticker_sentiment_score": "-0.038502", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For April 25 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/04/31992883/regeneron-pharmaceuticals-unusual-options-activity-for-april-25", "time_published": "20230425T154551", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 11 strange trades.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.16079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.71032", "ticker_sentiment_score": "0.057325", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2083259/4-pharma-biotech-stocks-poised-to-beat-q1-earnings-estimates", "time_published": "20230424T123800", "authors": ["Zacks Investment Research"], "summary": "We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.222022", "ticker_sentiment_score": "-0.046605", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.190761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.348103", "ticker_sentiment_score": "0.075985", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.134339", "ticker_sentiment_score": "-0.001252", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.222022", "ticker_sentiment_score": "0.025583", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For April 20 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/04/31923088/regeneron-pharmaceuticals-unusual-options-activity-for-april-20", "time_published": "20230420T191608", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.120203, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.77688", "ticker_sentiment_score": "0.283971", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD 16.23 Billion by 2028 Says Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/with-13-87-cagr-atopic-dermatitis-market-size-to-surpass-usd-16-23-billion-by-2028-says-brandessence-market-research-301799955.html", "time_published": "20230418T070700", "authors": ["Brandessence Market Research and Consulting Private Limited"], "summary": "With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.137931, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RYLPF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.113284", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.080721", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.029654", "ticker_sentiment_score": "0.080721", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.029654", "ticker_sentiment_score": "0.113284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059268", "ticker_sentiment_score": "0.115019", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.029654", "ticker_sentiment_score": "0.080721", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.029654", "ticker_sentiment_score": "0.080721", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UZS", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary", "url": "https://www.globenewswire.com/news-release/2023/04/17/2647803/0/en/Regeneron-Announces-Retirement-of-Board-Chair-Dr-P-Roy-Vagelos-Accomplished-Physician-Businessman-and-Industry-Luminary.html", "time_published": "20230417T113000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.262679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.205807", "ticker_sentiment_score": "0.074563", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.069294", "ticker_sentiment_score": "0.154735", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31826057/regeneron-announces-retirement-of-board-chair-dr-p-roy-vagelos-accomplished-physician-businessman-", "time_published": "20230417T113000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., April 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.253818, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.201244", "ticker_sentiment_score": "0.073268", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.067727", "ticker_sentiment_score": "0.154425", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aflibercept 8 mg and EYLEA\u00ae  ( aflibercept )  Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases", "url": "https://www.globenewswire.com/news-release/2023/04/17/2647753/0/en/Aflibercept-8-mg-and-EYLEA-aflibercept-Injection-Presentations-at-ARVO-Provide-New-Insights-into-the-Treatment-of-Serious-Retinal-Diseases.html", "time_published": "20230417T110000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.069262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.062271", "ticker_sentiment_score": "0.046145", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.015583", "ticker_sentiment_score": "0.114995", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.015583", "ticker_sentiment_score": "0.049892", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: 7 Stocks Near Buy Points", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-tesla-apple-stock-near-buy-points-in-market-rally/", "time_published": "20230416T203800", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Loom: Tesla, Apple Lead 7 Stocks Near Buy ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/08/Stock-teslacars-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.993781"}], "overall_sentiment_score": 0.02909, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.140661", "ticker_sentiment_score": "0.068319", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.040382", "ticker_sentiment_score": "0.168655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.140661", "ticker_sentiment_score": "-0.005071", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.040382", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.040382", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.020197", "ticker_sentiment_score": "-0.059299", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.120733", "ticker_sentiment_score": "-0.054495", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.25793", "ticker_sentiment_score": "-0.00396", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.040382", "ticker_sentiment_score": "-0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.040382", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.040382", "ticker_sentiment_score": "-0.040986", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.04513", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.060541", "ticker_sentiment_score": "0.152023", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How To Handle This Rally; Seven Stocks Near Buy Points", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-how-to-handle-volatile-market-rally-tesla-netflix-earnings-on-tap-apple-stock/", "time_published": "20230415T125600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: How To Handle This Market. Tesla, Netflix Near ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/08/Stock-teslacars-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.988787"}], "overall_sentiment_score": 0.021818, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.131523", "ticker_sentiment_score": "0.085119", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.131523", "ticker_sentiment_score": "-0.056902", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.044019", "ticker_sentiment_score": "0.168966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.131523", "ticker_sentiment_score": "-0.007401", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.259497", "ticker_sentiment_score": "-0.004004", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.044019", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.044019", "ticker_sentiment_score": "-0.048342", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.044019", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.044019", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.022018", "ticker_sentiment_score": "-0.060037", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.065987", "ticker_sentiment_score": "-0.04536", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/04/31776143/regeneron-pharmaceuticals-unusual-options-activity", "time_published": "20230412T191547", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_7001.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.12023, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.781591", "ticker_sentiment_score": "0.28462", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate - MAIA Biotechnology  ( AMEX:MAIA ) ", "url": "https://www.benzinga.com/general/biotech/23/04/31749899/maia-biotechnology-touts-positive-data-from-healthy-volunteer-study-of-potential-lung-cancer-cand", "time_published": "20230411T164356", "authors": ["Vandana Singh"], "summary": "MAIA Biotechnology Inc MAIA released topline data from the completed Part A safety lead-in of its THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer ( NSCLC ) and has commenced recruitment in Part B randomized efficacy/dose selection.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/11/maia.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.067889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For April 05 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/04/31682495/regeneron-pharmaceuticals-unusual-options-activity-for-april-05", "time_published": "20230405T153109", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_6510.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.19878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.708701", "ticker_sentiment_score": "0.347106", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/04/31634455/100-invested-in-this-stock-5-years-ago-would-be-worth-200-today", "time_published": "20230403T140042", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 11.14% on an annualized basis producing an average annual return of 20.69%. Currently, Regeneron Pharmaceuticals has a market capitalization of $89.47 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday - Braze  ( NASDAQ:BRZE ) , Conagra Brands  ( NYSE:CAG ) ", "url": "https://www.benzinga.com/news/23/03/31607802/nvidia-to-rally-around-18-here-are-10-other-analyst-forecasts-for-friday", "time_published": "20230331T124420", "authors": ["Lisa Levin"], "summary": "Benchmark cut the price target for CuriosityStream Inc. CURI from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in pre-market trading. Morgan Stanley lowered the price target for Hudson Pacific Properties, Inc. HPP from $10 to $6.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/31/nvidia-logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.09211, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.283323", "ticker_sentiment_score": "-0.053293", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRZE", "relevance_score": "0.283323", "ticker_sentiment_score": "-0.019211", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.371523", "ticker_sentiment_score": "0.139699", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.10749", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAG", "relevance_score": "0.19117", "ticker_sentiment_score": "0.004688", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPP", "relevance_score": "0.283323", "ticker_sentiment_score": "0.048432", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROG", "relevance_score": "0.283323", "ticker_sentiment_score": "0.591392", "ticker_sentiment_label": "Bullish"}, {"ticker": "OKTA", "relevance_score": "0.19117", "ticker_sentiment_score": "0.227208", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.19117", "ticker_sentiment_score": "-0.11425", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURI", "relevance_score": "0.283323", "ticker_sentiment_score": "0.006381", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRV", "relevance_score": "0.19117", "ticker_sentiment_score": "0.216405", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COF", "relevance_score": "0.283323", "ticker_sentiment_score": "-0.155238", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.283323", "ticker_sentiment_score": "-0.079611", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.283323", "ticker_sentiment_score": "-0.207434", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback", "url": "https://www.zacks.com/stock/news/2072025/biotech-stock-roundup-vktx-bmea-itci-soar-on-study-data-incy-faces-setback", "time_published": "20230329T152400", "authors": ["Zacks Investment Research"], "summary": "Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.031273, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMEA", "relevance_score": "0.0686", "ticker_sentiment_score": "0.084256", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.203786", "ticker_sentiment_score": "0.016231", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.102741", "ticker_sentiment_score": "-0.0633", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.0686", "ticker_sentiment_score": "-0.155884", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.0686", "ticker_sentiment_score": "0.0385", "ticker_sentiment_label": "Neutral"}]}, {"title": "Libtayo\u00ae  ( cemiplimab )  in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC )  - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31544436/libtayo-cemiplimab-in-combination-with-chemotherapy-approved-by-european-commission-for-the-first-", "time_published": "20230329T110000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., March 29, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the European Commission ( EC ) approved Libtayo\u00ae ( cemiplimab ) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.078011, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.121701", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014298", "ticker_sentiment_score": "0.006312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Libtayo\u00ae  ( cemiplimab )  in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC ) ", "url": "https://www.globenewswire.com/news-release/2023/03/29/2636521/0/en/Libtayo-cemiplimab-in-Combination-with-Chemotherapy-Approved-by-European-Commission-for-the-First-line-Treatment-of-Advanced-PD-L1-Positive-Non-small-Cell-Lung-Cancer-NSCLC.html", "time_published": "20230329T110000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.046382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.041901", "ticker_sentiment_score": "0.020793", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020958", "ticker_sentiment_score": "0.041898", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Unusual Options Activity For March 28 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/03/31539094/regeneron-pharmaceuticals-unusual-options-activity-for-march-28", "time_published": "20230328T204552", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.155562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.706282", "ticker_sentiment_score": "0.16512", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades' - Bank of America  ( NYSE:BAC ) , Hess  ( NYSE:HES ) ", "url": "https://www.benzinga.com/news/23/03/31523538/regeneron-pharmaceuticals-hess-and-1-of-worlds-biggest-bank-cnbcs-final-trades", "time_published": "20230328T122904", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. REGN. SVB Leerink analyst David Risinger upgraded Regeneron Pharmaceuticals from Market Perform to Outperform and raised the price target from $834 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/28/analyst_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.245587, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTS", "relevance_score": "0.17715", "ticker_sentiment_score": "0.192407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.629492", "ticker_sentiment_score": "0.43754", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.17715", "ticker_sentiment_score": "-0.172612", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CZBS", "relevance_score": "0.17715", "ticker_sentiment_score": "0.270607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FIZN", "relevance_score": "0.17715", "ticker_sentiment_score": "0.270607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HES", "relevance_score": "0.629492", "ticker_sentiment_score": "0.260425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.737032", "ticker_sentiment_score": "0.512508", "ticker_sentiment_label": "Bullish"}]}, {"title": "Immuneering Appoints Harold E. Brakewood as Chief Business Officer - Immuneering  ( NASDAQ:IMRX ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31527142/immuneering-appoints-harold-e-brakewood-as-chief-business-officer", "time_published": "20230328T120000", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass., March 28, 2023 ( GLOBE NEWSWIRE ) -- Immuneering Corporation IMRX, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.117466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.050679", "ticker_sentiment_score": "0.003976", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases", "url": "https://www.globenewswire.com/news-release/2023/03/28/2635542/0/en/Regeneron-and-Sonoma-Biotherapeutics-Announce-Collaboration-to-Discover-Develop-and-Commercialize-Treg-Cell-Therapies-for-Autoimmune-Diseases.html", "time_published": "20230328T113000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment. potential for an additional $45 million development milestone payment Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.160676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.091162", "ticker_sentiment_score": "0.053808", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.022837", "ticker_sentiment_score": "0.052133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday - Caterpillar  ( NYSE:CAT ) , Coinbase Glb  ( NASDAQ:COIN ) ", "url": "https://www.benzinga.com/news/23/03/31508425/pinterest-to-rally-over-27-here-are-10-other-analyst-forecasts-for-monday", "time_published": "20230327T113855", "authors": ["Lisa Levin"], "summary": "UBS cut the price target for DISH Network Corporation DISH from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in pre-market trading. Piper Sandler raised the price target for Victory Capital Holdings, Inc. VCTR from $27 to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/27/pinterest-logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.213676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GIS", "relevance_score": "0.28442", "ticker_sentiment_score": "0.135078", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.28442", "ticker_sentiment_score": "0.112797", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.191929", "ticker_sentiment_score": "0.004702", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLW", "relevance_score": "0.28442", "ticker_sentiment_score": "0.398177", "ticker_sentiment_label": "Bullish"}, {"ticker": "VCTR", "relevance_score": "0.28442", "ticker_sentiment_score": "0.277563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.28442", "ticker_sentiment_score": "-0.185126", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DISH", "relevance_score": "0.28442", "ticker_sentiment_score": "-0.167736", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRO", "relevance_score": "0.28442", "ticker_sentiment_score": "0.337383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PINS", "relevance_score": "0.28442", "ticker_sentiment_score": "0.264042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.28442", "ticker_sentiment_score": "0.585361", "ticker_sentiment_label": "Bullish"}, {"ticker": "COIN", "relevance_score": "0.28442", "ticker_sentiment_score": "0.00642", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSY", "relevance_score": "0.28442", "ticker_sentiment_score": "0.08687", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise; Bank Stocks Jump As Silicon Valley Bank Sold", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-banks-jump-first-citizens-buys-silicon-valley-bank/", "time_published": "20230327T105700", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Rise, First Citizens Buys Silicon Valley Bank ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.051053, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MTH", "relevance_score": "0.042159", "ticker_sentiment_score": "0.060286", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.042159", "ticker_sentiment_score": "-0.078919", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.042159", "ticker_sentiment_score": "0.011008", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.105141", "ticker_sentiment_score": "0.110606", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.063202", "ticker_sentiment_score": "-0.098227", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.063202", "ticker_sentiment_score": "-0.098227", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.042159", "ticker_sentiment_score": "0.011008", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.063202", "ticker_sentiment_score": "-0.07823", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.146788", "ticker_sentiment_score": "0.160934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.126008", "ticker_sentiment_score": "0.128523", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.126008", "ticker_sentiment_score": "0.081438", "ticker_sentiment_label": "Neutral"}, {"ticker": "PD", "relevance_score": "0.042159", "ticker_sentiment_score": "0.060286", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZBS", "relevance_score": "0.042159", "ticker_sentiment_score": "0.028433", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIZN", "relevance_score": "0.042159", "ticker_sentiment_score": "0.028433", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.084201", "ticker_sentiment_score": "0.120384", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.063202", "ticker_sentiment_score": "-0.07823", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.084201", "ticker_sentiment_score": "0.145676", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-bid-revive-cholesterol-drug-patents-comes-us-supreme-court-2023-03-27/", "time_published": "20230327T100400", "authors": ["Andrew Chung", "John Kruzel"], "summary": "Amgen bid to revive cholesterol drug patents comes to U.S. ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4DQBG4MPQFKLZBYAIWMQGLANYE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014643, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.072435", "ticker_sentiment_score": "0.034654", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.072435", "ticker_sentiment_score": "0.066305", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.475461", "ticker_sentiment_score": "0.028585", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise With No Big Bank News", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-bank-news-for-market-rally-microsoft-tesla-near-buy-points/", "time_published": "20230326T214900", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Due With No Big Bank News. Microsoft, Tesla ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.058251, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MTH", "relevance_score": "0.042915", "ticker_sentiment_score": "0.060424", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.042915", "ticker_sentiment_score": "-0.07909", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.042915", "ticker_sentiment_score": "0.011011", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.107016", "ticker_sentiment_score": "0.111284", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLY", "relevance_score": "0.042915", "ticker_sentiment_score": "0.068275", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064333", "ticker_sentiment_score": "-0.098302", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.064333", "ticker_sentiment_score": "-0.098302", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.042915", "ticker_sentiment_score": "0.011011", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.064333", "ticker_sentiment_score": "-0.078297", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.149391", "ticker_sentiment_score": "0.162622", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.128249", "ticker_sentiment_score": "0.129588", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.128249", "ticker_sentiment_score": "0.082144", "ticker_sentiment_label": "Neutral"}, {"ticker": "PD", "relevance_score": "0.042915", "ticker_sentiment_score": "0.060424", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZBS", "relevance_score": "0.021465", "ticker_sentiment_score": "0.061616", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIZN", "relevance_score": "0.021465", "ticker_sentiment_score": "0.061616", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.085706", "ticker_sentiment_score": "0.120761", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.064333", "ticker_sentiment_score": "-0.078297", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.085706", "ticker_sentiment_score": "0.146108", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Still Hasn't Done This; What To Do Now", "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-still-hasnt-done-this-microsoft-tesla-near-buy-points/", "time_published": "20230324T214048", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Market Rally Still Hasn't Done This. Microsoft, Tesla Lead 6 Nasdaq ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.019531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MTH", "relevance_score": "0.046953", "ticker_sentiment_score": "0.061064", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.070379", "ticker_sentiment_score": "-0.097146", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.046953", "ticker_sentiment_score": "0.011039", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.117028", "ticker_sentiment_score": "0.115205", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.070379", "ticker_sentiment_score": "-0.097146", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.070379", "ticker_sentiment_score": "-0.097146", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.046953", "ticker_sentiment_score": "0.011039", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.070379", "ticker_sentiment_score": "-0.078792", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.163275", "ticker_sentiment_score": "0.171955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.140212", "ticker_sentiment_score": "0.135622", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.140212", "ticker_sentiment_score": "0.086125", "ticker_sentiment_label": "Neutral"}, {"ticker": "PD", "relevance_score": "0.046953", "ticker_sentiment_score": "0.061064", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.093744", "ticker_sentiment_score": "0.12307", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.070379", "ticker_sentiment_score": "-0.078792", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.093744", "ticker_sentiment_score": "0.148777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investor Action Plan: Can The Market Bootstrap Itself To A Strong March Finish?", "url": "https://www.investors.com/research/investing-action-plan/stock-trading-action-plan-can-the-market-bootstrap-itself-to-a-strong-march-finish/", "time_published": "20230324T211048", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Investor Action Plan: Can The Market Bootstrap Itself To A Strong ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-monopolyshoe-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.131084, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CALM", "relevance_score": "0.05381", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.080638", "ticker_sentiment_score": "0.139757", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.080638", "ticker_sentiment_score": "0.047454", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.080638", "ticker_sentiment_score": "-0.008258", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.05381", "ticker_sentiment_score": "-0.062768", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRGS", "relevance_score": "0.080638", "ticker_sentiment_score": "0.051237", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMTC", "relevance_score": "0.080638", "ticker_sentiment_score": "0.038598", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEHR", "relevance_score": "0.080638", "ticker_sentiment_score": "0.047454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.080638", "ticker_sentiment_score": "0.139757", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.05381", "ticker_sentiment_score": "0.213837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.107375", "ticker_sentiment_score": "0.150302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.080638", "ticker_sentiment_score": "0.139757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.05381", "ticker_sentiment_score": "0.065763", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEM", "relevance_score": "0.05381", "ticker_sentiment_score": "0.008998", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.080638", "ticker_sentiment_score": "-0.048274", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.05381", "ticker_sentiment_score": "0.084108", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTAS", "relevance_score": "0.080638", "ticker_sentiment_score": "0.163187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.05381", "ticker_sentiment_score": "0.135992", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCMGF", "relevance_score": "0.02692", "ticker_sentiment_score": "0.008352", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.05381", "ticker_sentiment_score": "0.135992", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NEM", "relevance_score": "0.02692", "ticker_sentiment_score": "0.008352", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's  ( REGN )  Dupixent Meets Pivotal COPD Study Goal, Up 7%", "url": "https://www.zacks.com/stock/news/2070359/regenerons-regn-dupixent-meets-pivotal-copd-study-goal-up-7", "time_published": "20230324T182900", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.055405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.160277", "ticker_sentiment_score": "0.12023", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.263942", "ticker_sentiment_score": "0.018084", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.053749", "ticker_sentiment_score": "0.151746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.410338", "ticker_sentiment_score": "0.112221", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough", "url": "https://www.investors.com/stock-lists/new-highs/growth-stock-regeneron-pharmaceuticals-is-hitting-new-highs-after-news-of-clinical-trial-breakthrough-for-its-drug-to-treat-a-fatal-lung-disease-analysts-upgrade-sales-outlook/", "time_published": "20230324T181754", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Biotech Growth Stock Soars To New Highs On Lung Disease ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-Regeneron02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.311867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.269776", "ticker_sentiment_score": "0.223083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.269776", "ticker_sentiment_score": "0.527941", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Market Feeling Gloomy As Banks Are Back In The Hot Seat; Drug Stock Pops", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-overcomes-bank-gloom-as-s-drug-stock-pops/", "time_published": "20230324T175207", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Overcomes Bank Gloom As S&P 500 Turns Positive ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-finance-broken-bank-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.024399, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.103109", "ticker_sentiment_score": "-0.032719", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.103109", "ticker_sentiment_score": "-0.142926", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXM", "relevance_score": "0.103109", "ticker_sentiment_score": "0.031253", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.103109", "ticker_sentiment_score": "-0.142926", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.051663", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.051663", "ticker_sentiment_score": "0.098501", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.103109", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.051663", "ticker_sentiment_score": "0.082534", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.154125", "ticker_sentiment_score": "0.281448", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.357891", "ticker_sentiment_label": "Bearish"}]}, {"title": "Dow Jones, Financial Stocks Climb Off Lows Despite Economic Jitters; Baidu, ELF Beauty Show Strength", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-financial-stocks-take-more-heat-amid-economic-worries-sellers-hit-coinbase/", "time_published": "20230324T161054", "authors": ["KEN SHREVE", "Investor's Business Daily"], "summary": "Dow Jones, Financial Stocks Climb Off Lows Despite Economic ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/stock-bull-bear-figurines-close-1.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.04642, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMP", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.327812", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVX", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.256441", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LSCC", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.116895", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.182629", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.327812", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SMCI", "relevance_score": "0.175859", "ticker_sentiment_score": "0.079094", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.117774", "ticker_sentiment_score": "0.390823", "ticker_sentiment_label": "Bullish"}, {"ticker": "GS", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.182629", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COIN", "relevance_score": "0.175859", "ticker_sentiment_score": "0.123065", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.175859", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.327812", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ATVI", "relevance_score": "0.175859", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.182629", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.117774", "ticker_sentiment_score": "0.122363", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.059049", "ticker_sentiment_score": "-0.103997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street Has High Hopes for These 2 Nasdaq Stocks", "url": "https://www.fool.com/investing/2023/03/24/wall-street-has-high-hopes-for-these-2-nasdaq-stoc/", "time_published": "20230324T160233", "authors": ["Dan Caplinger"], "summary": "Even in choppy markets, there are smart investments you can make.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725544%2Fperson-stocks-2.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.337168, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.22421", "ticker_sentiment_score": "0.349168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CBRL", "relevance_score": "0.150592", "ticker_sentiment_score": "0.309234", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Market Split As Fed Hikes, Banks Keep Tumbling; Weekly Review", "url": "https://www.investors.com/news/stock-market-split-as-fed-hikes-rates-banks-tumble-nvidia-on-holding-in-focus/", "time_published": "20230324T155927", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Stock Market Split As Fed Hikes, Banks Keep Tumbling. Weekly ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-RoadSigns-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.029542, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.052056", "ticker_sentiment_score": "-0.041094", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.052056", "ticker_sentiment_score": "0.021004", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.129655", "ticker_sentiment_score": "-0.008829", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.206026", "ticker_sentiment_score": "0.020398", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.052056", "ticker_sentiment_score": "-0.056403", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.052056", "ticker_sentiment_score": "-0.041094", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSIQ", "relevance_score": "0.078014", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.10389", "ticker_sentiment_score": "-0.026996", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.052056", "ticker_sentiment_score": "-0.056401", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.026042", "ticker_sentiment_score": "0.313746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GIS", "relevance_score": "0.052056", "ticker_sentiment_score": "0.218641", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KBH", "relevance_score": "0.052056", "ticker_sentiment_score": "0.227202", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PDD", "relevance_score": "0.078014", "ticker_sentiment_score": "-0.069885", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.078014", "ticker_sentiment_score": "0.174744", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADBE", "relevance_score": "0.078014", "ticker_sentiment_score": "0.086838", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMC", "relevance_score": "0.052056", "ticker_sentiment_score": "0.125003", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.026042", "ticker_sentiment_score": "0.15978", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DRI", "relevance_score": "0.052056", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.052056", "ticker_sentiment_score": "0.141019", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.052056", "ticker_sentiment_score": "-0.154005", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OLLI", "relevance_score": "0.052056", "ticker_sentiment_score": "0.038994", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052056", "ticker_sentiment_score": "0.141019", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.026042", "ticker_sentiment_score": "-0.055061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.026042", "ticker_sentiment_score": "-0.055061", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/03/31492664/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230324T144631", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.155031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.819522", "ticker_sentiment_score": "0.190976", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.132325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31490991/regeneron-pharmaceuticals-analysts-react-to-drug-trial-results-why-whales-are-divin", "time_published": "20230324T140948", "authors": ["Priya Nigam"], "summary": "Regeneron Pharmaceuticals Inc REGN announced the Phase 3 trial of Dupixent ( dupilumab ) , developed with Sanofi SNY, for uncontrolled chronic obstructive pulmonary disease ( COPD ) met its primary and secondary endpoints, which attracted investments from whales.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/24/shutterstock_2118178424.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.248926, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.582526", "ticker_sentiment_score": "0.063066", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.31482", "ticker_sentiment_score": "-0.067189", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron's Asthma Drug Results Were 'Stellar.' Analyst Sees a Sales Bonanza.", "url": "https://www.barrons.com/articles/regeneron-asthma-stock-drug-buy-sanofi-8d75c18a", "time_published": "20230324T131922", "authors": ["Karishma Vanjani"], "summary": "Buy Regeneron. Asthma Drug Could Add Billions, Analyst Says. ...", "banner_image": "https://images.barrons.com/im-750364/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.041405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.733479", "ticker_sentiment_score": "-0.067082", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.733479", "ticker_sentiment_score": "-0.602606", "ticker_sentiment_label": "Bearish"}]}, {"title": "Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/news/23/03/31487106/regeneron-pharmaceuticals-options-traders-betting-on-stock-falling-this-much-by-april-expiration", "time_published": "20230324T124308", "authors": ["Priya Nigam"], "summary": "Sanofi SNY and Regeneron Pharmaceuticals, Inc. REGN shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial evaluating Dupixent in COPD.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/24/pharmacist-3646195_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.241773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.721785", "ticker_sentiment_score": "0.547659", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.721785", "ticker_sentiment_score": "0.547659", "ticker_sentiment_label": "Bullish"}]}, {"title": "US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/23/03/31488619/us-stocks-on-track-for-weak-start-friday-amid-renewed-banking-concerns-and-contagion-fears", "time_published": "20230324T111225", "authors": ["Shanthi Rexaline"], "summary": "Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. Contagion fears have continued to weigh on banking stocks in Europe and the worries could aggravate following a spike in German financial services giant ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/24/share_market_photo_by_jirapong_manustrong_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.152665, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CS", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.236209", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "META", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.180269", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.058047", "ticker_sentiment_score": "-0.160998", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAC", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.154744", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FRC", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.154744", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBS", "relevance_score": "0.058047", "ticker_sentiment_score": "-0.203793", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPGI", "relevance_score": "0.058047", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.058047", "ticker_sentiment_score": "0.141499", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.172919", "ticker_sentiment_score": "-0.125631", "ticker_sentiment_label": "Neutral"}]}, {"title": "KB Home, Worthington rise; MillerKnoll, Trupanion fall", "url": "https://apnews.com/article/financial-markets-stocks-wall-street-59e1010a4b8afcdc0cc86f01927eaf77", "time_published": "20230323T201823", "authors": [], "summary": "KB Home, Worthington rise. MillerKnoll, Trupanion fall The Associated Press ...", "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.246204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLKN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOR", "relevance_score": "0.428632", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Pares Gains As Homebuilders Outperform; Cathie Wood Stocks Sell Off, But Apple Makes Big Move", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-homebuilders-outperform-apple-makes-big-move/", "time_published": "20230323T175138", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Pares Gains As Homebuilders Outperform. Cathie Wood ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/Stock-AppleTVplus-05-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999606"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.100059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.235823", "ticker_sentiment_score": "0.131126", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.122073", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.310843", "ticker_sentiment_score": "0.061288", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHM", "relevance_score": "0.158519", "ticker_sentiment_score": "0.057569", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.158519", "ticker_sentiment_score": "0.239223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMAX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.098349", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.0124", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.158519", "ticker_sentiment_score": "0.122073", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.158519", "ticker_sentiment_score": "0.122073", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.044832", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.051796", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.032851", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more", "url": "https://www.cnbc.com/2023/03/23/stocks-making-the-biggest-moves-midday-nflx-sq-snap-kbh.html", "time_published": "20230323T172435", "authors": ["Michelle Fox"], "summary": "Block fell after Hindenburg Research unveiled its latest short position on the stock. KB Home popped on earnings.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107213550-16795140722023-03-22t193153z_119967516_rc26zz9u3p6q_rtrmadp_0_usa-stocks.jpeg?v=1679577816", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.038771, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KBH", "relevance_score": "0.138464", "ticker_sentiment_score": "0.115186", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.049834", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.024336", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.03223", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCP", "relevance_score": "0.138464", "ticker_sentiment_score": "0.187218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WOR", "relevance_score": "0.069495", "ticker_sentiment_score": "0.155505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.069495", "ticker_sentiment_score": "0.084924", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.138464", "ticker_sentiment_score": "0.029291", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.138464", "ticker_sentiment_score": "0.105079", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coinbase's stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move", "url": "https://www.marketwatch.com/story/coinbase-stock-tumbles-on-sec-warning-while-first-republic-and-regeneron-shares-rally-and-other-stocks-on-the-move-24240264", "time_published": "20230323T165500", "authors": ["", "Emily Bary", "Barbara Kollmeyer"], "summary": "Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.", "banner_image": "https://images.mktw.net/im-749459/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.128082, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.716023", "ticker_sentiment_score": "0.102888", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.716023", "ticker_sentiment_score": "0.102888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Regeneron Are Rising Thursday", "url": "https://www.fool.com/investing/2023/03/23/why-shares-of-regeneron-are-rising-thursday/", "time_published": "20230323T160833", "authors": ["Jim Halley"], "summary": "Regeneron released positive phase 3 trial results for its therapy Dupixent.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725429%2Fa-black-tesla-car-driving-on-an-open-road-in-the-snow.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019509, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.185902", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.392948", "ticker_sentiment_score": "-0.308935", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": " ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/03/31476445/regn-analyzing-regeneron-pharmaceuticalss-short-interest", "time_published": "20230323T144526", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has fallen 10.0% since its last report. The company recently reported that it has 1.20 million shares sold short, which is 1.17% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/03/31475168/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals", "time_published": "20230323T134556", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5588.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.188905, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.77735", "ticker_sentiment_score": "0.307291", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Stories Thursday, Mar. 23: Apple, In A Cinema Near You Soon, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund - Manchester United  ( NYSE:MANU ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31474197/apple-jumps-movie-production-bandwagon-billionaire-jim-ratcliffe-bids-for-manchester-united-elon-", "time_published": "20230323T132340", "authors": ["Vandana Singh"], "summary": "Apple Inc AAPL eyes splurging $1 billion annually to produce movies likely for theatrical release to draw subscribers to its streaming service. Apple has approached movie studios about partnering to release a few titles in theaters this year and a slate of more films in the future.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/23/apple_logo-1835211_1920_0.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.138487, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.096671", "ticker_sentiment_score": "0.210571", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.12865", "ticker_sentiment_score": "0.106269", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.064536", "ticker_sentiment_score": "-0.091081", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.191929", "ticker_sentiment_score": "0.140867", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPNRF", "relevance_score": "0.064536", "ticker_sentiment_score": "0.05103", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.064536", "ticker_sentiment_score": "0.117132", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064536", "ticker_sentiment_score": "0.130162", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROHCF", "relevance_score": "0.032294", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.064536", "ticker_sentiment_score": "-0.091081", "ticker_sentiment_label": "Neutral"}, {"ticker": "IX", "relevance_score": "0.064536", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.064536", "ticker_sentiment_score": "0.124148", "ticker_sentiment_label": "Neutral"}, {"ticker": "MANU", "relevance_score": "0.12865", "ticker_sentiment_score": "0.15568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TOSBF", "relevance_score": "0.032294", "ticker_sentiment_score": "0.15231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.096671", "ticker_sentiment_score": "0.265005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.064536", "ticker_sentiment_score": "-0.12515", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.064536", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSHZF", "relevance_score": "0.032294", "ticker_sentiment_score": "0.148755", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.064536", "ticker_sentiment_score": "-0.12515", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'", "url": "https://www.investors.com/news/technology/regn-stock-sny-stock-rocket-on-blow-out-results-in-copd/", "time_published": "20230323T130359", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "REGN Stock And SNY Stock Rocket On Blow-Out Results In COPD Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-regeneron-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.720339", "ticker_sentiment_score": "0.372717", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.720339", "ticker_sentiment_score": "0.372717", "ticker_sentiment_label": "Bullish"}]}, {"title": "S&P 500 Futures Rise in Premarket Trading; Coinbase Global, Apellis Pharmaceuticals Lag", "url": "https://www.barrons.com/articles/s-p-500-futures-rise-in-premarket-trading-coinbase-global-apellis-pharmaceuticals-lag-ea4f4d5e", "time_published": "20230323T113214", "authors": ["Barron's Automation"], "summary": "S&P 500 Futures Rise in Premarket Trading. Coinbase Global, Apellis Pharmaceuticals Lag ...", "banner_image": "https://images.barrons.com/im-744240?width=620&height=413", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.007245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FDS", "relevance_score": "0.7887", "ticker_sentiment_score": "0.024738", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.7887", "ticker_sentiment_score": "0.024738", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOOO", "relevance_score": "0.7887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.7887", "ticker_sentiment_score": "0.024738", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.7887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.7887", "ticker_sentiment_score": "0.024738", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.7887", "ticker_sentiment_score": "0.024738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron Pharmaceuticals  ( REGN )  And Sanofi  ( SNY )  Shares Are Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31470443/why-regeneron-pharmaceuticals-and-sanofi-shares-are-trading-higher-today", "time_published": "20230323T112007", "authors": ["Vandana Singh"], "summary": "Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA SNY and Regeneron Pharmaceuticals Inc's REGN Phase 3 trial of Dupixent ( dupilumab ) for uncontrolled chronic obstructive pulmonary disease ( COPD ) met its primary and secondary ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/23/sny-regn.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.138596, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.079964", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.128135", "ticker_sentiment_score": "0.270599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.580018", "ticker_sentiment_score": "0.079365", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2069416/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230323T102007", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.28271, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061631", "ticker_sentiment_score": "0.068004", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial", "url": "https://www.globenewswire.com/news-release/2023/03/23/2632823/0/en/Dupixent-dupilumab-Demonstrates-Potential-to-Become-First-Biologic-to-Treat-COPD-by-Showing-Significant-Reduction-in-Exacerbations-in-Pivotal-Trial.html", "time_published": "20230323T060000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "First and only biologic to demonstrate clinically meaningful and statistically significant reduction ( 30% ) in exacerbations compared to placebo ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.053285, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.035048", "ticker_sentiment_score": "0.023425", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.008765", "ticker_sentiment_score": "-0.047516", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.113556", "ticker_sentiment_score": "0.008068", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial", "url": "https://www.globenewswire.com/news-release/2023/03/23/2632822/0/en/Press-Release-Dupixent-demonstrates-potential-to-become-first-biologic-to-treat-COPD-by-showing-significant-reduction-in-exacerbations-in-pivotal-trial.html", "time_published": "20230323T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002428, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.024471", "ticker_sentiment_score": "0.036376", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.012237", "ticker_sentiment_score": "-0.060371", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.15804", "ticker_sentiment_score": "0.016512", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31468934/press-release-dupixent-demonstrates-potential-to-become-first-biologic-to-treat-copd-by-showing-si", "time_published": "20230323T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction ( 30% ) in exacerbations compared to placebo", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.002419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.024029", "ticker_sentiment_score": "0.03529", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.012016", "ticker_sentiment_score": "-0.051434", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.143415", "ticker_sentiment_score": "0.002592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Gets Label Extension for Cholesterol Drug", "url": "https://www.zacks.com/stock/news/2069254/regeneron-regn-gets-label-extension-for-cholesterol-drug", "time_published": "20230322T181500", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222577, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.264658", "ticker_sentiment_score": "0.209672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.067347", "ticker_sentiment_score": "0.202802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.200134", "ticker_sentiment_score": "0.266426", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US FDA expands use of Regeneron's cholesterol drug in young children", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-use-regenerons-cholesterol-drug-young-children-2023-03-22/", "time_published": "20230322T113500", "authors": ["Reuters"], "summary": "US FDA expands use of Regeneron's cholesterol drug in young ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TUVSCCQOZBPTPFFOC5TQTF2ZDA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.296541, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.272788", "ticker_sentiment_score": "0.260869", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's one for the battered bulls: the second-largest sector in the S&P 500 is stirring to life, says this strategist.", "url": "https://www.marketwatch.com/story/heres-one-for-the-battered-bulls-the-second-largest-sector-in-the-s-p-500-is-stirring-to-life-says-this-strategist-5e179744", "time_published": "20230322T105200", "authors": ["Barbara Kollmeyer"], "summary": "Everyone is watching the banks, but what about healthcare. It's breaking out, says this strategist.", "banner_image": "https://images.mktw.net/im-748521?width=700&height=406", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999606"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.06002, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.170485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.193007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BBBY", "relevance_score": "0.077593", "ticker_sentiment_score": "0.182797", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRKR", "relevance_score": "0.077593", "ticker_sentiment_score": "0.193007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.077593", "ticker_sentiment_score": "-0.308726", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TMDX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.170485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.077593", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.077593", "ticker_sentiment_score": "0.182797", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MYGN", "relevance_score": "0.077593", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.170485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.077593", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.077593", "ticker_sentiment_score": "0.182797", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.077593", "ticker_sentiment_score": "0.193007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.038843", "ticker_sentiment_score": "-0.180468", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:USD", "relevance_score": "0.038843", "ticker_sentiment_score": "-0.180468", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis", "url": "https://www.globenewswire.com/news-release/2023/03/21/2630956/0/en/Press-Release-Dupixent-dupilumab-approved-by-European-Commission-as-first-and-only-targeted-medicine-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.html", "time_published": "20230321T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002434, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025831", "ticker_sentiment_score": "0.031993", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.115849", "ticker_sentiment_score": "-0.009285", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31431265/press-release-dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medici", "time_published": "20230321T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025352", "ticker_sentiment_score": "0.0318", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.113717", "ticker_sentiment_score": "-0.004597", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31431264/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medicine-for-childre", "time_published": "20230321T055900", "authors": ["Globe Newswire"], "summary": "Dupixent is now a treatment option for the approximately 80,000 infants and young children living with uncontrolled severe atopic dermatitis in Europe TARRYTOWN, N.Y. and PARIS, March 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.05573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.037213", "ticker_sentiment_score": "0.037233", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.102092", "ticker_sentiment_score": "-0.003312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis", "url": "https://www.globenewswire.com/news-release/2023/03/21/2630953/0/en/Dupixent-dupilumab-Approved-by-European-Commission-as-First-and-Only-Targeted-Medicine-for-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html", "time_published": "20230321T055900", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.053384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.036351", "ticker_sentiment_score": "0.038167", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.09974", "ticker_sentiment_score": "0.010969", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis", "url": "https://www.globenewswire.com/news-release/2023/03/18/2629820/0/en/Dupixent-dupilumab-Late-Breaking-Data-at-AAD-Show-Significant-Improvements-in-Signs-and-Symptoms-of-Moderate-to-severe-Atopic-Hand-and-Foot-Dermatitis.html", "time_published": "20230318T140000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.019467, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.039112", "ticker_sentiment_score": "0.041354", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.097575", "ticker_sentiment_score": "0.017396", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis", "url": "https://www.globenewswire.com/news-release/2023/03/18/2629819/0/en/Press-Release-Dupixent-dupilumab-late-breaking-data-at-AAD-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis.html", "time_published": "20230318T140000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.060407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.02849", "ticker_sentiment_score": "0.039026", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.127682", "ticker_sentiment_score": "-0.001217", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31409769/press-release-dupixent-dupilumab-late-breaking-data-at-aad-show-significant-improvements-in-signs-", "time_published": "20230318T140000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.05541, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.028039", "ticker_sentiment_score": "0.037939", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.125679", "ticker_sentiment_score": "-0.002412", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Gains 9.3% in a Year: Will the Uptrend Last?", "url": "https://www.zacks.com/stock/news/2067509/regeneron-regn-gains-93-in-a-year-will-the-uptrend-last", "time_published": "20230317T161700", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.285762, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.2872", "ticker_sentiment_score": "0.131802", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.073321", "ticker_sentiment_score": "0.204047", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.146025", "ticker_sentiment_score": "0.219129", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Two Biotech Stocks Hit In Medicare Negotiation Crossfire", "url": "https://www.investors.com/research/ibd-industry-themes/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/", "time_published": "20230317T145045", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.050215, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.064104", "ticker_sentiment_score": "-0.008033", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.127795", "ticker_sentiment_score": "-0.070561", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.127795", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.426567", "ticker_sentiment_score": "-0.072737", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.426567", "ticker_sentiment_score": "-0.046624", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.127795", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.127795", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks To Watch In March 2022", "url": "https://stockmarket.com/featured/2-biotech-stocks-to-watch-in-march-2022-2023-03-16", "time_published": "20230316T215241", "authors": ["Joe Samuel"], "summary": "The biotech industry is a rapidly growing sector. The sector focuses on the development and commercialization of novel therapies, drugs, and medical technologies. Biotech companies often utilize advanced scientific techniques. These include techniques such as gene editing and immunotherapy.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/03/SRPT-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.209047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.398781", "ticker_sentiment_score": "0.296377", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.398781", "ticker_sentiment_score": "0.112484", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks To Watch In March 2023", "url": "https://stockmarket.com/featured/2-biotech-stocks-to-watch-in-march-2023-2023-03-16", "time_published": "20230316T215241", "authors": ["Joe Samuel"], "summary": "The biotech industry is a rapidly growing sector. The sector focuses on the development and commercialization of novel therapies, drugs, and medical technologies. Biotech companies often utilize advanced scientific techniques. These include techniques such as gene editing and immunotherapy.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/03/SRPT-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.209047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.398781", "ticker_sentiment_score": "0.296377", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.398781", "ticker_sentiment_score": "0.112484", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-even-as-fed-powells-pivot-remains-uncertain-health-care-stocks-fall-on-new-medicare-plan-news/", "time_published": "20230316T175606", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises Even As Fed's Pivot Remains Uncertain. Health ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/Stock-SafeDeposite-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.108665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.108466", "ticker_sentiment_score": "0.126529", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.108466", "ticker_sentiment_score": "0.126529", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.162073", "ticker_sentiment_score": "0.15458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.108466", "ticker_sentiment_score": "0.214971", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CFG", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.406026", "ticker_sentiment_label": "Bearish"}, {"ticker": "MSFT", "relevance_score": "0.108466", "ticker_sentiment_score": "0.126529", "ticker_sentiment_label": "Neutral"}, {"ticker": "FITB", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.406026", "ticker_sentiment_label": "Bearish"}, {"ticker": "FIVE", "relevance_score": "0.108466", "ticker_sentiment_score": "0.030129", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMA", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.087781", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.108466", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.108466", "ticker_sentiment_score": "0.212814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.054359", "ticker_sentiment_score": "0.026109", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.214937", "ticker_sentiment_score": "0.189336", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.108466", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.108466", "ticker_sentiment_score": "0.19364", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.121041", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two Biotech Stocks Hit In Medicare Negotiation Crossfire", "url": "https://www.investors.com/news/technology/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/", "time_published": "20230316T160545", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.083011, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.008054", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.086582", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.442522", "ticker_sentiment_score": "-0.077151", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.442522", "ticker_sentiment_score": "-0.050521", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31383718/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-200-today", "time_published": "20230316T160040", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 9.56% on an annualized basis producing an average annual return of 17.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.07 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease", "url": "https://www.globenewswire.com/news-release/2023/03/15/2627323/0/en/Students-Win-More-Than-1-8-Million-at-2023-Regeneron-Science-Talent-Search-for-Remarkable-Scientific-Research-on-RNA-Molecule-Structure-Media-Bias-and-Diagnostics-for-Pediatric-Hea.html", "time_published": "20230315T013000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "$250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors $250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.44842, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.072876", "ticker_sentiment_score": "0.102028", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.024322", "ticker_sentiment_score": "0.251131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.024322", "ticker_sentiment_score": "0.251131", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/03/31348658/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity", "time_published": "20230314T194559", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.101355, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.832645", "ticker_sentiment_score": "0.219471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.09989", "ticker_sentiment_score": "-0.129779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2065154/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230314T102011", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.159936, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.067919", "ticker_sentiment_score": "0.034065", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises With Gold, Bitcoin Amid Bank Sell-Off; Analysts See Rate Freeze In March", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-as-gold-bitcoin-rise-amidst-bank-run-fears-analysts-see-rate-hike-pause-as-banks-crater/", "time_published": "20230313T171031", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises With Gold, Bitcoin Amid Bank Sell-Off. Analysts ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/01/BOB23_schwab2_012723_shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.988915"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.026779, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DG", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.148984", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.227606", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.109705", "ticker_sentiment_score": "0.436994", "ticker_sentiment_label": "Bullish"}, {"ticker": "COIN", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.110827", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.202145", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNH", "relevance_score": "0.109705", "ticker_sentiment_score": "0.436994", "ticker_sentiment_label": "Bullish"}, {"ticker": "IRDM", "relevance_score": "0.109705", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVE", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.148984", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.109705", "ticker_sentiment_score": "0.079733", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.202145", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FDX", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.148984", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.202145", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PANW", "relevance_score": "0.109705", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.227606", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARRY", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.148984", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.109705", "ticker_sentiment_score": "0.110602", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.025963", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.121516", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.135844", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.109705", "ticker_sentiment_score": "0.436994", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.109705", "ticker_sentiment_score": "0.110602", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.109705", "ticker_sentiment_score": "0.110602", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBNY", "relevance_score": "0.217346", "ticker_sentiment_score": "-0.113971", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFC", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.20692", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.109705", "ticker_sentiment_score": "0.436994", "ticker_sentiment_label": "Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.02301", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.054983", "ticker_sentiment_score": "0.208072", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2064866/the-zacks-analyst-blog-highlights-nvidia-mcdonalds-intuit-att-and-regeneron-pharmaceuticals", "time_published": "20230313T145700", "authors": ["Zacks Investment Research"], "summary": "NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals are part of the Zacks top Analyst ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/355.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.733479", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.733479", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.421485", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.733479", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "T", "relevance_score": "0.421485", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCD", "relevance_score": "0.733479", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Best ETFs Tracking CRISPR Gene Editing", "url": "https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/", "time_published": "20230310T204533", "authors": ["Keith Speights"], "summary": "These exchange-traded funds track companies in this biotech space.", "banner_image": "https://m.foolcdn.com/media/dubs/images/original_imageshttpsg.foolcdn.comeditorialimag.width-880_mOUIjpd.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980509"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.17576, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.087503", "ticker_sentiment_score": "0.136786", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.130926", "ticker_sentiment_score": "0.065929", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.087503", "ticker_sentiment_score": "0.094818", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043818", "ticker_sentiment_score": "0.05428", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKI", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.087503", "ticker_sentiment_score": "0.094818", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.056825", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.130926", "ticker_sentiment_score": "0.061935", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.130926", "ticker_sentiment_score": "0.052824", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.087503", "ticker_sentiment_score": "0.136786", "ticker_sentiment_label": "Neutral"}, {"ticker": "WT", "relevance_score": "0.043818", "ticker_sentiment_score": "0.047067", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.046284", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.130926", "ticker_sentiment_score": "0.133773", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for NVIDIA, McDonald's & Intuit", "url": "https://www.zacks.com/research-daily/2064075/top-analyst-reports-for-nvidia-mcdonalds-intuit", "time_published": "20230310T180900", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.289813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.261117", "ticker_sentiment_score": "0.243324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.323078", "ticker_sentiment_score": "0.285754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.261117", "ticker_sentiment_score": "0.243324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "T", "relevance_score": "0.066414", "ticker_sentiment_score": "0.125814", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.132368", "ticker_sentiment_score": "0.151858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.132368", "ticker_sentiment_score": "0.151858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCD", "relevance_score": "0.132368", "ticker_sentiment_score": "0.151858", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Analyst Reports for NVIDIA, McDonald's & Intuit", "url": "https://www.zacks.com/research-daily/2064075/top-analyst-reports-for-nvidia-mcdonalds-intuit", "time_published": "20230310T170900", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.289766, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.261117", "ticker_sentiment_score": "0.243278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.323078", "ticker_sentiment_score": "0.285706", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.261117", "ticker_sentiment_score": "0.243278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.132368", "ticker_sentiment_score": "0.15183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "T", "relevance_score": "0.066414", "ticker_sentiment_score": "0.125809", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.132368", "ticker_sentiment_score": "0.15183", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20", "time_published": "20230309T134617", "authors": ["Globe Newswire"], "summary": "New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, \"Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002392, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.049835", "ticker_sentiment_score": "0.05679", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPNRF", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/03/09/2-biotech-stocks-you-can-buy-and-hold-for-the-next/", "time_published": "20230309T133000", "authors": ["Prosper Junior Bakiny"], "summary": "Regeneron and Sarepta Therapeutics have been on fire so far this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723734%2Fperson-looking-closely-at-computer-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.19693, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.112269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.378777", "ticker_sentiment_score": "0.109387", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.056275", "ticker_sentiment_score": "0.102259", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash", "url": "https://www.fool.com/investing/2023/03/09/2-cathie-wood-stocks-that-tripled-since-2020-crash/", "time_published": "20230309T124500", "authors": ["David Jagielski"], "summary": "Are these stocks still good buys today?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723734%2Fperson-looking-closely-at-computer-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.149253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.066784", "ticker_sentiment_score": "0.08449", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.262522", "ticker_sentiment_score": "0.204456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.549265", "ticker_sentiment_score": "0.198441", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/short-sellers/23/03/31239936/how-is-the-market-feeling-about-regeneron-pharmaceuticals", "time_published": "20230307T151525", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals's REGN short percent of float has fallen 8.45% since its last report. The company recently reported that it has 1.34 million shares sold short, which is 1.3% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  application for treatment of chronic spontaneous urticaria  ( CSU )  in adults and adolescents accepted for FDA review", "url": "https://www.globenewswire.com/news-release/2023/03/07/2621670/0/en/Press-Release-Dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-CSU-in-adults-and-adolescents-accepted-for-FDA-review.html", "time_published": "20230307T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) application for treatment of chronic spontaneous urticaria ( CSU ) in adults and adolescents accepted for FDA review ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.009695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.03319", "ticker_sentiment_score": "0.039704", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.148527", "ticker_sentiment_score": "-0.001325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Application for Treatment of Chronic Spontaneous Urticaria  ( CSU )  in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31230817/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adults-and-ad", "time_published": "20230307T060000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y. and PARIS, March 07, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.055658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.032676", "ticker_sentiment_score": "0.045198", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.119397", "ticker_sentiment_score": "0.004692", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Application for Treatment of Chronic Spontaneous Urticaria  ( CSU )  in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review", "url": "https://www.globenewswire.com/news-release/2023/03/07/2621674/0/en/Dupixent-dupilumab-Application-for-Treatment-of-Chronic-Spontaneous-Urticaria-CSU-in-Adults-and-Adolescents-Aged-12-Years-and-Older-Accepted-for-FDA-Review.html", "time_published": "20230307T060000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.05327, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.032617", "ticker_sentiment_score": "0.048158", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.119182", "ticker_sentiment_score": "0.018779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  application for treatment of chronic spontaneous urticaria  ( CSU )  in adults and adolescents accepted for FDA review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31230818/press-release-dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in", "time_published": "20230307T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) application for treatment of chronic spontaneous urticaria ( CSU ) in adults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines Paris and Tarrytown, N.Y. March 7, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.007249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.032338", "ticker_sentiment_score": "0.037598", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.192183", "ticker_sentiment_score": "-0.001577", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31217002/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-5-years", "time_published": "20230306T140040", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 10.14% on an annualized basis producing an average annual return of 17.93%. Currently, Regeneron Pharmaceuticals has a market capitalization of $85.20 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval", "url": "https://www.fool.com/investing/2023/03/06/sanofi-could-be-on-a-roll-with-a-strong-performanc/", "time_published": "20230306T120500", "authors": ["Martin Berman-Gorvine"], "summary": "The French drug company got the nod for a hemophilia treatment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723227%2Frolled-up-cash-money-invest-save-three-hundred-dollars-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.091208, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.091335", "ticker_sentiment_score": "0.121585", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.471943", "ticker_sentiment_score": "0.172253", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback", "url": "https://www.zacks.com/stock/news/2060596/biotech-stock-roundup-mrna-q4-earnings-regns-updates-cytk-receives-setback", "time_published": "20230301T172400", "authors": ["Zacks Investment Research"], "summary": "Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.077273, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.116631", "ticker_sentiment_score": "0.200014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CYTK", "relevance_score": "0.174167", "ticker_sentiment_score": "0.02611", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.230782", "ticker_sentiment_score": "-0.039812", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.116631", "ticker_sentiment_score": "-0.001182", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116631", "ticker_sentiment_score": "-0.046615", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.058472", "ticker_sentiment_score": "-0.001006", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31123522/fda-approves-regeneron-sanofis-sarilumab-as-first-biologic-for-stiffness-pain-in-muscles", "time_published": "20230301T152834", "authors": ["Vandana Singh"], "summary": "The FDA approved Regeneron Pharmaceuticals Inc's REGN and Sanofi SA's SNY Kevzara ( sarilumab ) for polymyalgia rheumatica ( PMR ) , an inflammatory rheumatic disease, The approval covers adult patients who have had an inadequate response to corticosteroids or cannot tolerate ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/01/regn_logo_light__fd7b073a3150a40b008b6dddd0ef8ef1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.041421, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.550532", "ticker_sentiment_score": "0.127877", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.550532", "ticker_sentiment_score": "0.127877", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kevzara\u00ae  ( sarilumab )  Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/02/g31109773/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalg", "time_published": "20230301T010000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.052977", "ticker_sentiment_score": "0.039999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.144986", "ticker_sentiment_score": "0.02982", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kevzara\u00ae  ( sarilumab )  Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica", "url": "https://www.globenewswire.com/news-release/2023/03/01/2617778/0/en/Kevzara-sarilumab-Approved-by-FDA-as-First-and-Only-Biologic-Indicated-for-Patients-with-Polymyalgia-Rheumatica.html", "time_published": "20230301T010000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.029173, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.046028", "ticker_sentiment_score": "0.041818", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.126119", "ticker_sentiment_score": "0.027657", "ticker_sentiment_label": "Neutral"}]}, {"title": "Get Ready For The Holy Grail In Cancer Treatment", "url": "https://www.investors.com/news/technology/moderna-stock-may-usher-in-new-cancer-vaccines-whats-in-it-for-biotech-stocks/", "time_published": "20230224T165700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Moderna Stock May Usher In A New Generation Of Cancer Vaccines ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/wA1market_022723.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}], "overall_sentiment_score": -0.103512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ILMN", "relevance_score": "0.032056", "ticker_sentiment_score": "-0.127849", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTS", "relevance_score": "0.032056", "ticker_sentiment_score": "-0.128261", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.398635", "ticker_sentiment_score": "-0.218506", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.032056", "ticker_sentiment_score": "-0.218111", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.032056", "ticker_sentiment_score": "-0.030046", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.159253", "ticker_sentiment_score": "-0.055704", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.032056", "ticker_sentiment_score": "-0.218111", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Intellia's  ( NTLA )  Q4 Loss Matches Estimates, Revenues Up Y/Y", "url": "https://www.zacks.com/stock/news/2058858/intellias-ntla-q4-loss-matches-estimates-revenues-up-yy", "time_published": "20230224T163600", "authors": ["Zacks Investment Research"], "summary": "Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.120994, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.128822", "ticker_sentiment_score": "0.171105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BGNE", "relevance_score": "0.192183", "ticker_sentiment_score": "0.083898", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.855561", "ticker_sentiment_score": "0.303141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com has raised its rating on Regeneron Pharmaceuticals  ( NASDAQ:REGN ) .", "url": "https://beststocks.com/stocknews-com-has-raised-its-rating-on-regeneron-p/", "time_published": "20230224T152014", "authors": ["Elaine Mendon\u00e7a"], "summary": "StockNews.com has raised its rating on Regeneron ... Best Stocks ...", "banner_image": "https://beststocks.com/wp-content/uploads/2023/02/financial-regulation-news2.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "beststocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.187963, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.681957", "ticker_sentiment_score": "0.275303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.0362", "ticker_sentiment_score": "0.12498", "ticker_sentiment_label": "Neutral"}]}, {"title": "Libtayo\u00ae  ( cemiplimab )  in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC ) ", "url": "https://www.globenewswire.com/news-release/2023/02/24/2615182/0/en/Libtayo-cemiplimab-in-Combination-with-Chemotherapy-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Advanced-PD-L1-Positive-Non-small-Cell-Lung-Cancer-NSCLC.html", "time_published": "20230224T124500", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.051175, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.044949", "ticker_sentiment_score": "0.031826", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.011243", "ticker_sentiment_score": "0.050001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/02/23/2614167/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20230223T123000", "authors": ["Intellia Therapeutics", "Inc."], "summary": "CAMBRIDGE, Mass., Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.122445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.040923", "ticker_sentiment_score": "0.04723", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.670397", "ticker_sentiment_score": "0.222371", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/02/g31024435/aflibercept-8-mg-bla-for-treatment-of-wet-age-related-macular-degeneration-and-diabetic-macular-ed", "time_published": "20230223T120000", "authors": ["Globe Newswire"], "summary": "BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA\u00ae ( aflibercept ) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks TARRYTOWN, N.Y., Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.00239, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.080819", "ticker_sentiment_score": "-0.011405", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.026981", "ticker_sentiment_score": "0.123027", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/02/23/regeneron-pharmaceuticals-nasdaqregn-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20230223T085442", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Stock Rating ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.235252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.046006", "ticker_sentiment_score": "0.049336", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOL", "relevance_score": "0.046006", "ticker_sentiment_score": "0.079389", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.726989", "ticker_sentiment_score": "0.329292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.046006", "ticker_sentiment_score": "0.049336", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/news/earnings/23/02/31012424/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-300-today", "time_published": "20230222T180422", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 10.76% on an annualized basis producing an average annual return of 18.62%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.40 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech Rivals Apellis, Iveric Diverge - Why One Soared As The Other Toppled", "url": "https://www.investors.com/news/technology/apls-stock-rockets-after-winning-a-first-ever-approval-in-geographic-atrophy/", "time_published": "20230221T165300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "APLS Stock Rockets After Winning A First-Ever Approval In ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/03/Stock-apellispharma-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.157679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.395903", "ticker_sentiment_score": "0.204334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISEE", "relevance_score": "0.117774", "ticker_sentiment_score": "0.046892", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.059049", "ticker_sentiment_score": "0.133", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.117774", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRMY", "relevance_score": "0.059049", "ticker_sentiment_score": "-0.167004", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Regeneron  ( REGN )  Rare Disease Drug Gets FDA's Priority Review", "url": "https://www.zacks.com/stock/news/2056975/regeneron-regn-rare-disease-drug-gets-fdas-priority-review", "time_published": "20230221T163600", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.172682, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.171485", "ticker_sentiment_score": "0.070352", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pozelimab  ( C5 Antibody )  BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/pressreleases/23/02/g30982945/pozelimab-c5-antibody-bla-for-treatment-of-children-and-adults-with-ultra-rare-chaple-disease-acce", "time_published": "20230221T120000", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y., Feb. 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.012193, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.069194", "ticker_sentiment_score": "-0.017247", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pozelimab  ( C5 Antibody )  BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review", "url": "https://www.globenewswire.com/news-release/2023/02/21/2611922/0/en/Pozelimab-C5-Antibody-BLA-for-Treatment-of-Children-and-Adults-with-Ultra-rare-CHAPLE-Disease-Accepted-for-FDA-Priority-Review.html", "time_published": "20230221T120000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "If approved, pozelimab would be the first and only treatment for those living with CHAPLE ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.055622, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.01924", "ticker_sentiment_score": "0.051947", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057674", "ticker_sentiment_score": "0.04803", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01924", "ticker_sentiment_score": "0.051947", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ophthalmic Disease Therapeutics Market Exhibits 6.4% CAGR and to Hit USD 54.87 billion by 2030", "url": "https://www.benzinga.com/pressreleases/23/02/g30956403/ophthalmic-disease-therapeutics-market-exhibits-6-4-cagr-and-to-hit-usd-54-87-billion-by-2030", "time_published": "20230217T090228", "authors": ["Globe Newswire"], "summary": "Pune, India, Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- The global Ophthalmic Disease Therapeutics Market size was valued at USD 33.56 billion in 2022 and is projected to reach a valuation of USD 35.57 billion in 2023. The market is expected to reach USD 54.87 billion by 2030 with a CAGR of 6.4% during ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.223903, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UBEOF", "relevance_score": "0.033328", "ticker_sentiment_score": "0.108136", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPHF", "relevance_score": "0.099752", "ticker_sentiment_score": "0.077421", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.033328", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.033328", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.033328", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.033328", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.099752", "ticker_sentiment_score": "0.062523", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Healthcare Mutual Funds to Buy in the Post-Pandemic Period", "url": "https://www.zacks.com/stock/news/2054428/4-healthcare-mutual-funds-to-buy-in-the-post-pandemic-period", "time_published": "20230215T103400", "authors": ["Zacks Investment Research"], "summary": "FBTIX, PHSYX, JNGLX and VGHCX are four healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.245949, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.100941", "ticker_sentiment_score": "0.069131", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHG", "relevance_score": "0.050572", "ticker_sentiment_score": "0.103346", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.064481", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.100941", "ticker_sentiment_score": "0.069131", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.050572", "ticker_sentiment_score": "0.064481", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.050572", "ticker_sentiment_score": "0.079992", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.050572", "ticker_sentiment_score": "0.064481", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.150906", "ticker_sentiment_score": "0.082615", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/02/15/regeneron-pharmaceuticals-nasdaqregn-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230215T082244", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Stock Rating ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.304987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KO", "relevance_score": "0.049322", "ticker_sentiment_score": "0.061618", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.806045", "ticker_sentiment_score": "0.490756", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.049322", "ticker_sentiment_score": "0.000992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Cut to \"Hold\" at StockNews.com", "url": "https://www.etfdailynews.com/2023/02/15/regeneron-pharmaceuticals-nasdaqregn-cut-to-hold-at-stocknews-com/", "time_published": "20230215T082244", "authors": ["MarketBeat News"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Cut to \"Hold\" at ... ETF Daily News ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.197847, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBCPF", "relevance_score": "0.049629", "ticker_sentiment_score": "0.021922", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.049629", "ticker_sentiment_score": "0.061645", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.763021", "ticker_sentiment_score": "0.322298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.049629", "ticker_sentiment_score": "0.021922", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.049629", "ticker_sentiment_score": "0.021922", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks That Could Help Set You Up for Life", "url": "https://www.fool.com/investing/2023/02/11/2-biotech-stocks-that-could-help-set-up-for-life/", "time_published": "20230211T181300", "authors": ["Jim Halley"], "summary": "The two companies have seen similar share growth over the past year.", "banner_image": "https://media.ycharts.com/charts/41700ebe73ae807248cb14a9992f7dfd.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.242019, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.098054", "ticker_sentiment_score": "0.200652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.098054", "ticker_sentiment_score": "0.200652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.146618", "ticker_sentiment_score": "-0.010627", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/23/02/30855683/new-data-shows-roches-vabysmo-improves-vision-retinal-fluid-in-retinal-disorder", "time_published": "20230210T152629", "authors": ["Vandana Singh"], "summary": "Roche Holdings AG RHHBY announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo ( faricimab ) in macular edema due to branch and central retinal vein occlusion ( BRVO and CRVO ) at 24 weeks.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/10/roche_storytemplate_history_1991_02.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.211056, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.350564", "ticker_sentiment_score": "0.443066", "ticker_sentiment_label": "Bullish"}]}, {"title": "Regeneron's  ( REGN )  Eylea Gets FDA Nod for ROP in Infants", "url": "https://www.zacks.com/stock/news/2052527/regenerons-regn-eylea-gets-fda-nod-for-rop-in-infants", "time_published": "20230209T183500", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.188723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.144275", "ticker_sentiment_score": "0.159013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.144275", "ticker_sentiment_score": "0.054379", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.144275", "ticker_sentiment_score": "0.054379", "ticker_sentiment_label": "Neutral"}]}, {"title": "EYLEA\u00ae  ( aflibercept )  Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity  ( ROP )  by the FDA", "url": "https://www.globenewswire.com/news-release/2023/02/08/2604539/0/en/EYLEA-aflibercept-Injection-Approved-as-the-First-Pharmacologic-Treatment-for-Preterm-Infants-with-Retinopathy-of-Prematurity-ROP-by-the-FDA.html", "time_published": "20230208T234500", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "ROP is a leading cause of childhood blindness worldwide ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.138311, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.070362", "ticker_sentiment_score": "0.057686", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.017612", "ticker_sentiment_score": "0.048791", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tom Gayner's Firm Buys Brookfield Asset Management, Dumps Texas Pacific Land", "url": "https://www.forbes.com/sites/gurufocus/2023/02/08/tom-gayners-firm-buys-brookfield-asset-management-dumps-texas-pacific-land/", "time_published": "20230208T224242", "authors": ["GuruFocus"], "summary": "Markel Gayner reveals 4th-quarter portfolio ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6376b7dc849dee57a91a9f12/0x0.jpg?format=jpg&crop=3042,1711,x0,y263,safe&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.979222"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.23689, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FPAFF", "relevance_score": "0.031241", "ticker_sentiment_score": "0.10237", "ticker_sentiment_label": "Neutral"}, {"ticker": "BN", "relevance_score": "0.155251", "ticker_sentiment_score": "0.103568", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAM", "relevance_score": "0.155251", "ticker_sentiment_score": "0.08017", "ticker_sentiment_label": "Neutral"}, {"ticker": "MKL", "relevance_score": "0.031241", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENOV", "relevance_score": "0.062434", "ticker_sentiment_score": "0.094026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.062434", "ticker_sentiment_score": "0.044004", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPL", "relevance_score": "0.124486", "ticker_sentiment_score": "0.067704", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.185781", "ticker_sentiment_score": "0.109678", "ticker_sentiment_label": "Neutral"}, {"ticker": "WSO", "relevance_score": "0.062434", "ticker_sentiment_score": "0.094026", "ticker_sentiment_label": "Neutral"}, {"ticker": "CABO", "relevance_score": "0.062434", "ticker_sentiment_score": "0.094026", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.185781", "ticker_sentiment_score": "0.103811", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.124486", "ticker_sentiment_score": "0.044413", "ticker_sentiment_label": "Neutral"}, {"ticker": "VALU", "relevance_score": "0.124486", "ticker_sentiment_score": "0.180027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ODFL", "relevance_score": "0.031241", "ticker_sentiment_score": "0.088021", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/02/08/regeneron-pharmaceuticals-nasdaqregn-upgraded-by-stocknews-com-to-buy.html", "time_published": "20230207T120000", "authors": ["Defense World Staff"], "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Upgraded by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/regeneron-pharmaceuticals-inc-logo.png?v=20221021082404", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBCPF", "relevance_score": "0.04497", "ticker_sentiment_score": "0.008876", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.740604", "ticker_sentiment_score": "0.376251", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.04497", "ticker_sentiment_score": "0.008876", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTZ", "relevance_score": "0.04497", "ticker_sentiment_score": "0.060448", "ticker_sentiment_label": "Neutral"}, {"ticker": "MKL", "relevance_score": "0.089797", "ticker_sentiment_score": "0.17816", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCNX", "relevance_score": "0.04497", "ticker_sentiment_score": "0.060448", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall: Market Rally Strong; Don't Get Complacent", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stock-market-rally-signals-its-not-a-bear-run-what-to-do-now/", "time_published": "20230206T000700", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall: Stock Market Rally Signals It's No Bear Run ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.993856"}], "overall_sentiment_score": 0.124119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.04143", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.04143", "ticker_sentiment_score": "0.196577", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.103331", "ticker_sentiment_score": "0.002193", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALV", "relevance_score": "0.123844", "ticker_sentiment_score": "0.055555", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTHM", "relevance_score": "0.04143", "ticker_sentiment_score": "0.129982", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.164609", "ticker_sentiment_score": "0.06439", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTG", "relevance_score": "0.144275", "ticker_sentiment_score": "0.099484", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.244723", "ticker_sentiment_score": "0.09025", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.082748", "ticker_sentiment_score": "0.114464", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.054563", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04143", "ticker_sentiment_score": "0.159731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.107863", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.020722", "ticker_sentiment_score": "-0.054152", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.020722", "ticker_sentiment_score": "0.105141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Shows It's Not A Bear Run; Here's What To Do", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-rally-signals-its-not-a-bear-run-what-to-do-now/", "time_published": "20230203T221700", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Market Rally Shows It's Not A Bear Run. Here's What To Do Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-Bull-arena-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.993856"}], "overall_sentiment_score": 0.144761, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.047797", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.047797", "ticker_sentiment_score": "0.198752", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.119117", "ticker_sentiment_score": "0.002311", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALV", "relevance_score": "0.142706", "ticker_sentiment_score": "0.059767", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTHM", "relevance_score": "0.047797", "ticker_sentiment_score": "0.131776", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.189484", "ticker_sentiment_score": "0.071166", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTG", "relevance_score": "0.166169", "ticker_sentiment_score": "0.108717", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.142706", "ticker_sentiment_score": "0.08471", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.095422", "ticker_sentiment_score": "0.117675", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.119117", "ticker_sentiment_score": "-0.057386", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.047797", "ticker_sentiment_score": "0.161732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.119117", "ticker_sentiment_score": "-0.113877", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.023909", "ticker_sentiment_score": "-0.055312", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.023909", "ticker_sentiment_score": "0.106984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern", "url": "https://www.investors.com/stock-lists/new-highs/new-highs-drug-and-chip-stocks-hit-52-week-highs-break-out-on-strong-earnings-record/", "time_published": "20230203T212000", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-analogdevices-wideband-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.223417, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.256989", "ticker_sentiment_score": "-0.031283", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.021064", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Q4 Earnings & Sales Beat, Eylea Sales Decline", "url": "https://www.zacks.com/stock/news/2049666/regeneron-regn-q4-earnings-sales-beat-eylea-sales-decline", "time_published": "20230203T163500", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.229877, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.156207", "ticker_sentiment_score": "0.197065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.039289", "ticker_sentiment_score": "0.14796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.232439", "ticker_sentiment_score": "0.213233", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron Outplays Fourth-Quarter Decline, But Sanofi Topples", "url": "https://www.investors.com/news/technology/regeneron-stock-regeneron-earnings-sny-stock-sanofi-earnings-q4-2022/", "time_published": "20230203T140200", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Regeneron Stock Outplays Fourth-Quarter Decline, But SNY Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-sanofi-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.074086, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.310843", "ticker_sentiment_score": "-0.331362", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.838487", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/02/30705910/regeneron-pharmaceuticals-q4-earnings-revenue-falls-as-covid-19-related-sales-dwindle", "time_published": "20230203T133327", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. Revenues decreased 31% Y/Y to $3.41 billion; excluding REGEN-COV and Ronapreve, revenues increased 14%, slightly ahead of the analyst consensus of $3.13 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/03/aapharma_3.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.060081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.498188", "ticker_sentiment_score": "0.148495", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.17715", "ticker_sentiment_score": "-0.373857", "ticker_sentiment_label": "Bearish"}]}, {"title": "Regeneron's Earnings Beat Forecasts, With No Sales of Covid-19 Treatment", "url": "https://www.barrons.com/articles/regeneron-stock-earnings-covid-19-antibody-51675430047", "time_published": "20230203T131500", "authors": ["Karishma Vanjani"], "summary": "Regeneron Pharmaceuticals delivered higher fourth-quarter profit and sales than expected, though it made no sales of its Covid-19 antibody cocktail. The pharmaceuticals company reported adjusted earnings of $12.56 per share for the quarter that ended in December, while analysts tracked by FactSet ...", "banner_image": "https://images.barrons.com/im-429019/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.180131, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.546745", "ticker_sentiment_score": "0.105954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Futures Deflate As Apple Leads Tech Disappointments - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/23/02/30704099/nasdaq-futures-deflate-as-apple-leads-tech-disappointments-traders-look-to-jobs-data-for-mitigating", "time_published": "20230203T120004", "authors": ["Shanthi Rexaline"], "summary": "Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each incoming economic data.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/03/stock_market_photo_by_adolescentchat_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.016881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JWN", "relevance_score": "0.101582", "ticker_sentiment_score": "0.093885", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.092813", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.42722", "ticker_sentiment_label": "Bearish"}, {"ticker": "QCOM", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.092813", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.092813", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.050894", "ticker_sentiment_score": "0.066505", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.050894", "ticker_sentiment_score": "0.051252", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.135239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron quarterly profit plunges as COVID drug sales dry up", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-quarterly-profit-drops-46-2023-02-03/", "time_published": "20230203T115100", "authors": ["Reuters"], "summary": "Feb 3 ( Reuters ) - Regeneron Pharmaceuticals Inc ( REGN.O ) reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TUVSCCQOZBPTPFFOC5TQTF2ZDA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.004924, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.245339", "ticker_sentiment_score": "0.055013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results", "url": "https://www.globenewswire.com/news-release/2023/02/03/2601193/0/en/Regeneron-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-and-Operating-Results.html", "time_published": "20230203T113000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "TARRYTOWN, N.Y., Feb. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the fourth quarter and full year 2022 and provided a business update.", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.182733, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSBHF", "relevance_score": "0.010985", "ticker_sentiment_score": "0.030474", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.010985", "ticker_sentiment_score": "0.076094", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.032946", "ticker_sentiment_score": "0.049912", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACET", "relevance_score": "0.010985", "ticker_sentiment_score": "0.068859", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.076777", "ticker_sentiment_score": "0.071363", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.010985", "ticker_sentiment_score": "0.127916", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.010985", "ticker_sentiment_score": "0.127916", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.010985", "ticker_sentiment_score": "0.127916", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Regeneron  ( REGN )  Might Surprise This Earnings Season", "url": "https://www.zacks.com/stock/news/2048263/why-regeneron-regn-might-surprise-this-earnings-season", "time_published": "20230202T133200", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.463498, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.812724", "ticker_sentiment_score": "0.583932", "ticker_sentiment_label": "Bullish"}]}, {"title": "Time to Buy Cigna or Regeneron Stock Before Earnings?", "url": "https://www.zacks.com/commentary/2048006/time-to-buy-cigna-or-regeneron-stock-before-earnings", "time_published": "20230202T000000", "authors": ["Zacks Investment Research"], "summary": "Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/b2/35984.jpg?v=1207968057", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.26982, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.113062", "ticker_sentiment_score": "0.128573", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.522854", "ticker_sentiment_score": "0.434902", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCSG", "relevance_score": "0.056674", "ticker_sentiment_score": "0.158964", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today", "url": "https://www.benzinga.com/news/earnings/23/02/30669060/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-300-today", "time_published": "20230201T150418", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 8.86% on an annualized basis producing an average annual return of 17.41%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.31 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-fourth-quarter-and-full-year-2022-financial-results/", "time_published": "20230131T212941", "authors": [], "summary": "Amgen ( NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Economy - Macro", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.125889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.128899", "ticker_sentiment_score": "0.075902", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.014384", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.028764", "ticker_sentiment_score": "0.149844", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVB", "relevance_score": "0.014384", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.014384", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.014384", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.240769", "ticker_sentiment_score": "0.128417", "ticker_sentiment_label": "Neutral"}]}, {"title": "February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More", "url": "https://www.benzinga.com/general/biotech/23/01/30648889/february-pdufa-catalysts-biotech-investors-must-know-sanofis-bleeding-disorder-drug-regenerons-tw", "time_published": "20230131T193301", "authors": ["Shanthi Rexaline"], "summary": "The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year. NME approvals assume importance as the metric is an indicator of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/31/biotech_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019422, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.067727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.067727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.067727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.118348", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.101439", "ticker_sentiment_score": "-0.076833", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.067727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.040075", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.134968", "ticker_sentiment_score": "0.224911", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.240173", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.048888", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.067727", "ticker_sentiment_score": "0.051103", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.033894", "ticker_sentiment_score": "0.07113", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.074462", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.101439", "ticker_sentiment_score": "-0.033539", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Eylea and Dupixent Fuel Regeneron's  ( REGN )  Q4 Earnings?", "url": "https://www.zacks.com/stock/news/2046381/will-eylea-and-dupixent-fuel-regenerons-regn-q4-earnings", "time_published": "20230130T160300", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default57.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.197435, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.139265", "ticker_sentiment_score": "0.070365", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.27432", "ticker_sentiment_score": "0.150979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.046633", "ticker_sentiment_score": "0.036871", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.139265", "ticker_sentiment_score": "0.048457", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.27432", "ticker_sentiment_score": "0.191914", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis", "url": "https://www.benzinga.com/general/biotech/23/01/30621825/europe-approves-regeneron-sanofis-dupixent-for-expanded-use-in-eosinophilic-esophagitis", "time_published": "20230130T140405", "authors": ["Vandana Singh"], "summary": "The European Commission approved Regeneron Pharmaceuticals Inc REGN and Sanofi SA's SNY Dupixent ( dupilumab ) for expanded use in eosinophilic esophagitis ( EoE ) in adults and adolescents 12 years and older.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/30/regn_logo_light__fd7b073a3150a40b008b6dddd0ef8ef1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.388879", "ticker_sentiment_score": "0.30691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.388879", "ticker_sentiment_score": "0.30691", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis", "url": "https://www.globenewswire.com/news-release/2023/01/30/2597237/0/en/Dupixent-dupilumab-Approved-by-European-Commission-as-the-First-and-Only-Targeted-Medicine-Indicated-for-Eosinophilic-Esophagitis.html", "time_published": "20230130T060000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission. patients also significantly improved their ability to swallow compared to placebo ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.063181, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.036407", "ticker_sentiment_score": "0.038168", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.09989", "ticker_sentiment_score": "0.004407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis", "url": "https://www.globenewswire.com/news-release/2023/01/30/2597236/0/en/Press-Release-Dupixent-dupilumab-approved-by-European-Commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis.html", "time_published": "20230130T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.014647, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025873", "ticker_sentiment_score": "0.035697", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.128822", "ticker_sentiment_score": "-0.008543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis", "url": "https://www.benzinga.com/pressreleases/23/01/g30617210/press-release-dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-me", "time_published": "20230130T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.012162, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.025325", "ticker_sentiment_score": "0.035467", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.016068", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch", "url": "https://www.benzinga.com/news/earnings/23/01/30616031/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among", "time_published": "20230129T222532", "authors": ["Shanthi Rexaline"], "summary": "With a full week of earnings behind us, it's time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. Some of the big tech names that fell short are Intel Corp. INTC and Texas Instruments, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/29/nyse2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.011859, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVX", "relevance_score": "0.054114", "ticker_sentiment_score": "0.103015", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.054114", "ticker_sentiment_score": "0.21787", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "F", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.163012", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.081092", "ticker_sentiment_score": "0.236315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.081092", "ticker_sentiment_score": "0.229106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.115317", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.054114", "ticker_sentiment_score": "0.42603", "ticker_sentiment_label": "Bullish"}, {"ticker": "QCOM", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.027072", "ticker_sentiment_score": "-0.155247", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UPS", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.081092", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.191833", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KLAC", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.163012", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WHR", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.054114", "ticker_sentiment_score": "0.157789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CI", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.081092", "ticker_sentiment_score": "0.226017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXPI", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMUS", "relevance_score": "0.054114", "ticker_sentiment_score": "0.157789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BZH", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.163012", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAT", "relevance_score": "0.107978", "ticker_sentiment_score": "0.245104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHC", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.054114", "ticker_sentiment_score": "0.157789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.081092", "ticker_sentiment_score": "-0.109957", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.054114", "ticker_sentiment_score": "0.252919", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Apple, Amazon earnings, jobs data and Fed decision top week ahead", "url": "https://www.foxbusiness.com/markets/apple-amazon-earnings-jobs-data-fed-decision-top-week-ahead", "time_published": "20230129T211217", "authors": [], "summary": "Mega Cap earnings and Fed decision top week ahead Fox Business ...", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/6396fd49-caf9-414c-8351-a4b9125ff223/9a4b204c-6d69-4951-8be9-aec269c55eb3/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.076256, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MPC", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.04912", "ticker_sentiment_score": "0.12506", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.04912", "ticker_sentiment_score": "0.111094", "ticker_sentiment_label": "Neutral"}, {"ticker": "HP", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.04912", "ticker_sentiment_score": "0.111094", "ticker_sentiment_label": "Neutral"}, {"ticker": "HBI", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.098054", "ticker_sentiment_score": "0.087674", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.04912", "ticker_sentiment_score": "0.111094", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.04912", "ticker_sentiment_score": "0.111094", "ticker_sentiment_label": "Neutral"}, {"ticker": "WM", "relevance_score": "0.04912", "ticker_sentiment_score": "0.12506", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.04912", "ticker_sentiment_score": "0.15603", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.098054", "ticker_sentiment_score": "-0.087674", "ticker_sentiment_label": "Neutral"}, {"ticker": "EA", "relevance_score": "0.04912", "ticker_sentiment_score": "0.15603", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOG", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHDRF", "relevance_score": "0.04912", "ticker_sentiment_score": "0.003989", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.04912", "ticker_sentiment_score": "0.12506", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WWE", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWK", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEN", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMG", "relevance_score": "0.04912", "ticker_sentiment_score": "0.12506", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMUS", "relevance_score": "0.04912", "ticker_sentiment_score": "0.12506", "ticker_sentiment_label": "Neutral"}, {"ticker": "JJSF", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COLM", "relevance_score": "0.04912", "ticker_sentiment_score": "0.111094", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYY", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOFI", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXP", "relevance_score": "0.04912", "ticker_sentiment_score": "0.15603", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Action Plan - January Wrap: Apple, OPEC, Exxon And The Fed", "url": "https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-january-wrap-apple-opec-exxon-and-the-fed/", "time_published": "20230127T232000", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Investing Action Plan - January Wrap: Apple, OPEC, Exxon And ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-marketBoard-29-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MXL", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.147316", "ticker_sentiment_score": "0.011708", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.032916", "ticker_sentiment_score": "-0.019423", "ticker_sentiment_label": "Neutral"}, {"ticker": "HP", "relevance_score": "0.049356", "ticker_sentiment_score": "0.060998", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.032916", "ticker_sentiment_score": "-0.021146", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.082167", "ticker_sentiment_score": "0.00207", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCB", "relevance_score": "0.032916", "ticker_sentiment_score": "0.016309", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.049356", "ticker_sentiment_score": "-0.001997", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGM", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.032916", "ticker_sentiment_score": "0.141926", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.065775", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "STX", "relevance_score": "0.032916", "ticker_sentiment_score": "0.09927", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.032916", "ticker_sentiment_score": "0.09927", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.049356", "ticker_sentiment_score": "0.049853", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.065775", "ticker_sentiment_score": "0.092134", "ticker_sentiment_label": "Neutral"}, {"ticker": "X", "relevance_score": "0.032916", "ticker_sentiment_score": "0.067052", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPS", "relevance_score": "0.032916", "ticker_sentiment_score": "0.151693", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EA", "relevance_score": "0.032916", "ticker_sentiment_score": "0.066703", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.032916", "ticker_sentiment_score": "0.047876", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.032916", "ticker_sentiment_score": "-0.114718", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.049356", "ticker_sentiment_score": "0.086646", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0553", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.032916", "ticker_sentiment_score": "0.136576", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.049356", "ticker_sentiment_score": "0.091202", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.049356", "ticker_sentiment_score": "0.057394", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.065775", "ticker_sentiment_score": "0.002039", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.032916", "ticker_sentiment_score": "0.047876", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.032916", "ticker_sentiment_score": "0.109883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAL", "relevance_score": "0.065775", "ticker_sentiment_score": "0.092134", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.082167", "ticker_sentiment_score": "0.076139", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.065775", "ticker_sentiment_score": "0.100154", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.032916", "ticker_sentiment_score": "0.047876", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.016461", "ticker_sentiment_score": "-0.006118", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.032916", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.032916", "ticker_sentiment_score": "0.047876", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.065775", "ticker_sentiment_score": "0.092134", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis", "url": "https://www.globenewswire.com/news-release/2023/01/27/2596599/0/en/Press-Release-Dupixent-dupilumab-recommended-for-expanded-EU-approval-by-the-CHMP-to-treat-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.html", "time_published": "20230127T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.033949, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.031529", "ticker_sentiment_score": "0.044292", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.141171", "ticker_sentiment_score": "0.002573", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis", "url": "https://www.benzinga.com/pressreleases/23/01/g30598142/press-release-dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-childre", "time_published": "20230127T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only targeted medicine in the EU for these young children", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.033841, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.030858", "ticker_sentiment_score": "0.042203", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.16849", "ticker_sentiment_score": "0.002876", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis", "url": "https://www.benzinga.com/pressreleases/23/01/g30598138/dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-children-as-young-as-", "time_published": "20230127T055900", "authors": ["Globe Newswire"], "summary": "TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.043676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.043011", "ticker_sentiment_score": "0.046596", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.107255", "ticker_sentiment_score": "0.007854", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dupixent\u00ae  ( dupilumab )  Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis", "url": "https://www.globenewswire.com/news-release/2023/01/27/2596596/0/en/Dupixent-dupilumab-Recommended-for-Expanded-EU-Approval-by-the-CHMP-to-Treat-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html", "time_published": "20230127T055900", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "If approved, Dupixent would be the first and only targeted medicine in the EU for these young children ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.04129, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.041993", "ticker_sentiment_score": "0.048523", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.104728", "ticker_sentiment_score": "0.02115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition", "url": "https://www.benzinga.com/pressreleases/23/01/g30552825/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nat", "time_published": "20230124T170000", "authors": ["Globe Newswire"], "summary": "Nation's Most Innovative Teens will Showcase Research with Prizes of Over $1.8 million TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.447023, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.083541", "ticker_sentiment_score": "0.130262", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.027892", "ticker_sentiment_score": "0.240589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.027892", "ticker_sentiment_score": "0.240589", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO", "url": "https://www.globenewswire.com/news-release/2023/01/24/2594040/0/en/Decibel-Therapeutics-Announces-Approval-of-Clinical-Trial-Application-by-the-U-K-Medicines-and-Healthcare-Products-Regulatory-Agency-for-Lead-Gene-Therapy-Candidate-DB-OTO.html", "time_published": "20230124T120000", "authors": ["Inc.", "Decibel Therapeutics"], "summary": "The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/83689706-9e23-448c-9c5e-fa03a8df7d44?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.082913, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.036983", "ticker_sentiment_score": "0.113543", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.147141", "ticker_sentiment_score": "0.12522", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Housing Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-housing-data-netflix-surges-on-subscriber-growth/", "time_published": "20230120T135600", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures fell modestly Friday morning ahead of housing data, threatening to extend a three-day losing streak. China's markets rallied heading into their Lunar New Year break, giving a boost to global markets. Netflix ( NFLX ) stock surged more than 6% after the company's ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-nyse-flag-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.161981, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.150278", "ticker_sentiment_score": "0.228154", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NFLX", "relevance_score": "0.075476", "ticker_sentiment_score": "0.080934", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.050359", "ticker_sentiment_score": "0.15794", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.12546", "ticker_sentiment_score": "0.043689", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.12546", "ticker_sentiment_score": "0.202621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.025192", "ticker_sentiment_score": "-0.058539", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.12546", "ticker_sentiment_score": "0.134482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.050359", "ticker_sentiment_score": "0.008961", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.075476", "ticker_sentiment_score": "0.186306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.100518", "ticker_sentiment_score": "0.097882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.050359", "ticker_sentiment_score": "0.036867", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.025192", "ticker_sentiment_score": "0.106804", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLR", "relevance_score": "0.150278", "ticker_sentiment_score": "0.067842", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.100518", "ticker_sentiment_score": "-0.005423", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.048669", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.12546", "ticker_sentiment_score": "0.099225", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.100518", "ticker_sentiment_score": "0.111083", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.050359", "ticker_sentiment_score": "-0.062917", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves premarket: Netflix, Alphabet, Nordstrom, PagerDuty and more", "url": "https://www.cnbc.com/2023/01/20/stocks-making-the-biggest-moves-premarket-netflix-alphabet-nordstrom-pagerduty-and-more.html", "time_published": "20230120T124322", "authors": ["Sarah Min"], "summary": "These are the stocks posting the largest moves in early trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107145898-1667510273534-gettyimages-1393876536-0j7a4557_34171d4c-3964-4bfa-ac93-3394a0db95ff.jpeg?v=1674218602&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.012333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JWN", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.288493", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NFLX", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.09744", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.088472", "ticker_sentiment_score": "0.053606", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.088472", "ticker_sentiment_score": "0.083425", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.088472", "ticker_sentiment_score": "0.190204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KSS", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.208077", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "M", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.384632", "ticker_sentiment_label": "Bearish"}, {"ticker": "COST", "relevance_score": "0.175859", "ticker_sentiment_score": "0.128025", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDS", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.208077", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.175859", "ticker_sentiment_score": "0.158517", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PD", "relevance_score": "0.175859", "ticker_sentiment_score": "0.268185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RL", "relevance_score": "0.175859", "ticker_sentiment_score": "0.158517", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.088472", "ticker_sentiment_score": "0.083425", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years", "url": "https://www.benzinga.com/news/earnings/23/01/30490765/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-15-years", "time_published": "20230119T193328", "authors": ["Benzinga Insights"], "summary": "Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.8% on an annualized basis producing an average annual return of 26.24%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.59 billion.", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Outlook Therapeutics\u00ae Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence", "url": "https://www.globenewswire.com/news-release/2023/01/19/2591759/0/en/Outlook-Therapeutics-Strengthens-Medical-Affairs-and-Commercial-Expertise-with-Appointments-of-Surendra-Sharma-MD-Senior-Vice-President-of-Medical-Affairs-and-Glen-Olsheim-Executiv.html", "time_published": "20230119T130500", "authors": ["Outlook Therapeutics", "Inc."], "summary": "Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic products Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/cbff3302-f8d2-466a-beff-8c33252f9c70?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.190051, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.029078", "ticker_sentiment_score": "0.07201", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTLK", "relevance_score": "0.577415", "ticker_sentiment_score": "0.33755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.029078", "ticker_sentiment_score": "0.07201", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.029078", "ticker_sentiment_score": "0.07201", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2039887/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230117T112008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.294012, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.060236", "ticker_sentiment_score": "0.123005", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12013", "ticker_sentiment_score": "0.062124", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.12013", "ticker_sentiment_score": "0.062124", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.12013", "ticker_sentiment_score": "0.062124", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More", "url": "https://www.zacks.com/stock/news/2037977/biotech-stock-roundup-regn-down-on-eylea-data-cinc-surges-on-azn-offer-more", "time_published": "20230111T161000", "authors": ["Zacks Investment Research"], "summary": "Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default234.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.140233, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CINC", "relevance_score": "0.086245", "ticker_sentiment_score": "0.169443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.171485", "ticker_sentiment_score": "0.227952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.043186", "ticker_sentiment_score": "0.034665", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.33514", "ticker_sentiment_score": "0.054775", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTX", "relevance_score": "0.043186", "ticker_sentiment_score": "0.064399", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.295358", "ticker_sentiment_score": "0.109124", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.129052", "ticker_sentiment_score": "-0.014112", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.043186", "ticker_sentiment_score": "0.064399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and more", "url": "https://www.cnbc.com/2023/01/10/stocks-making-the-biggest-moves-midday-virgin-orbit-bed-bath-beyond-coinbase-and-more.html", "time_published": "20230110T174340", "authors": ["Michelle Fox"], "summary": "These are the stocks posting the largest moves midday.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106998378-1641575583614-Image_from_iOS_17.jpg?v=1673372620&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.095706, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.054732", "ticker_sentiment_score": "0.135824", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.054732", "ticker_sentiment_score": "0.143831", "ticker_sentiment_label": "Neutral"}, {"ticker": "VORB", "relevance_score": "0.054732", "ticker_sentiment_score": "-0.120193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.054732", "ticker_sentiment_score": "0.133822", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSH", "relevance_score": "0.109206", "ticker_sentiment_score": "0.157668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.109206", "ticker_sentiment_score": "0.029983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.054732", "ticker_sentiment_score": "-0.222923", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EURN", "relevance_score": "0.109206", "ticker_sentiment_score": "0.112528", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.054732", "ticker_sentiment_score": "0.061041", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.109206", "ticker_sentiment_score": "-0.070231", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHC", "relevance_score": "0.109206", "ticker_sentiment_score": "0.010141", "ticker_sentiment_label": "Neutral"}, {"ticker": "DISH", "relevance_score": "0.054732", "ticker_sentiment_score": "0.061041", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.054732", "ticker_sentiment_score": "0.03388", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.109206", "ticker_sentiment_score": "0.067142", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054732", "ticker_sentiment_score": "0.071017", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/01/30357184/check-out-what-whales-are-doing-with-regn", "time_published": "20230110T164819", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 15 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_648.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.104183, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.802374", "ticker_sentiment_score": "0.228994", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regeneron  ( REGN )  Down on Ophthalmology Drug Eylea Sales Update", "url": "https://www.zacks.com/stock/news/2037409/regeneron-regn-down-on-ophthalmology-drug-eylea-sales-update", "time_published": "20230110T144600", "authors": ["Zacks Investment Research"], "summary": "Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252547, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.294446", "ticker_sentiment_score": "0.280652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.060236", "ticker_sentiment_score": "0.175033", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.179343", "ticker_sentiment_score": "0.220424", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Company News for Jan 10, 2023", "url": "https://www.zacks.com/stock/news/2037351/company-news-for-jan-10-2023", "time_published": "20230110T143200", "authors": ["Zacks Investment Research"], "summary": "Companies In The News Are: REGN, LULU, DCT, BAX.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9f/412.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.085166, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.601928", "ticker_sentiment_score": "0.454156", "ticker_sentiment_label": "Bullish"}, {"ticker": "LULU", "relevance_score": "0.601928", "ticker_sentiment_score": "-0.502216", "ticker_sentiment_label": "Bearish"}, {"ticker": "DCT", "relevance_score": "0.601928", "ticker_sentiment_score": "0.481028", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.601928", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones, S&P 500 Reverse Lower; A Few Stocks Break Out But Volume Mixed", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-new-data-shows-strong-economy-in-2023-retailers-fall-but-bed-bath-beyond-pops/", "time_published": "20230109T213300", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones, S&P Reverse Lower As Nasdaq Pares Gains Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/stock-NYSE-Cmas-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.004867, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JPM", "relevance_score": "0.167322", "ticker_sentiment_score": "0.084168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.112008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.056143", "ticker_sentiment_score": "-0.236994", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ORCL", "relevance_score": "0.112008", "ticker_sentiment_score": "0.064219", "ticker_sentiment_label": "Neutral"}, {"ticker": "HEES", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.16132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "M", "relevance_score": "0.056143", "ticker_sentiment_score": "-0.269144", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNH", "relevance_score": "0.167322", "ticker_sentiment_score": "0.084168", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGRC", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.16132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HAL", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.262745", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMC", "relevance_score": "0.112008", "ticker_sentiment_score": "0.234765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.112008", "ticker_sentiment_score": "0.11124", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.150196", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBER", "relevance_score": "0.167322", "ticker_sentiment_score": "-0.011267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/markets/options/23/01/30339228/check-out-what-whales-are-doing-with-regn", "time_published": "20230109T194939", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 30 strange trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_580.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.149155, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.718897", "ticker_sentiment_score": "0.057628", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises; Retailers Fall But Bed Bath & Beyond Pops", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-retailers-fall-but-bed-bath-beyond-pops/", "time_published": "20230109T185300", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises. Retailers Fall But Bed Bath & Beyond Pops Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-WallStreet-TrafficLight-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.093777, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JPM", "relevance_score": "0.214304", "ticker_sentiment_score": "0.10104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMC", "relevance_score": "0.143843", "ticker_sentiment_score": "0.348101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.143843", "ticker_sentiment_score": "0.075326", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.143843", "ticker_sentiment_score": "0.126253", "ticker_sentiment_label": "Neutral"}, {"ticker": "HEES", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.085296", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.186162", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "M", "relevance_score": "0.072217", "ticker_sentiment_score": "-0.282335", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBER", "relevance_score": "0.214304", "ticker_sentiment_score": "-0.013548", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.214304", "ticker_sentiment_score": "0.10104", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGRC", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.085296", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Stock Sinks on Disappointing Sales of Eylea Vaccine", "url": "https://www.barrons.com/articles/regeneron-stock-eylea-vaccine-sales-51673283975", "time_published": "20230109T170700", "authors": ["Angela Palumbo"], "summary": "Regeneron Pharmaceuticals stock was tumbling after the medicine maker reported lower sales of its Eylea vaccine than Wall Street was anticipating for the fourth quarter. In a preliminary update on its fourth quarter on Monday, Regeneron ( REGN ) said fourth-quarter sales of Eylea were $1.5 ...", "banner_image": "https://images.barrons.com/im-699747/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.181243, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.866386", "ticker_sentiment_score": "-0.311833", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Regeneron Stock Sinks", "url": "https://www.investors.com/news/technology/regn-stock-sinks-as-eylea-sales-suffer/", "time_published": "20230109T165100", "authors": ["Investor's Business Daily", "APARNA NARAYANAN"], "summary": "REGN Stock Sinks As Eylea Sales Suffer| Investor's Business Daily Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/03/stock-regeneron-03-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": -0.011996, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.550532", "ticker_sentiment_score": "-0.306757", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea\u00ae Biosimilar FYB203 from Klinge Biopharma", "url": "https://www.globenewswire.com/news-release/2023/01/09/2585235/33333/en/Coherus-Agrees-to-Acquire-Exclusive-U-S-Commercial-Rights-to-Eylea-Biosimilar-FYB203-from-Klinge-Biopharma.html", "time_published": "20230109T132000", "authors": ["Inc.", "Coherus BioSciences"], "summary": "Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1e7cdf14-470b-43b2-bf7a-d88d844a34ef?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.195668, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.032825", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.098255", "ticker_sentiment_score": "0.100468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea\u00ae Biosimilar FYB203 from Klinge Biopharma - Coherus BioSciences  ( NASDAQ:CHRS ) ", "url": "https://www.benzinga.com/pressreleases/23/01/g30331669/coherus-agrees-to-acquire-exclusive-u-s-commercial-rights-to-eylea-biosimilar-fyb203-from-klinge-b", "time_published": "20230109T132000", "authors": ["Globe Newswire"], "summary": "REDWOOD CITY, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( Coherus or Coherus BioSciences, NASDAQ:CHRS ) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH ( Klinge Biopharma ) for the exclusive commercialization rights to FYB203, a ...", "banner_image": "", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.188501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.031992", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.063933", "ticker_sentiment_score": "0.088057", "ticker_sentiment_label": "Neutral"}]}, {"title": "What This Drug News Could Mean for Sanofi Shareholders", "url": "https://www.fool.com/investing/2023/01/08/what-this-drug-news-could-mean-for-sanofis-stock/", "time_published": "20230108T140000", "authors": ["Kody Kester"], "summary": "This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F715480%2Fa-doctor-examines-a-patient-with-a-stethoscope.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.168311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.111488", "ticker_sentiment_score": "0.228907", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.274012", "ticker_sentiment_score": "0.230972", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why CytomX Therapeutics  ( CTMX )  Shares Are Soaring Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/general/biotech/23/01/30310896/cytomx-shares-move-higher-on-collaborating-pact-with-this-famed-covid-19-vaccine-maker", "time_published": "20230106T153029", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA and CytomX Therapeutics Inc CTMX announced a collaboration and licensing agreement to create mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/06/ctmx_logo_dark__d8d313a56b93966616d4a30b15c9bd27.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.249361, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.7887", "ticker_sentiment_score": "0.610894", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.17108", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CTMX", "relevance_score": "0.546745", "ticker_sentiment_score": "0.508679", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Growth Stocks That Could Rocket Higher in 2023", "url": "https://www.fool.com/investing/2023/01/06/3-growth-stocks-that-could-rocket-higher-in-2023/", "time_published": "20230106T103900", "authors": ["Cory Renauer"], "summary": "Upcoming binary events could push these stocks to new all-time highs.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F715234%2Finvestor-stock-charts-screens-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.026856, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.108958", "ticker_sentiment_score": "-0.028358", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.108958", "ticker_sentiment_score": "0.176285", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.054607", "ticker_sentiment_score": "0.160837", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq - T-Mobile US  ( NASDAQ:TMUS ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30305723/jim-cramer-says-hes-still-feeling-good-about-these-5-stocks-from-mutilated-nasdaq", "time_published": "20230106T024240", "authors": ["Bhavik Nair"], "summary": "Prominent market commentator Jim Cramer has recommended five stocks from the Nasdaq Index that he believes could be decent additions to investors' portfolios. \"In an index that's been folded, spindled and mutilated, I am still feeling good about a few of these stocks,\" Cramer said according to a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/05/cramer.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.210641, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TMUS", "relevance_score": "0.271274", "ticker_sentiment_score": "0.4902", "ticker_sentiment_label": "Bullish"}, {"ticker": "TJX", "relevance_score": "0.271274", "ticker_sentiment_score": "0.334404", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DLTR", "relevance_score": "0.271274", "ticker_sentiment_score": "0.334404", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.271274", "ticker_sentiment_score": "0.312294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEP", "relevance_score": "0.397098", "ticker_sentiment_score": "0.408497", "ticker_sentiment_label": "Bullish"}, {"ticker": "AEP", "relevance_score": "0.271274", "ticker_sentiment_score": "0.452262", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.271274", "ticker_sentiment_score": "-0.294272", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "VERA Dips Despite Positive Data From IgA Nephropathy Study", "url": "https://www.zacks.com/stock/news/2035300/vera-dips-despite-positive-data-from-iga-nephropathy-study", "time_published": "20230104T172000", "authors": ["Zacks Investment Research"], "summary": "VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.028573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.287762", "ticker_sentiment_score": "0.066164", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.461283", "ticker_sentiment_score": "0.148452", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.287762", "ticker_sentiment_score": "0.066164", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERA", "relevance_score": "0.194242", "ticker_sentiment_score": "0.236927", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's in Store for Regeneron Pharmaceuticals  ( REGN )  in 2023?", "url": "https://www.zacks.com/stock/news/2034721/whats-in-store-for-regeneron-pharmaceuticals-regn-in-2023", "time_published": "20230103T171300", "authors": ["Zacks Investment Research"], "summary": "Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.303643, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.221481", "ticker_sentiment_score": "0.400269", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.176965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.148731", "ticker_sentiment_score": "0.243457", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics", "url": "https://www.prnewswire.com/news-releases/zielbio-appoints-alan-bash-ceo-as-company-advances-oncology-therapeutics-301712159.html", "time_published": "20230103T130000", "authors": ["ZielBio", "Inc."], "summary": "ZielBio Appoints Alan Bash CEO as Company Advances Oncology ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1730148/ZielBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.154059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.064973", "ticker_sentiment_score": "-0.077664", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.064973", "ticker_sentiment_score": "-0.077664", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should Invesco S&P 500 GARP ETF  ( SPGP )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2034288/should-invesco-sp-500-garp-etf-spgp-be-on-your-investing-radar", "time_published": "20230102T112006", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default237.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.285293, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NRG", "relevance_score": "0.124164", "ticker_sentiment_score": "0.068777", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.303926", "ticker_sentiment_score": "0.203477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.124164", "ticker_sentiment_score": "0.068777", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.124164", "ticker_sentiment_score": "0.068777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors - iShares Biotechnology ETF  ( NASDAQ:IBB ) , SPDR Series Trust SPDR S&P Biotech ETF  ( ARCA:XBI ) ", "url": "https://www.benzinga.com/general/biotech/22/12/30200244/biogens-2nd-alzheimers-antibody-beigenes-cancer-drug-label-expansion-adcom-test-for-regeneron-and", "time_published": "20221227T141156", "authors": ["Shanthi Rexaline"], "summary": "Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF IBB, which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech XBI.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/27/photo_by_nednapa_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.009717, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDWD", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.151273", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BGNE", "relevance_score": "0.109289", "ticker_sentiment_score": "0.051439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.072987", "ticker_sentiment_score": "0.044284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHAT", "relevance_score": "0.072987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLCO", "relevance_score": "0.036532", "ticker_sentiment_score": "0.136623", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.072987", "ticker_sentiment_score": "0.074552", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.072987", "ticker_sentiment_score": "0.074552", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDTX", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.086602", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.072987", "ticker_sentiment_score": "0.044284", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.197876", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.072987", "ticker_sentiment_score": "0.047288", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCEL", "relevance_score": "0.109289", "ticker_sentiment_score": "-0.068665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.036532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.109289", "ticker_sentiment_score": "0.094444", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rewind 2022: Innovative research, slew of crucial FDA approvals and new strides in genetic therapies became pivotal moments | The Financial Express", "url": "https://www.financialexpress.com/healthcare/news-healthcare/rewind-2022-innovative-research-slew-of-crucial-fda-approvals-and-new-strides-in-genetic-therapies-became-pivotal-moments/2928131/", "time_published": "20221227T103726", "authors": [], "summary": "Rewind 2022: Innovative research, slew of crucial FDA approvals and new strides in genetic therapies became pivotal moments The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2022/12/scientist-rp.jpg", "source": "The Financial Express", "category_within_source": "IndustryGoogleRSS", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.130847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.075635", "ticker_sentiment_score": "0.005101", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.03786", "ticker_sentiment_score": "0.049739", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.03786", "ticker_sentiment_score": "0.023542", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.03786", "ticker_sentiment_score": "0.100212", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.03786", "ticker_sentiment_score": "-0.049118", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.03786", "ticker_sentiment_score": "0.100212", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.03786", "ticker_sentiment_score": "-0.058426", "ticker_sentiment_label": "Neutral"}]}, {"title": "Libtayo\u00ae  ( cemiplimab )  Approved in Japan for Advanced or Recurrent Cervical Cancer", "url": "https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer-301709636.html", "time_published": "20221223T133000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "Libtayo\u00ae ( cemiplimab ) Approved in Japan for Advanced or ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.16679, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.051924", "ticker_sentiment_score": "-0.129962", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.03463", "ticker_sentiment_score": "0.101915", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Positive Dupixent\u00ae  ( dupilumab )  Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine", "url": "https://www.globenewswire.com/news-release/2022/12/21/2578278/0/en/Press-Release-Positive-Dupixent-dupilumab-Phase-3-results-in-adults-and-adolescents-with-eosinophilic-esophagitis-published-in-the-New-England-Journal-of-Medicine.html", "time_published": "20221221T223000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Positive Dupixent\u00ae ( dupilumab ) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.026684, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.014071", "ticker_sentiment_score": "0.039212", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.004832", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Positive Dupixent\u00ae  ( dupilumab )  Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine", "url": "https://www.benzinga.com/pressreleases/22/12/g30168512/press-release-positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophi", "time_published": "20221221T223000", "authors": ["Globe Newswire"], "summary": "Positive Dupixent\u00ae ( dupilumab ) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.024188, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.01374", "ticker_sentiment_score": "0.037272", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.15025", "ticker_sentiment_score": "-0.003993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF  ( GSEW )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2030362/is-goldman-sachs-equal-weight-us-large-cap-equity-etf-gsew-a-strong-etf-right-now", "time_published": "20221220T112007", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default207.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.174453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZS", "relevance_score": "0.110973", "ticker_sentiment_score": "0.060244", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.219809", "ticker_sentiment_score": "0.050259", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.060244", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.060244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop - Invivyd  ( NASDAQ:IVVD ) ", "url": "https://www.benzinga.com/pressreleases/22/12/g30125428/invivyd-presented-joint-industry-rationale-on-potential-expedited-development-pathways-for-monoclo", "time_published": "20221219T120000", "authors": ["Globe Newswire"], "summary": "WALTHAM, Mass., Dec. 19, 2022 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. IVVD, a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.13607, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.030064", "ticker_sentiment_score": "0.094737", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVVD", "relevance_score": "0.14947", "ticker_sentiment_score": "0.069716", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis", "url": "https://www.globenewswire.com/news-release/2022/12/16/2575389/0/en/Press-Release-Dupixent-dupilumab-recommended-for-EU-approval-by-the-CHMP-for-the-treatment-of-eosinophilic-esophagitis.html", "time_published": "20221216T123000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.043607, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.015757", "ticker_sentiment_score": "0.040556", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.14108", "ticker_sentiment_score": "-0.003853", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis", "url": "https://www.benzinga.com/pressreleases/22/12/g30106839/press-release-dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosi", "time_published": "20221216T123000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in the European Union", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.041061, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.015452", "ticker_sentiment_score": "0.038606", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.183779", "ticker_sentiment_score": "0.009158", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/news/large-cap/22/12/30088891/regeneron-sanofis-dupixent-wins-european-approval-for-prurigo-nodularis", "time_published": "20221215T120558", "authors": ["Vandana Singh"], "summary": "The European Commission ( EC ) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc REGN and Sanofi SA's SNY Dupixent ( dupilumab ) for moderate-to-severe prurigo nodularis. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/15/people-doing-science_2.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.501398", "ticker_sentiment_score": "0.251078", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.633079", "ticker_sentiment_score": "0.021825", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis", "url": "https://www.globenewswire.com/news-release/2022/12/15/2574183/0/en/Press-Release-Dupixent-dupilumab-approved-by-European-Commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis.html", "time_published": "20221215T060000", "authors": ["Sanofi - Aventis Groupe"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for prurigo ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.029166, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.013297", "ticker_sentiment_score": "0.03815", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.00867", "ticker_sentiment_label": "Neutral"}]}, {"title": "Press Release: Dupixent\u00ae  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis", "url": "https://www.benzinga.com/pressreleases/22/12/g30086358/press-release-dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-me", "time_published": "20221215T060000", "authors": ["Globe Newswire"], "summary": "Dupixent\u00ae ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients experienced a clinically meaningful reduction in itch at 24 weeks", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.026658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.013065", "ticker_sentiment_score": "0.036253", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.14295", "ticker_sentiment_score": "-0.006456", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron  ( REGN )  Presents Positive Data on MM and FL Drugs", "url": "https://www.zacks.com/stock/news/2028343/regeneron-regn-presents-positive-data-on-mm-and-fl-drugs", "time_published": "20221213T160700", "authors": ["Zacks Investment Research"], "summary": "Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.169246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.182967", "ticker_sentiment_score": "0.155306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.061473", "ticker_sentiment_score": "0.114147", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/22/12/30057066/regeneron-reveals-an-early-cut-data-from-follicular-lymphoma-study-at-ash-meeting", "time_published": "20221213T133154", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN gave the first look at interim results from its Phase 2 study of odronextamab, a CD20xCD3 bispecific antibody in patients with relapsed/refractory follicular lymphoma.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/13/people-doing-science_1.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.028172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.574235", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year", "url": "https://www.prnewswire.com/news-releases/regeneron-named-on-dow-jones-sustainability-world-index-for-fourth-consecutive-year-301699910.html", "time_published": "20221212T123000", "authors": ["Regeneron Pharmaceuticals", "Inc."], "summary": "DJSI World recognizes the top 10 percent of most sustainable companies by industry; Regeneron ranked among top three biotechnology companies1", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.345609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.2035", "ticker_sentiment_score": "0.106411", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/22/12/30037258/regeneron-highlights-its-first-phase-2-data-to-build-case-in-cd20xc3-bispecific-space", "time_published": "20221212T114232", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN announced updated data from a Phase 1 and Phase 2 trial ( ELM-1 and ELM-2 ) evaluating investigational odronextamab in patients with relapsed/refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/12/people-doing-science.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.053918, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.504646", "ticker_sentiment_score": "0.152321", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pivotal Odronextamab  ( CD20xCD3 )  Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH", "url": "https://www.prnewswire.com/news-releases/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-debut-at-ash-301699791.html", "time_published": "20221211T153000", "authors": ["Inc.", "Regeneron Pharmaceuticals"], "summary": "TARRYTOWN, N.Y., Dec. 11, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial ( ELM-1 and ELM-2 ) evaluating investigational odronextamab in patients with relapsed/refractory ( R/R ) diffuse ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.096925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05833", "ticker_sentiment_score": "-0.006001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.029184", "ticker_sentiment_score": "0.102147", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pivotal Odronextamab  ( CD20xCD3 )  Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH", "url": "https://markets.businessinsider.com/news/stocks/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-debut-at-ash-1031964159", "time_published": "20221211T153000", "authors": [], "summary": "Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH ...", "banner_image": "https://c212.net/c/img/favicon.png?sn=NY62046&sd=2022-12-11", "source": "Business Insider", "category_within_source": "n/a", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092204, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.058259", "ticker_sentiment_score": "-0.006001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.029149", "ticker_sentiment_score": "0.102132", "ticker_sentiment_label": "Neutral"}]}]}